<SEC-DOCUMENT>0001437749-24-025899.txt : 20240809
<SEC-HEADER>0001437749-24-025899.hdr.sgml : 20240809
<ACCEPTANCE-DATETIME>20240809164018
ACCESSION NUMBER:		0001437749-24-025899
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		22
FILED AS OF DATE:		20240809
DATE AS OF CHANGE:		20240809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioCardia, Inc.
		CENTRAL INDEX KEY:			0000925741
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				232753988
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-281448
		FILM NUMBER:		241193438

	BUSINESS ADDRESS:	
		STREET 1:		320 SOQUEL WAY
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94085
		BUSINESS PHONE:		650-226-0123

	MAIL ADDRESS:	
		STREET 1:		320 SOQUEL WAY
		CITY:			SUNNYVALE
		STATE:			CA
		ZIP:			94085

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiger X Medical, Inc.
		DATE OF NAME CHANGE:	20110616

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cardo Medical, Inc.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CLICKNSETTLE COM INC
		DATE OF NAME CHANGE:	20000823
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>bcda20240808_s1.htm
<DESCRIPTION>FORM S-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:bcda="http://www.bcda.com/20240809"><head>
	<title>bcda20240808_s1.htm</title>

	<!-- Generated by ThunderDome Portal - 8/9/2024 8:20:49 PM -->
<meta http-equiv="Content-Type" content="text/html"/></head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none">
<ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="d2024S1" name="dei:AmendmentFlag" id="ixv-3506">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d2024S1" name="dei:EntityCentralIndexKey" id="ixv-3507">0000925741</ix:nonNumeric>
<ix:nonNumeric contextRef="d2024S1" name="dei:EntitySmallBusiness" id="ixv-3508">true</ix:nonNumeric>

</ix:hidden>
<ix:references>
<link:schemaRef xlink:href="bcda-20240809.xsd" xlink:type="simple"/>
</ix:references>
<ix:resources>
<xbrli:context id="d2024S1">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000925741</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2024-08-09</xbrli:startDate>
<xbrli:endDate>2024-08-09</xbrli:endDate>
</xbrli:period>
</xbrli:context>



</ix:resources>
</ix:header>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><b>As filed with the Securities and Exchange Commission on August 9, 2024.</b></div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: right;"><b>Registration No.</b>&#160;<b>333-</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<div style="font-family: Times New Roman; font-size: 16pt; margin: 0pt; text-align: center;"><b>UNITED STATES</b><br/>
<b>SECURITIES AND EXCHANGE COMMISSION</b></div>

<div style="font-family: Times New Roman; font-size: 12pt; margin: 0pt; text-align: center;"><b>Washington, D.C. 20549</b></div>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 15%; border: none; margin: 6pt auto 6pt auto;"/>
<div style="font-family: Times New Roman; font-size: 16pt; margin: 0pt; text-align: center;"><b>FORM</b>&#160;<b><ix:nonNumeric contextRef="d2024S1" name="dei:DocumentType" id="ixv-3518">S-1</ix:nonNumeric></b></div>

<div style="font-family: Times New Roman; font-size: 16pt; margin: 0pt; text-align: center;"><b>REGISTRATION STATEMENT</b></div>

<div style="font-family: Times New Roman; font-size: 12pt; margin: 0pt; text-align: center;"><i>Under</i></div>

<div style="font-family: Times New Roman; font-size: 12pt; margin: 0pt; text-align: center;"><i>THE SECURITIES ACT OF 1933</i></div>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 15%; border: none; margin: 6pt auto 6pt auto;"/>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td colspan="3" style="vertical-align:top;width:99.8%;">
			<div style="font-family: Times New Roman; font-size: 16pt; font-variant: normal; text-align: center; margin: 0pt;"><ix:nonNumeric contextRef="d2024S1" name="dei:EntityRegistrantName" id="ixv-37"><b>BioCardia, Inc.</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:99.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:1pt;"><b>(Exact name of Registrant as specified in its charter)</b></div>
			</td>
		</tr>

</tbody></table>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 15%; border: none; margin: 6pt auto 6pt auto;"/>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d2024S1" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-49"><b>Delaware</b></ix:nonNumeric></div>
			</td>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2836</b></div>
			</td>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d2024S1" name="dei:EntityTaxIdentificationNumber" id="ixv-56"><b>23-2753988</b></ix:nonNumeric></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:1pt;"><b>(State or other jurisdiction of</b><br/>
			<b>incorporation or organization)</b></div>
			</td>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:1pt;"><b>(Primary Standard Industrial</b><br/>
			<b>Classification Code Number)</b></div>
			</td>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:1pt;"><b>(I.R.S. Employer</b><br/>
			<b>Identification Number)</b></div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:33.3%;">&#160;</td>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="d2024S1" name="dei:EntityAddressAddressLine1" id="ixv-81"><b>320 Soquel Way</b></ix:nonNumeric></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric contextRef="d2024S1" name="dei:EntityAddressCityOrTown" id="ixv-85"><b>Sunnyvale</b></ix:nonNumeric>, <ix:nonNumeric contextRef="d2024S1" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-87"><b>California</b></ix:nonNumeric> <ix:nonNumeric contextRef="d2024S1" name="dei:EntityAddressPostalZipCode" id="ixv-89"><b>94085</b></ix:nonNumeric></b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(650) 226-0120</b></div>
			</td>
			<td style="vertical-align:top;width:33.3%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:99.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:1pt;"><b>(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)</b></div>
			</td>
		</tr>

</tbody></table>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 15%; border: none; margin: 6pt auto 6pt auto;"/>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align:top;width:33.3%;">&#160;</td>
			<td style="vertical-align:top;width:33.3%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Peter Altman</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>President and Chief Executive Officer</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>320 Soquel Way</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Sunnyvale, California 94085</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(650) 226-0120</b></div>
			</td>
			<td style="vertical-align:top;width:33.3%;">&#160;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:99.8%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:1pt;"><b>(Name, address, including zip code, and telephone number, including area code, of agent for service)</b></div>
			</td>
		</tr>

</tbody></table>

<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 15%; border: none; margin: 6pt auto 6pt auto;"/>
<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-align: center;"><i>Copies to:</i></div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 50%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Michael J. Danaher</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Austin D. March</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Wilson Sonsini Goodrich &amp; Rosati,</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Professional Corporation</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>650 Page Mill Road</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Palo Alto, CA 94304</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(650) 493-9300</b></div>
			</td>
			<td style="vertical-align: top; width: 50%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Ron Ben-Bassat</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Eric Victorson</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Sullivan &amp; Worcester LLP</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>1251 Avenue of the Americas</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>New York, NY 10020</b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(212) 660-3000</b></div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;"><b>Approximate date of commencement of proposed sale to the public:</b>&#160;As soon as practicable after this Registration Statement becomes effective.</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, or Securities Act, check the following box. &#9746;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221;&#160;&#8220;accelerated filer,&#8221;&#160;&#8220;smaller reporting company,&#8221;&#160;and &#8220;emerging growth company&#8221;&#160;in Rule&#160;12b-2 of the Securities Exchange Act of 1934, or the Exchange Act.</div>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 30%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt;">Large accelerated filer</div>
			</td>
			<td style="vertical-align: top; width: 30%;">&#9744;</td>
			<td colspan="1" style="vertical-align: top; width: 20%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Accelerated filer</div>
			</td>
			<td style="vertical-align: top; width: 20%;">&#9744;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 30%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 108pt;"><ix:nonNumeric contextRef="d2024S1" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-3519">Non-accelerated filer</ix:nonNumeric></div>
			</td>
			<td style="vertical-align: top; width: 30%;">&#9746;</td>
			<td colspan="1" style="vertical-align: top; width: 20%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Smaller reporting company</div>
			</td>
			<td style="vertical-align: top; width: 20%;"><ix:nonNumeric contextRef="d2024S1" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-3520">&#9746;</ix:nonNumeric></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 30%;">&#160;</td>
			<td style="vertical-align: top; width: 30%;">&#160;</td>
			<td colspan="1" style="vertical-align: top; width: 20%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Emerging growth company</div>
			</td>
			<td style="vertical-align: top; width: 20%;"><ix:nonNumeric contextRef="d2024S1" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-3521">&#9744;</ix:nonNumeric></td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; vertical-align: top; text-indent: 36pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#9744;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; vertical-align: top; text-indent: 36pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin: 0pt; text-indent: 36pt; vertical-align: top;"><b>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section</b>&#160;<b>8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section</b>&#160;<b>8(a), may determine.</b></div>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0"/>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0"/>
<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="color:#cc0000;"><b>The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</b></span></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="color:#cc0000;"><b>Preliminary Prospectus subject to completion dated August 9, 2024</b></span></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Up to</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b> Shares of Common Stock</b><br/>
<b>Up to</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b> Pre-Funded Warrants to Purchase Shares of Common Stock</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Up to</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b> Warrants to Purchase Shares of Common Stock</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b>Up to</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b> Shares of Common Stock issuable upon exercise of the Pre-Funded Warrants</b><br/>
<b>Up to</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b> Shares of Common Stock issuable upon exercise of the Warrants</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<div style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="bcda20240808_s1img001.jpg" src="bcda20240808_s1img001.jpg" style="width:286;height:55;"/></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We are offering, on a best efforts basis, up to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our common stock, par value $0.001 per share (&#8220;Common Stock&#8221;), together with up to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; common warrants each of which is exercisable for one share of Common Stock (the &#8220;Common Warrants&#8221;). Each share of our Common Stock or each pre-funded warrant to purchase a share of Common Stock (a &#8220;Pre-Funded Warrant&#8221;) in lieu thereof, is being sold together with one half (1/2) of a Common Warrant. The shares of Common Stock and Common Warrants are immediately separable and will be issued separately in this offering but must be purchased together in this offering.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We have assumed a combined public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;per share of Common Stock and accompanying one-half Common Warrant. The Common Warrants will be exercisable immediately, have an exercise price equal to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the combined public offering price per share of Common Stock and accompanying one-half Common Warrant in this offering (or $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; per share at such assumed combined public offering price) and will expire five years from the date of issuance. The actual combined public offering price will be determined between us, A.G.P./Alliance Global Partners (&#8220;AGP&#8221; or the &#8220;Placement Agent&#8221;) and the investors in the offering at pricing and may be at a discount to the current market price of our Common Stock. Therefore, the assumed combined public offering price used throughout this prospectus may not be indicative of the final offering price.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We are also offering Pre-Funded Warrants to purchase up to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of Common Stock to those purchasers whose purchase of shares of Common Stock in this offering would result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock immediately following the consummation of this offering, in lieu of shares of Common Stock that would result in beneficial ownership in excess of 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock. Each Pre-Funded Warrant is exercisable for one share of our Common Stock and has an exercise price of $0.001 per share. Each Pre-Funded Warrant is being offered together with one half (1/2) of a Common Warrant. The Pre-Funded Warrants and Common Warrants are immediately separable and will be issued separately in this offering, but must be purchased together in this offering. For each Pre-Funded Warrant that we sell, the number of shares of Common Stock we are offering will be reduced on a one-for-one basis.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Pursuant to this prospectus, we are also offering the shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants and Common Warrants offered hereby. These securities are being sold in this offering to certain purchasers under a securities purchase agreement dated&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024 between us and the purchasers.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We have engaged the Placement Agent in connection with the securities offered by this prospectus. The Placement Agent has no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of securities but has agreed to use its best efforts to sell the securities offered by this prospectus. We have agreed to pay the Placement Agent a fee based upon the aggregate gross proceeds raised in this offering as set forth in the table below.</div>

<div style="margin: 0pt; text-indent: 36pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In addition, certain members of our Board of Directors and a non-director executive officer, have indicated their preliminary interest in purchasing up to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our Common Stock and the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; accompanying Common Warrants resulting in aggregate expected gross proceeds to us of approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;million at the assumed combined public offering price. Because this indication of preliminary interest is not a binding agreement or commitment to purchase, such persons could determine to purchase more, fewer or no securities in this offering, or we could determine to sell more, fewer or no securities to them.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The shares of our Common Stock, or Pre-Funded Warrants in lieu thereof, and accompanying Common Warrants being offered will be sold in a single closing. The shares issuable upon exercise of the Pre-Funded Warrants or Common Warrants will be issued upon the exercise thereof. Because there is no minimum number of securities or minimum aggregate amount of proceeds for this offering to close, we may sell fewer than all of the securities offered hereby, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to pursue the business goals outlined in this prospectus. Because there is no escrow account and there is no minimum offering amount, investors could be in a position where they have invested in our company, but we are unable to fulfill our objectives due to a lack of interest in this offering. Also, any proceeds from the sale of securities offered by us will be available for our immediate use, despite uncertainty about whether we would be able to use such funds to effectively implement our business plan. The offering of the shares of our Common Stock, or Pre-Funded Warrants in lieu thereof, and accompanying Common Warrants will terminate no later than&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024; however, the shares of our Common Stock underlying the Pre-Funded Warrants and the Common Warrants will be offered on a continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Our Common Stock is listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;BCDA.&#8221; On &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024, the last reported closing sale price of our Common Stock on Nasdaq was $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; per share. There is no established trading market for any of the Common Warrants and we do not expect a market to develop. We do not intend to apply for a listing for the Pre-Funded Warrants or Common Warrants on any national securities exchange.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 58%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share and One-</b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Half Common </b></div>

			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Warrant</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td colspan="2" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%; border-bottom: 1px solid black;">
			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: center;"><b>Per Pre-Funded</b></div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: center;"><b>Warrant and One-</b></div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: center;"><b>Half Common </b></div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: center;"><b>Warrant</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 58%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Public offering price</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="nowrap: true; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 58%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Placement Agent Fees(1)</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="nowrap: true; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 58%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proceeds, before expenses, to us(2)</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="nowrap: true; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Upon the closing of this offering, we will pay the Placement Agent a cash placement commission equal to 7.0% of the aggregate gross proceeds to us from the sale of the shares of Common Stock, or Pre-Funded Warrants in lieu thereof, together with the accompanying Common Warrants, sold in this offering; provided, however, that such commission percentage will be reduced to a fee of up to 3.5% for any proceeds to us from sales to our directors, our executive officers or certain other identified purchasers (each, an &#8220;Identified Purchaser&#8221;) (collectively, the &#8220;Cash Fee&#8221;). No Cash Fee will be payable in respect of any Pre-Funded Warrant or Common Warrant exercises that may occur in the future. We have also agreed to reimburse the Placement Agent at closing (i) for legal and other expenses incurred by it in connection with the offering in an aggregate amount of up to $50,000, and (ii) non-accountable expenses payable to the Placement Agent of up to $10,000. See &#8220;Plan of Distribution&#8221; for a complete description of compensation payable to the Placement Agent.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-align: justify;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2)</div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The amount of proceeds, before expenses, to us does not give effect to any exercise of the Pre-Funded Warrants or Common Warrants.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investing in our securities involves a high degree of risk. See </b>&#8220;<b>Risk Factors</b>&#8221;<b> beginning on page 5</b><b>&#160;of this prospectus to read about the factors you should consider before buying our securities.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Delivery of the Common Stock, or Pre-Funded Warrants in lieu thereof, and Common Warrants to purchasers is expected to be made on or about&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2024.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>Sole Placement Agent</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 18pt; font-variant: normal; text-align: center; margin: 0pt;"><b>A.G.P.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b> </b>, 2024.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>TABLE OF CONTENTS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 95%;">&#160;</td>
			<td style="vertical-align: top; width: 5%; text-align: right;"><span style="text-decoration: underline;"><b>Page</b></span></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 95%;">&#160;</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">&#160;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PROSPECTUS SUMMARY</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">1</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">RISK FACTORS</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">5</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">9</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">MARKET, INDUSTRY AND OTHER DATA</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">10</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">USE OF PROCEEDS</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">11</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DIVIDEND POLICY</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">12</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CAPITALIZATION</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">13</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DILUTION</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">14</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DESCRIPTION OF SECURITIES</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">15</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF OUR COMMON STOCK, PRE-FUNDED WARRANTS AND COMMON WARRANTS</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">18</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PLAN OF DISTRIBUTION</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">25</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LEGAL MATTERS</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">26</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">EXPERTS</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">26</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">WHERE YOU CAN FIND MORE INFORMATION</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">26</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 95%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</div>
			</td>
			<td style="vertical-align: top; width: 5%; text-align: right;">26</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b>Neither we nor the Placement Agent have authorized anyone to provide any information or to make any representations other than those contained or incorporated by reference in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained or incorporated by reference in this prospectus is accurate only as of its date regardless of the time of delivery of this prospectus or of any sale of securities.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">For investors outside the United States, neither we nor the Placement Agent have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required. Persons outside the United States who come into possession of this prospectus and any free writing prospectus related to this offering are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus and any such free writing prospectus applicable to that jurisdiction.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">-i-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div class="PGBRDR" style="border: Black solid 1px; width: 98%; padding: 11px;">
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PROSPECTUS SUMMARY</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>This summary highlights certain information about us and this offering. Because it is a summary, it does not contain all of the information that you should consider before investing. Before investing in our securities, you should read this entire prospectus and the documents incorporated by reference carefully, including the </i>&#8220;<i>Risk Factors,</i>&#8221;<i> and the financial statements and accompanying notes and other information included and incorporated by reference in this prospectus. Unless otherwise indicated or the context otherwise requires, references in this prospectus to </i>&#8220;<i>BioCardia,</i>&#8221;<i> the </i>&#8220;<i>Company,</i>&#8221;&#160;&#8220;<i>we,</i>&#8221;&#160;&#8220;<i>us</i>&#8221;<i> and </i>&#8220;<i>our</i>&#8221;<i> refer to BioCardia, Inc. and its subsidiaries taken as a whole.</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our Business</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">We are a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. We are advancing two cell therapy platforms derived from the bone marrow in clinical trials today. Our CardiAMP&#174; autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Our immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as an &#8220;off the shelf&#8221; cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO&#8482;), which is actively enrolling, and acute respiratory distress syndrome (ARDS).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">Our autologous CardiAMP and our allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by our Helix&#8482; minimally invasive intramyocardial therapeutic delivery platform. We partner this therapeutic delivery platform and provide development services selectively with others seeking to develop biotherapeutic interventions for local delivery to the heart.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Associated with Our Business</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our business is subject to numerous risks and uncertainties that you should consider before investing in our company. See &#8220;Risk Factors&#8221; below. The principal factors and uncertainties that make investing in our company risky include, among others:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Business, Financial Condition and Capital Requirements</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We will require substantial additional financing to achieve our goals, and our failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We have a history of operating losses, and we may not be able to achieve or sustain profitability.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our existing and any future contractual arrangement that we expect will provide us access to capital may provide less capital than expected and on a delayed basis.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Development and Commercialization</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our success depends in large part on our ability to obtain approval for, and successfully commercialize, the CardiAMP Cell Therapy System. Because the CardiAMP Cell Therapy System is, to our knowledge, the first cardiac cell-based therapy with an accepted pivotal trial that is to be regulated by the FDA via the premarket approval pathway, the approval process for the CardiAMP Cell Therapy System is uncertain.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our cell therapy systems and other therapeutic candidates are based on novel technology, which makes it difficult to accurately and reliably predict the time and cost of product development and subsequently obtaining regulatory approval. At the moment, no cell-based therapies have been approved in the United States for a cardiac indication.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We have encountered, and may in the future encounter, substantial delays in our clinical studies.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We may find it difficult to enroll patients in our clinical trials, which could delay or prevent development of our therapeutic candidates.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We rely on third parties to conduct some or all aspects of our product manufacturing, diagnostic protocol development, research, and preclinical and clinical testing, and these third parties may not perform satisfactorily.</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>
</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-1-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div class="PGBRDR" style="border: Black solid 1px; width: 98%; padding: 11px;">
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We rely on third parties to conduct, supervise and monitor our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We depend on third-party vendors to manufacture some of our components and sub-assemblies, which could make us vulnerable to supply shortages and price fluctuations that could harm our business.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our future commercial success depends upon attaining significant market acceptance of our therapeutic candidates, if approved, among physicians, patients and healthcare payors.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our ability to compete is highly dependent on demonstrating the benefits of CardiAMP to physicians, hospitals and patients.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully, than we do.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our therapeutic candidates, if approved, we may be unable to generate any revenues.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We have limited experience manufacturing our therapeutic candidates or products in commercial quantities, which could harm our business.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If we fail to obtain and sustain an adequate level of reimbursement for our products by third-party payors, sales and profitability would be adversely affected.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Relating to Government Regulation, Compliance and Litigation</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Even if we obtain regulatory approval for a product candidate, including our cell therapy systems and other therapeutic candidates, these products or therapies, along with our other regulated products, will be subject to ongoing regulatory scrutiny.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory agencies.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If we fail to obtain and maintain necessary regulatory clearances or approvals for our therapeutic candidates or products, or if clearances or approvals for our therapeutic candidates or products in additional indications are delayed or not issued, our commercial operations would be harmed.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Serious adverse events or other safety risks could require us to abandon development and preclude, delay or limit approval of our therapeutic candidates or products or limit the scope of any approved indication or market acceptance.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our therapeutic candidates are intended to treat patients who are extremely ill, and patient deaths that occur in our clinical trials could negatively impact our business even if they are not shown to be related to our therapeutic candidates.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If we or our suppliers fail to comply with the FDA's QSRs, or QMSR, when it goes into effect in 2026, our manufacturing operations could be delayed or shut down and product sales could suffer.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The requirements to obtain regulatory approval of the FDA and regulators in other jurisdictions can be costly, time-consuming, and unpredictable. If we are unable to obtain timely regulatory approval for our therapeutic candidates, our business may be substantially harmed.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Even if we obtain and maintain approval for our therapeutic candidates or products from the FDA, we may never obtain approval for our therapeutic candidates or products outside of the United States, which would limit our market opportunities and adversely affect our business.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We may face competition from biosimilars due to changes in the regulatory environment.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">A recall of any of our commercialized products, or the discovery of serious safety issues, could have a significant negative impact on us.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Modifications to our products may require reclassifications, new regulatory approvals or clearances, or may require us to cease marketing or recall the modified products until new CE marking is obtained.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our employees, principal investigators, consultants and collaboration partners may engage in misconduct or other improper activities, including noncompliance with laws and regulatory standards and requirements and insider trading.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our therapeutic candidates or product.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to the Operation of Our Business</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop our therapeutic candidates, conduct our clinical trials and commercialize our therapeutic candidates.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations.</div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>
</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-2-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div class="PGBRDR" style="border: Black solid 1px; width: 98%; padding: 11px;">
<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our business and operations would suffer in the event of system failures.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Relating to Our Intellectual Property</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We may not be able to protect our proprietary technology in the marketplace.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The patent protection of biotherapeutics is complex and uncertain.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We may be forced to litigate to enforce or defend our intellectual property rights, and/or the intellectual property rights of our licensors.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Intellectual property disputes could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Patent reform legislation and recent court decisions could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If third parties claim that our therapeutic candidates or other products infringe upon their intellectual property, commercialization of our therapeutic candidates or products and our operating profits could be adversely affected.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity of our therapeutic candidates or products, our business may be materially harmed.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Securities</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">If we do not regain compliance with or continue to satisfy the Nasdaq continued listing requirements, our securities could be delisted from the Nasdaq.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We may be exposed to additional risks as a result of our reverse merger transaction.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Our annual and quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Raising additional funds through debt or equity financing could be dilutive and may cause the market price of our Common Stock to decline.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Future sales and issuances of our Common Stock or rights to purchase our Common Stock, including pursuant to the HCW Sales Agreement or under our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>General Risks</b></div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 9pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">We are at risk of securities class action litigation.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Implications of Being a Smaller Reporting Company</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&#160;the market value of our Common Stock held by non-affiliates exceeds $250 million as of the prior June&#160;30 or (ii)&#160;our annual revenue exceeded $100 million during such completed fiscal year and the market value of our Common Stock held by non-affiliates exceeds $700 million as of the prior June&#160;30.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Corporate Information</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our principal executive offices are located at 320 Soquel Way, Sunnyvale, California 94085. Our telephone number is (650) 226-0120. Our website address is www.biocardia.com. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act are available free of charge on our investor relations website as soon as reasonably practicable after we electronically file or furnish such material to the Securities and Exchange Commission (&#8220;SEC&#8221;). The SEC also maintains a website that contains these reports and our other electronic SEC filings. The information contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this prospectus.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>
</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-3-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div class="PGBRDR" style="border: Black solid 1px; width: 98%; padding: 11px;">
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>THE OFFERING</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common Stock offered</b>:</div>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;"><b>Pre-Funded Warrants offered:</b></td>
			<td style="vertical-align: bottom; width: 75%;">We are also offering to those purchasers whose purchase of Common Stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding Common Stock immediately following the closing of this offering, in lieu of purchasing Common Stock, Pre-Funded Warrants to purchase up to an aggregate of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our Common Stock. Each Pre-Funded Warrant is exercisable for one share of our Common Stock. The purchase price of each Pre-Funded Warrant is equal to the price at which a share of Common Stock is being sold to the public in this offering, minus $0.001, and the exercise price of each Pre-Funded Warrant is $0.001 per share. The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. This offering also relates to the shares of Common Stock issuable upon exercise of any Pre-Funded Warrants sold in this offering. For each Pre-Funded Warrant that we sell, the number of shares of Common Stock that we are offering will be reduced on a one-for-one basis.</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common Warrants offered:</b></div>
			</td>
			<td style="vertical-align: bottom; width: 75%;">Every share of our Common Stock, or Pre-Funded Warrant in lieu thereof, is being sold together with one half (1/2) of a Common Warrant. Each Common Warrant will be exercisable immediately for one share of our Common Stock, have an assumed initial exercise price equal to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;% of the combined public offering price per share of Common Stock and accompanying one-half Common Warrant in this offering (or $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;per share at such assumed combined public offering price), and will expire five years from the date of issuance. The shares of Common Stock, or Pre-Funded Warrants in lieu thereof, and Common Warrants are immediately separable and will be issued separately in this offering, but must initially be purchased together in this offering.</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common Stock to be&#160;</b><b>outstanding </b></div>

			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>after this&#160;</b><b>offering:</b></div>
			</td>
			<td style="vertical-align: top; width: 75%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Use of proceeds:</b></div>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">We estimate that the net proceeds from the offering will be approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;, based on an assumed combined public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;, after deducting Placement Agent fees and offering expenses payable by us.</div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&#160;</div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">We intend to use the net proceeds from this offering for working capital and general corporate purposes, which include, but are not limited to, advancing our investigational biotherapeutic candidates and our biotherapeutic delivery partnering business. See &#8220;Use of Proceeds.&#8221;</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Current market for the</b><br/>
			<b>securities:</b></div>
			</td>
			<td style="vertical-align: bottom; width: 75%;">Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;BCDA.&#8221; There is no established trading market for the Pre-Funded Warrants or Common Warrants and we do not expect a market to develop. In addition, we do not intend to apply for the listing of the Pre-Funded Warrants or Common Warrants on any national securities exchange or other trading market. Without an active trading market, the liquidity of the Pre-Funded Warrants and Common Warrants will be limited.</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Affiliate share purchases:</b></div>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">In addition, certain members of our Board of Directors and a non-director executive officer, have indicated their preliminary interest in purchasing up to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our Common Stock and the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; accompanying Common Warrants resulting in aggregate expected gross proceeds to us of approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;million at the assumed combined public offering price.</div>

			<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</div>

			<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Because this indication of preliminary interest is not a binding agreement or commitment to purchase, such persons could determine to purchase more, fewer or no securities in this offering, or we could determine to sell more, fewer or no securities to them.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;"><b>Best efforts offering:</b></td>
			<td style="vertical-align: bottom; width: 75%;">We have agreed to offer and sell the securities offered hereby to the purchasers through the Placement Agent. The Placement Agent is not required to buy or sell any specific number or dollar amount of the securities offered hereby, but will use its reasonable best efforts to solicit offers to purchase the securities offered by this prospectus. See &#8220;Plan of Distribution&#8221; on page 25 of this prospectus.&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">&#160;</td>
			<td style="vertical-align: bottom; width: 75%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 25%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risk Factors:</b></div>
			</td>
			<td style="vertical-align: bottom; width: 75%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">You should carefully read &#8220;Risk Factors&#8221;&#160;beginning on page 5 and other information included in this prospectus for a discussion of factors that you should consider before deciding to invest in our securities.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The number of shares of Common Stock to be outstanding after the offering is based on 2,123,876 shares of Common Stock outstanding as of July 31, 2024, and excludes:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; shares of Common Stock issuable upon exercise of the Pre-Funded Warrants;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of Common Stock issuable upon exercise of the Common Warrants;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">153,290 shares of Common Stock issuable upon exercise of stock options outstanding under our equity incentive plans, with a weighted-average exercise price of $52.43 per share&#894;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">208,993 shares of Common Stock issuable upon exercise of our other outstanding warrants to purchase Common Stock, with a weighted average exercise price of $66.30 per share; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99,675 shares of Common Stock available for future issuance under our 2016 Equity Incentive Plan.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Unless expressly indicated or the context requires otherwise, all information in this prospectus is as of July 31, 2024, assumes no exercise of any outstanding warrants or options described above.&#160;Also, except as otherwise indicated, all information in this prospectus assumes no exercise of any Pre-Funded Warrants or Common Warrants.</div>
</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-4-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>RISK FACTORS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"><i>Investing in our securities involves a high degree of risk.</i>&#160;<i>Before making an investment decision, you should carefully consider the risks described below, and those discussed under the headings </i>&#8220;<i>Risk Factors</i>&#8221;<i> contained in our Quarterly Reports on Form</i>&#160;<i>10-Q for the quarters ended March 31, 2024 and June 30, 2024, and our Annual Report on Form</i>&#160;<i>10-K for the year ended December</i>&#160;<i>31, 2023, which are incorporated by reference into this prospectus, together with the other information contained in this prospectus and the documents incorporated by reference herein.</i>&#160;<i>If any of these risks is realized, our business, financial condition, results of operations and prospects could be materially and adversely affected.</i>&#160;<i>In that event, the trading price of our securities could decline and you could lose part or all of your investment.</i>&#160;<i>Additional risks and uncertainties that are not yet identified or that we think are immaterial may also materially harm our business, operating results and financial condition and could result in a complete loss of your investment.</i></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>If we do not regain compliance with or continue to satisfy the Nasdaq continued listing requirements, our Common Stock could be delisted from the Nasdaq.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The listing of our Common Stock on the Nasdaq is contingent on our compliance with the Nasdaq&#8217;s conditions for continued listing. We are currently not in compliance with Nasdaq listing requirements, specifically the requirement to maintain a minimum market value of listed securities of at least $35.0 million (&#8220;MVLS Requirements&#8221;), and we were previously not in compliance with the Nasdaq listing requirement&#160;to maintain a minimum $1.00 per share closing bid price for our Common Stock (&#8220;Minimum Bid Price Requirement&#8221;). On March 6, 2024, and March 12, 2024, we received delisting determination letters from the Nasdaq advising us that we did not regain compliance with the MVLS Requirement and the Minimum Bid Price Requirement, respectively, by the initial compliance dates afforded by the Nasdaq. As a result, trading of our securities on the Nasdaq was subject to suspension at the opening of business on March 15, 2024, and a Form 25-NSE would have been filed with the SEC to remove our securities from listing and registration on the Nasdaq unless we requested an appeal of these determinations to a Nasdaq Hearings Panel (&#8220;Panel&#8221;). On March 12, 2024, we submitted a hearing request to the Panel to appeal the delisting determinations. Our request for a hearing stayed the suspension of our securities and the filing of a Form 25-NSE pending the Panel&#8217;s decision. Following our hearing with the Panel, on May 13, 2024, the Panel granted our request for continued listing on Nasdaq subject to, among other things, (i) us maintaining compliance with the Minimum Bid Price Requirement for ten consecutive trading days on or before June 24, 2024, which occurred following a reverse stock split, and (ii) us demonstrating compliance with minimum stockholders&#8217; equity continued listing requirements under Nasdaq rules on or before September 2, 2024.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">If we fail to demonstrate our compliance with the requirements of the Panel&#8217;s order, our Common Stock will be subject to delisting by the Nasdaq. In the event our Common Stock is no longer listed for trading on Nasdaq, our trading volume and share price may decrease and we may experience further difficulties in raising capital, which could materially affect our operations and financial results. Further, delisting from the Nasdaq could also have other negative effects, including potential loss of confidence by partners, lenders, suppliers and employees and could also trigger various defaults under our financing arrangements and other outstanding agreements.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Management will have broad discretion as to the use of proceeds from this offering and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our management will have broad discretion over the use of proceeds from this offering, including for any of the purposes described in the section of this prospectus entitled &#8220;Use of Proceeds,&#8221; and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our Common Stock. You may not agree with our decisions, and our use of the proceeds may not yield any return on your investment. Our failure to apply the net proceeds from the sale of our shares in this offering could effectively have a material adverse effect on our business, delay the development of our products, compromise our ability to pursue our business strategy, and cause the price of our Common Stock to decline, and we might not be able to yield a significant return, if any, on our investment of these net proceeds.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-5-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>You will experience immediate dilution in the book value per share of the Common Stock you purchase.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">You will incur immediate and substantial dilution as a result of this offering.&#160;The assumed combined public offering price per share of Common Stock and accompanying one-half Common Warrant of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;and assumed combined public offering price per Pre-Funded Warrant and accompanying one-half Common Warrant of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;are substantially higher than the as adjusted net tangible book value per share of our Common Stock.&#160;If you purchase Common Stock in this offering, you will incur immediate and substantial dilution of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;per share in the as adjusted net tangible book value of shares of our Common Stock, based on the assumed offering price per share of Common Stock and accompanying one-half Common Warrant of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;.&#160;In addition, the purchase of Common Warrants in this offering will not result in the immediate acquisition of shares of our Common Stock unless and until you exercise the purchased Common Warrants.&#160;As a result of the dilution to investors purchasing shares in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of liquidation. In addition, to the extent outstanding options and warrants are ultimately exercised, there will be further dilution of the securities sold in this offering.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we raise additional capital through the sale of shares of our Common Stock, convertible securities or debt in the future, your ownership in us could be diluted and restrictions could be imposed on our business. </i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We may issue shares of our Common Stock or securities convertible into our Common Stock to raise additional capital in the future. While this offering may not be consummated due to a variety of reasons, including the SEC not declaring the registration statement effective, poor market conditions or a decline in the trading price of our Common Stock, to the extent we issue such securities, our stockholders may experience substantial dilution and the trading price of our Common Stock could decline. If we obtain funds through a credit facility or through the issuance of debt or preferred securities, such debt or preferred securities could have rights senior to your rights as a common shareholder, which could impair the value of our Common Stock.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Sales of a substantial number of shares of our Common Stock in the public market or raising additional funds through debt or equity financing could cause our stock price to fall. </i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic collaborations or partnerships, or marketing, distribution or licensing arrangements with third parties, we may be required to limit valuable rights to our intellectual property, technologies, therapeutic candidates or future revenue streams, or grant licenses or other rights on terms that are not favorable to us. Furthermore, any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our therapeutic candidates.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Sales of a substantial number of shares of our Common Stock in the public market or the perception that these sales might occur, could depress the market price of our Common Stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our Common Stock. A substantial number of shares of Common Stock are being offered by this prospectus supplement. We cannot predict the number of these shares that might be sold nor the effect that future sales of the shares of our Common Stock would have on the market price of our Common Stock.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have not paid dividends in the past and do not expect to pay dividends in the future, and, as a result, any return on investment may be limited to the value of our stock. </i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have never paid dividends and do not anticipate paying dividends in the foreseeable future. The payment of dividends will depend on our earnings, capital requirements, financial condition, prospects and other factors our board of directors may deem relevant. If we do not pay dividends, our stock may be less valuable because a return on your investment will only occur if our stock price appreciates and you sell our Common Stock thereafter.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The market price and trading volume of our Common Stock may be volatile and may be affected by economic conditions beyond our control.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The market price of our Common Stock is likely to be volatile. Some specific factors that could negatively affect the price of our Common Stock or result in fluctuations in its price and trading volume include:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">results of clinical trials of our therapeutic candidates;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-6-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">results of clinical trials of our competitors&#8217;&#160;products;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">regulatory actions with respect to our therapeutic candidates or products or our competitors&#8217;&#160;products;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">actual or anticipated fluctuations in our quarterly operating results or those of our competitors;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">publication of research reports by securities analysts about us or our competitors in the industry;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our failure or the failure of our competitors to meet analysts&#8217;&#160;projections or guidance that we or our competitors may give to the market;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our liquidity positions;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">issuances by us of debt or equity securities;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">litigation involving our company, including stockholder litigation, investigations or audits by regulators into the operations of our company, or proceedings initiated by our competitors or clients;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the passage of legislation or other regulatory developments affecting us or our industry, fluctuations in the valuation of companies perceived by investors to be comparable to us;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">trading volume of our Common Stock and warrants;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">sales or perceived potential sales of our Common Stock and/or warrants by us, our directors, senior management or our stockholders in the future;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">short selling or other market manipulation activities;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">announcement or expectation of additional financing efforts;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">terrorist acts, acts of war or periods of widespread civil unrest;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">natural disasters, pandemics and other calamities;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">changes in market conditions for biopharmaceutical stocks; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">conditions in the U.S. financial markets or changes in general economic conditions, including as a result of inflation and changes in interest rates.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our Common Stock, the price and trading volume of our securities could decline.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The trading market for our Common Stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If no or few securities or industry analysts commence coverage of us, the trading price for our Common Stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, the price of our Common Stock would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause the price or trading volume of our Common Stock to decline.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-7-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Participation in this offering by certain of our affiliates would reduce the available public float of our Common Stock. </i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Certain members of our Board of Directors and a non-director executive officer have indicated an interest in purchasing up to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; shares of our Common Stock and the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; accompanying Common Warrants in this offering at the combined public offering price per share of Common Stock and accompanying one-half Common Warrant. However, because indications of interest are not binding agreements or commitments to purchase, we could determine to sell more, fewer or no securities such potential purchasers, and such potential purchasers could determine to purchase more, fewer or no securities in this offering. Moreover, no guarantee will be or has been given by us or the Placement Agent as to the final allocation to any of the aforementioned persons or other persons, that any allocation will be made to them, or as to the size of any such allocation. To the extent such members of the Board of Directors and non-director executive officer participate in this offering, such purchases would reduce the non-affiliate public float for our Common Stock, meaning the number of shares of Common Stock that are not held by officers, directors and controlling shareholders. A reduction in the public float could reduce the number of shares of Common Stock that are available to be traded at any given time, thereby adversely impacting the liquidity of our Common Stock and depressing the price at which you may be able to sell Common Stock purchased in this offering.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The Common Warrants are speculative in nature.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The Common Warrants, which have an initial exercise price of $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; per share of Common Stock, subject to adjustments, are exercisable beginning on the issuance date and will expire five years from the date of issuance. If the price of the Common Stock does not increase to an amount sufficiently above the exercise price of the Common Warrants during the period during which the Common Warrants are exercisable, you will be unable to recover any of your investment in the Common Warrants. In such event, the Common Warrants will not have any value.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">There can be no assurance that the market price of the Common Stock will ever equal or exceed the exercise price of the Common Warrants, and consequently, whether it will ever be profitable for holders of the Common Warrants to exercise such Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><b>There is no public market for the Pre-Funded Warrants or Common Warrants.</b></i></div>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">There is no established public trading market for the Pre-Funded Warrants or Common Warrants and we do not expect a market to develop. In addition, we do not intend to apply for listing of the Pre-Funded Warrants or Common Warrants on any securities exchange. Without an active market, the liquidity of such warrants will be limited.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Holders of Pre-Funded Warrants or Common Warrants will have no rights as a common stockholder until they acquire our Common Stock.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Until you acquire shares of our Common Stock upon exercise of your Pre-Funded Warrants or Common Warrants, you will have no rights with respect to shares of our Common Stock issuable upon exercise of your Pre-Funded Warrants or Common Warrants.&#160; Upon exercise of your Pre-Funded Warrants or Common Warrants, you will be entitled to exercise the rights of a holder of our Common Stock only as to matters for which the record date occurs after the exercise date.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>The reasonable best efforts structure of this offering may have an adverse effect on our business plan.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Placement Agent is offering the shares of Common Stock, or Pre-Funded Warrants, and accompanying Common Warrants on a &#8220;reasonable best efforts&#8221; basis, and the Placement Agent is under no obligation to purchase any securities for its own account. The Placement Agent is not required to sell any specific number or dollar amount of shares of Common Stock, or Pre-Funded Warrants, and accompanying Common Warrants in this offering but will use its best efforts to sell the securities offered in this prospectus supplement. As a &#8220;reasonable best efforts&#8221; offering, there can be no assurance that the offering contemplated hereby will ultimately be consummated or will result in any proceeds being made available to us or, if consummated, the amount of proceeds to be received. The success of this offering will impact our ability to use the proceeds to execute our business plan. An adverse effect on the business may result from raising less than anticipated and from the fact that there is no minimum raise.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Purchasers who purchase our securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement. </i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In addition to rights and remedies available to all purchasers in this offering under federal securities and state law, the purchasers that enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract provides those investors with the means to enforce the covenants uniquely available to them under the securities purchase agreement.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may redeem your unexercised Common Warrants on or after the Redemption Conditions are satisfied, and they will have no value after such redemption.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We may redeem all unexercised Common Warrants at our sole option at any time on or after the Redemption Conditions (as defined below) are satisfied. If we redeem your unexercised Common Warrants at a redemption price of $0.001 per Common Warrant, such Common Warrants will cease to be outstanding after the redemption date.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>If we do not maintain a current and effective registration statement relating to the Common Stock issuable upon exercise of the Pre-Funded Warrants and Common Warrants being offered in this offering, holders will be able to exercise such warrants on a </i></b>&#8220;<b><i>cashless</i></b>&#8221;<b><i> basis and we may not receive any additional funds upon the exercise of such warrants.</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">If we do not maintain a current and effective registration statement relating to the Common Stock issuable upon exercise of the Pre-Funded Warrants and Common Warrants being offered in this offering, such warrants may be exercised by way of a &#8220;cashless&#8221; exercise, meaning that the holder would not pay a cash purchase price upon exercise, but instead would receive upon such exercise the net number of shares of our Common Stock determined according to the formula set forth in the warrant. Accordingly, we may not receive any additional funds upon the exercise of such warrants.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-8-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This prospectus and the documents we have filed with the SEC that are incorporated by reference in this prospectus contain certain statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements, including statements regarding (i) expectations concerning our ability to raise additional funding from equity or debt financings and to continue as a going concern; (ii) our ability to retain the listing of our securities on the Nasdaq Capital Market; (iii) the plans and objectives of management for future operations, including plans or objectives relating to the development of our cell therapy systems; (iv) the timing and conduct of the clinical trials for our products, including statements regarding the timing, progress and results of current and future preclinical studies and clinical trials as well as our research and development programs; (v) the timing or likelihood of regulatory filing, approvals and required licenses for our cell therapy systems; (vi) our ability to adequately protect our intellectual property rights and enforce such rights to avoid violation of the intellectual property rights of others; (vii) the timing, costs and other aspects of the commercial launch of our products; (viii) our estimates regarding the market opportunity, clinical utility, potential advantages and market acceptance of our products; (ix) the impact of government laws and regulations; (x) our ability to recruit and retain qualified clinical, regulatory and research and development personnel; (xi) the availability of reimbursement or other forms of funding for our products from government and commercial payors; (xii) difficulties in maintaining commercial scale manufacturing capacity and capability and our ability to generate growth; (xiii) uncertainty in industry demand; (xiv) general economic conditions and market conditions in our industry; (xv) the effects of pandemics on our business, preclinical studies and clinical trials; (xvi) the depth of the trading market in our securities; (xvii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (xviii) our future financial performance, including any such statement contained in a discussion and analysis of financial condition by management or in the results of operations included pursuant to the rules and regulations of the SEC; and (xix) the assumptions underlying or relating to any statement described in points (i)-(xix) above. These statements are not guarantees of future performance and are subject to numerous risks, uncertainties, and assumptions that are difficult to predict. The words &#8220;may,&#8221; &#8220;might,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;pro-forma,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;strategy,&#8221; &#8220;anticipate,&#8221; &#8220;attempt,&#8221; &#8220;develop,&#8221; &#8220;plan,&#8221; &#8220;help,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;future,&#8221; and similar expressions (including the negative of any of the foregoing) are intended to identify forward-looking statements. Those statements appear in this prospectus and the documents we have filed with the SEC that are incorporated by reference in this prospectus, particularly in the sections captioned &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and include statements regarding the intent, belief or current expectations of our management that are subject to known and unknown risks, uncertainties and assumptions. You are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely upon forward-looking statements as predictions of future events. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we do not plan to publicly update or revise any forward-looking statements contained herein after we distribute this prospectus or any free writing prospectus, as applicable, whether as a result of any new information, future events or otherwise.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This prospectus and the information incorporated by reference herein and therein include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus are the property of their respective owners.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-9-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>MARKET, INDUSTRY AND OTHER DATA</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This prospectus and the documents incorporated by reference in this prospectus contain estimates and information concerning our industry, including market size and growth rates of the markets in which we participate, that are based on industry publications and reports. We relied on industry, market data, peer reviewed journals, formal presentations at medical society meetings and other sources. We also rely on our own research and estimates in this prospectus. This information involves a number of assumptions and limitations, and you are cautioned not to give undue weight to these estimates. We have not independently verified the accuracy or completeness of the data contained in these industry publications and reports. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section entitled &#8220;Risk Factors,&#8221; and in the &#8220;Risk Factors&#8221; section in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023 and our Quarterly Reports on Form&#160;10-Q for the quarters ended March 31, 2024 and June 30, 2024, which are incorporated by reference herein. These and other factors could cause results to differ materially from those expressed in these publications and reports.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-10-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>USE OF PROCEEDS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We estimate that the net proceeds to us from the issuance and sale of securities in this offering will be approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;, based on an assumed combined public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;per share of Common Stock and accompanying one-half Common Warrant or an assumed combined public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;per Pre-Funded Warrant and accompanying one-half Common Warrant, after deducting Placement Agent fees and offering expenses payable by us. This amount excludes the proceeds, if any, from the exercise of any Pre-Funded Warrants and the Common Warrants issued in this offering. If all of the Common Warrants sold in this offering were to be exercised in cash at an assumed exercise price of $&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share, we would receive additional net proceeds of approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;million. We cannot predict when or if these Common Warrants will be exercised. It is possible that the Common Warrants may expire and may never be exercised. Additionally, because this is a &#8220;best efforts&#8221; offering and there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, the Placement Agent&#8217;s fees and net proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover page of this prospectus. As a result, we may receive significantly less in net proceeds. Based on the assumed offering price set forth above, we estimate that our net proceeds from the sale of 75%, 50%, and 25% of the securities offered in this offering would be approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;million, $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;million, and $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;million, respectively, after deducting the estimated Placement Agent fees and estimated offering expenses payable by us, and assuming we do not issue any Pre-Funded Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We intend to use the net proceeds from this offering for general corporate purposes, which may include working capital and other general corporate purposes, which include, but are not limited to, advancing our investigational biotherapeutic candidates and our biotherapeutic delivery partnering business.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The expected use of net proceeds of this offering represents our current intentions based on our present plans and business conditions. We cannot specify with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering. Pending these uses, we plan to invest the net proceeds of this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-11-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DIVIDEND POLICY</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We have never declared or paid any cash dividend on our capital stock. We currently intend to retain any future earnings and do not expect to pay any dividends in the foreseeable future. Any determination to declare or pay dividends in the future will be at the discretion of our board of directors and will depend on a number of factors, including our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-12-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CAPITALIZATION</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following table sets forth our capitalization as of June 30, 2024 on:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">an actual basis; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">an as adjusted basis, giving effect to the sale and issuance of securities by us in this offering, based on an assumed combined public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;per share and accompanying one-half Common Warrant, after deducting Placement Agent fees and estimated offering expenses payable by us. The as adjusted basis assumes no sale of Pre-Funded Warrants, which, if sold, would reduce the number of shares of Common Stock that we are offering on a one-for-one basis, and excludes the proceeds, if any, from the exercise of any Pre-Funded Warrants or Common Warrants.</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">You should read this table together with the section of our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2023 and our Quarterly Report on Form&#160;10-Q for the quarter ended June 30, 2024 entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our financial statements and related notes included therein, each of which incorporated by reference in this prospectus.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of June 30, 2024</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Actual</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As Adjusted<span style="font-size:9pt;"><sup style="vertical-align:top;line-height:120%;">(1)</sup></span></b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>(Unaudited, in thousands, except share and per share data)</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#160;</b></td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash, cash equivalents and short-term investments</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Long-term debt</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Stockholders&#8217; equity:</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Convertible preferred stock, $0.001 par value; 25,000,000 shares authorized, no shares issued and outstanding, actual and as adjusted</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Common stock, par value $0.001; 50,000,000 shares authorized, 2,123,876 shares issued and outstanding, actual; 50,000,000 shares authorized and&#160; &#160; &#160; &#160; &#160; &#160; &#160; shares issued and outstanding, as adjusted</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Additional paid-in capital</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accumulated other comprehensive income</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Accumulated deficit</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stockholders&#8217; equity</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total capitalization</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1)</div>
			</td>
			<td style="width: auto;">
			<div style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A $&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160;increase (decrease) in the assumed combined public offering price per share of Common Stock and accompanying one-half Common Warrant of $ would increase (decrease) the as adjusted amount of additional paid-in capital, total stockholders&#8217; equity and total capitalization by approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;($&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;) assuming that the number of shares of Common Stock offered by us as set forth on the cover page of this prospectus remains the same and after deducting estimated Placement Agent fees and estimated offering expenses payable by us and assuming no exercise of Common Warrants or sale of Pre-Funded Warrants. An increase (decrease) of in the number of shares of Common Stock and accompanying Common Warrants offered by us would increase (decrease) the as adjusted amount of additional paid-in capital, total stockholders&#8217; equity and total capitalization by approximately $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;($&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;), assuming no change in the assumed combined public offering price per share of Common Stock and accompanying one-half Common Warrant, and after deducting estimated Placement Agent fees and estimated offering expenses payable by us.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The number of shares of Common Stock to be outstanding after the offering is based on 2,123,876 shares of Common Stock outstanding as of June 30, 2024, and excludes:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; shares of Common Stock issuable upon exercise of the Pre-Funded Warrants;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of Common Stock issuable upon exercise of the Common Warrants;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">155,642 shares of Common Stock issuable upon exercise of stock options outstanding under our equity incentive plans, with a weighted-average exercise price of $52.85 per share;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">208,993 shares of Common Stock issuable upon exercise of our other outstanding warrants to purchase Common Stock, with a weighted average exercise price of $66.30 per share; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">97,323 shares of Common Stock available for future issuance under our 2016 Equity Incentive Plan.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-13-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DILUTION</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">If you purchase our Common Stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the combined public offering price per share of Common Stock and accompanying one-half Common Warrant and the net tangible book value per share of our Common Stock immediately after this offering.&#160;Net tangible book value per share is determined by dividing the number of shares of Common Stock outstanding as of June 30, 2024 into our total tangible assets less total liabilities.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our net tangible book value as of June 30, 2024 was approximately $ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; million, or $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; per share, based on 2,123,876 shares of our Common Stock outstanding as of that date.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">After giving effect to the sale of securities by us at the assumed combined public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;per share of Common Stock and accompanying one-half Common Warrant, and after deducting the Placement Agent fees and estimated offering expenses payable by us and assuming no exercise of Common Warrants in the offering, our as adjusted net tangible book value as of June 30, 2024 would have been $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;million, or $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;per share.&#160;This represents an immediate increase in net tangible book value of $ per share to existing stockholders and immediate dilution of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;per share to investors in this offering. The dilution figures assume no sale of Pre-Funded Warrants, which, if sold, would reduce the number of shares of Common Stock that we are offering on a one-for-one basis and excludes the proceeds, if any, from the exercise of any Pre-Funded Warrants or Common Warrants issued in this offering.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The following table illustrates this dilution on a per share basis:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">Assumed combined public offering price per share of Common Stock and accompanying one-half Common Warrant</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Net tangible book value per share as of June 30, 2024</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Increase in net tangible book value per share attributable to investors participating in this offering</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">As adjusted net tangible book value per share after giving effect to this offering</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Dilution per share to investors in this offering</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Each $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;increase (decrease) in the assumed combined public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;per share of Common Stock and accompanying one-half Common Warrant would increase (decrease) the as adjusted net tangible book value by $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;per share and the dilution to investors participating in this offering by $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;per share, assuming the number of shares of Common Stock, or Pre-Funded Warrants in lieu thereof, and accompanying Common Warrants offered by us as set forth on the cover page of this prospectus, remains the same, and after deducting estimated Placement Agent fees and estimated expenses payable by us. Similarly, an increase of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;in the shares of Common Stock, or Pre-Funded Warrants in lieu thereof, and accompanying Common Warrants offered by us, as set forth on the cover page of this prospectus, would increase the as adjusted net tangible book value by $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;per share and decrease the dilution to investors participating in this offering by $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;per share, assuming the assumed combined public offering of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;remains the same and after deducting estimated Placement Agent fees and estimated offering expenses payable by us. Conversely, a decrease of &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;in the shares of Common Stock, or Pre-Funded Warrants in lieu thereof, and accompanying Common Warrants offered by us, as set forth on the cover page of this prospectus, would decrease the as adjusted net tangible book value by $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;per share and increase the dilution to investors participating in this offering by $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;per share, assuming the assumed combined public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;per share of Common Stock and accompanying one-half Common Warrant remains the same and after deducting estimated Placement Agent fees and estimated offering expenses payable by us.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The table and discussion above based on 2,123,876 shares of Common Stock outstanding as of June 30, 2024, and excludes:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; shares of Common Stock issuable upon exercise of the Pre-Funded Warrants;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of Common Stock issuable upon exercise of the Common Warrants;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">155,642 shares of Common Stock issuable upon exercise of stock options outstanding under our equity incentive plans, with a weighted-average exercise price of $52.85 per share;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">208,993 shares of Common Stock issuable upon exercise of our other outstanding warrants to purchase Common Stock, with a weighted average exercise price of $66.30 per share; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">97,323 shares of Common Stock available for future issuance under our 2016 Equity Incentive Plan.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">To the extent that additional shares are issued pursuant to the foregoing, investors purchasing our Common Stock in this offering will experience further dilution. In addition, we may offer other securities in other offerings due to market conditions or strategic considerations. To the extent we issue such securities, you may experience further dilution.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-14-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;"><b>DESCRIPTION OF SECURITIES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Capital Stock</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The description of our capital stock is incorporated by reference to Exhibit 4.10 to our Annual Report on Form 10&#8209;K for the fiscal year ended December 31, 2023, filed with the SEC on March 27, 2024.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Pre-Funded Warrants</b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The following summary of certain terms and conditions of the Pre-Funded Warrants is not complete and is subject to, and qualified in its entirety by, the provisions of Pre-Funded Warrant, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of Pre-Funded Warrant for a complete description of the terms and conditions of the Pre-Funded Warrants.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>General</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The term &#8220;pre-funded&#8221; refers to the fact that the purchase price of the Pre-Funded Warrants in this offering includes almost the entire exercise price that will be paid under the Pre-Funded Warrants, except for a nominal remaining exercise price of $0.001 per share. The purpose of the Pre-Funded Warrants is to enable investors that may have restrictions on their ability to beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of our outstanding Common Stock following the consummation of this offering the opportunity to invest capital into the Company without triggering their ownership restrictions, by receiving Pre-Funded Warrants in lieu of shares of our Common Stock, which would result in such ownership of more than 4.99% (or, at the election of the holder, 9.99%), and receiving the ability to exercise their option to purchase the shares underlying the Pre-Funded Warrants at a nominal price at a later date.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Form</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Pre-Funded Warrants will be issued as individual warrant agreements to the investors. You should review the form of Pre-Funded Warrant, filed as an exhibit to the registration statement of which this prospectus forms a part, for a complete description of the terms and conditions applicable to the Pre-Funded Warrants.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Exercisability</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Pre-Funded Warrants are exercisable at any time after their original issuance. The Pre-Funded Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full in immediately available funds for the number of shares of our Common Stock purchased upon such exercise (except in the case of a cashless exercise as described below). A holder (together with its affiliates) may not exercise any portion of the Pre-Funded Warrant to the extent that the holder would own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding Common Stock immediately after exercise, except that upon at least 61 days&#8217; prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder&#8217;s Pre-Funded Warrants up to 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. Purchasers of Pre-Funded Warrants in this offering may also elect prior to the issuance of the Pre-Funded Warrants to have the initial exercise limitation set at 9.99% of our outstanding Common Stock. No fractional shares of Common Stock will be issued in connection with the exercise of a Pre-Funded Warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Duration and Exercise Price</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The exercise price per whole share of our Common Stock purchasable upon the exercise of the Pre-Funded Warrants is $0.001 per share of Common Stock. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until the Pre-Funded Warrants are exercised in full. The exercise price of the Pre-Funded Warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our Common Stock and also upon any distributions of assets, including cash, stock or other property to our stockholders.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Cashless Exercise</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">If, at any time after the issuance of the Pre-Funded Warrants, the holder exercises its Pre-Funded Warrants and a registration statement registering the issuance of the shares of Common Stock underlying the Pre-Funded Warrants under the Securities Act is not then effective or available (or a prospectus is not available for the resale of shares of Common Stock underlying the Pre-Funded Warrants), then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder shall instead receive upon such exercise (either in whole or in part) only the net number of shares of Common Stock determined according to a formula set forth in the Pre-Funded Warrants. Notwithstanding anything to the contrary, in the event we do not have or maintain an effective registration statement, there are no circumstances that would require us to make any cash payments or net cash settle the Pre-Funded Warrants to the holders.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Transferability</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Subject to applicable laws, the Pre-Funded Warrants may be offered for sale, sold, transferred or assigned at the option of the holder upon surrender of the Pre-Funded Warrant to us together with the appropriate instruments of transfer.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-15-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Exchange Listing</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">There is no established trading market for the Pre-Funded Warrants and we do not plan on applying to list the Pre-Funded Warrants on The Nasdaq Capital Market any other national securities exchange or any other nationally recognized trading system.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Rights as a Stockholder</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Except by virtue of such holder&#8217;s ownership of shares of our Common Stock, the holder of a Pre-Funded Warrant does not have the rights or privileges of a holder of our Common Stock, including any voting rights, until the holder exercises the Pre-Funded Warrant.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Common Warrants</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The following summary of certain terms and provisions of the Common Warrants offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the form of Common Warrant, which is filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions set forth in the form of Common Warrant.&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Duration and Exercise Price</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Each Common Warrant offered hereby will have an assumed initial exercise price per share equal to $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;(assuming an exercise price equal to &#160;&#160;&#160;&#160;&#160;% of the combined public offering price per share of Common Stock and accompanying one-half Common Warrant in this offering). The Common Warrants will be immediately exercisable and will expire five years from the date of issuance. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our Common Stock and the exercise price.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Exercisability</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Common Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our Common Stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of the Common Warrant to the extent that the holder would own more than 4.99% (or, at the election of the purchaser, 9.99%) of the outstanding Common Stock immediately after exercise, except that upon notice from the holder to us, the holder may increase or decrease the beneficial ownership limitation up to 9.99% of the number of shares of our Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Common Warrants, provided that any change in such beneficial ownership limitation shall not be effective until 61 days following notice from the holder to us. No fractional shares of Common Stock will be issued in connection with the exercise of a Common Warrant. In lieu of fractional shares, we will, at our election, either pay a cash adjustment in respect of such fractional amount or round up to the next whole share.&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Cashless Exercise</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">If, at the time a holder exercises its Common Warrants, a registration statement registering the issuance of the shares of Common Stock underlying the Common Warrants under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), is not then effective or available, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Common Warrants.&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Transferability</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Subject to applicable laws, the Common Warrants may be transferred at the election of the holder upon surrender of the Common Warrant to the Company together with the appropriate instruments of transfer.&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Exchange Listing</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">There is no established public trading market for the Common Warrants, and we do not expect a market to develop. In addition, we do not intend to list the Common Warrants on any securities exchange or nationally recognized trading system.&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Fundamental Transaction</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">If, at any time while the Common Warrants are outstanding, we effect a Fundamental Transaction, then upon any subsequent exercise of Common Warrants, the holders thereof will have the right to receive the same amount and kind of securities, cash or property as they would have been entitled to receive upon the occurrence of such Fundamental Transaction if they had been, immediately prior to such Fundamental Transaction, the holder of the number of shares of Common Stock then issuable upon exercise of those Common Warrants, or any other consideration payable as part of the Fundamental Transaction.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-16-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Redemption at the Option of the Company</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Common Warrants may be redeemed at our option, in whole or in part on a pro rata basis, any at any time upon the occurrence of (i)&#160;our submission of an application for approval of our CardiAMP Cell Therapy System with the Japanese Pharmaceuticals and Medical Devices Agency (such submission date, the &#8220;Japanese Regulatory Filing Date&#8221; and, such event, the &#8220;PMDA Submission&#8221;) and (ii)&#160;our Common Stock closing at a price that is at or above &#160;&#160;&#160;&#160;&#160;% of the exercise price of the Common Warrants for &#160;&#160;&#160;&#160;&#160;&#160;of &#160;&#160;&#160;&#160;&#160;&#160;trading days for any period starting &#160;&#160;&#160;&#160;&#160;&#160;trading days prior to the Japanese Regulatory Filing Date (the &#8220;Trading Condition&#8221; and, together with the PMDA Submission, the &#8220;Redemption Conditions&#8221;), at a redemption price of $0.001 per Common Warrant (the &#8220;Redemption Price&#8221;). As more fully described in the Common Warrants, we shall provide prompt notice to the holders following the PMDA Submission (the &#8220;First Notice&#8221;) and upon meeting the Redemption Conditions (the &#8220;Second Notice&#8221;). Following or concurrently with the delivery of the Second Notice, the Company may, at its option, notify holders of its election to redeem the Common Warrants (the &#8220;Redemption Notice&#8221;), which notice shall be sent promptly to holders. From and after the date on which the Common Warrants are redeemed, holders of redeemed Common Warrants will have no further rights pursuant to the Common Warrants except to receive payment of the Redemption Price upon surrender of their warrant certificates and the Common Warrants will be deemed cancelled and void.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Common Warrants noticed for redemption may not be exercised at any time after notice of redemption shall have been given by the Company and prior to the redemption date unless the Company defaults on payment of the Redemption Price on the redemption date.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Right as a Stockholder</i></b></div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;Except as otherwise provided in the Common Warrants or by virtue of such holder&#8217;s ownership of shares of our Common Stock, the holders of the Common Warrants do not have the rights or privileges of holders of our Common Stock, including any voting rights, until they acquire shares of our Common Stock upon exercise of their Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Listing</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Our Common Stock is listed on Nasdaq under the symbol &#8220;BDCA.&#8221;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-17-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 36pt; text-align: center;"><b>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF OUR COMMON STOCK, PRE-FUNDED WARRANTS AND COMMON WARRANTS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The following discussion describes the material U.S. federal income tax consequences of the acquisition, ownership and disposition of our Common Stock, Pre-Funded Warrants and Common Warrants acquired in this Offering. This discussion is based on the current provisions of the Internal Revenue Code of 1986, as amended, or the Code, existing and proposed U.S. Treasury regulations promulgated thereunder, and administrative rulings and court decisions in effect as of the date hereof, all of which are subject to change at any time, possibly with retroactive effect. No ruling has been or will be sought from the Internal Revenue Service, or IRS, with respect to the matters discussed below, and there can be no assurance the IRS will not take a contrary position regarding the tax consequences of the acquisition, ownership or disposition of our Common Stock, Pre-Funded Warrants and Common Warrants, or that any such contrary position would not be sustained by a court.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We assume in this discussion that the shares of our Common Stock, Pre-Funded Warrants and Common Warrants will be held as capital assets (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxes, does not discuss the potential application of the Medicare contribution tax on net investment income or the alternative minimum tax and does not deal with state or local taxes, U.S. federal gift and estate tax laws, except as specifically provided below with respect to non-U.S. holders, or any non- U.S. tax consequences that may be relevant to holders in light of their particular circumstances. This discussion also does not address the special tax rules applicable to particular holders, such as</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">financial institutions;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">brokers or dealers in securities or currencies or traders in securities that elect to use a mark-to-market method of accounting for their securities holdings;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">tax-exempt organizations;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">pension plans;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">regulated investment companies, real estate investment trusts;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">owners that hold our Common Stock or Common Warrants as part of a straddle, hedge, conversion transaction, synthetic security or other integrated investment;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">insurance companies;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">persons that own, or are deemed to own, more than 5% of our capital stock and/or Pre-Funded Warrants (except to the extent specifically set forth below);</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">entities or arrangements treated as partnerships for U.S. federal income tax purposes and other pass-through entities (and partners or other investors therein);</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">controlled foreign corporations, passive foreign investment companies, or corporations that accumulate earnings to avoid U.S. federal income tax;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">persons subject to special tax accounting rules as a result of any item of gross income with respect to our Common Stock, Pre-Funded Warrants or Common Warrants being taken into account in an applicable financial statement;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">persons deemed to sell our Common Stock, Pre-Funded Warrants or Common Warrants under the constructive sale provisions of the Code; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 36pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">certain U.S. expatriates and certain former citizens or long-term residents of the United States.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-18-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In addition, this discussion does not address the tax treatment of partnerships or other pass-through entities or persons who hold our Common Stock, Pre-Funded Warrants or Common Warrants through partnerships or other entities which are pass-through entities for U.S. federal income tax purposes. A partner in a partnership or other pass-through entity that will hold our Common Stock, Pre-Funded Warrants or Common Warrants should consult his, her or its own tax advisor regarding the tax consequences of the ownership and disposition of our Common Stock, Pre-Funded Warrants or Common Warrants through a partnership or other pass-through entity, as applicable.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">This discussion of U.S. federal income tax considerations is for general information purposes only and is not tax advice. Prospective investors should consult their own tax advisors regarding the U.S. federal, state, local and non-U.S. income and other tax considerations of acquiring, holding and disposing of our Common Stock, Pre-Funded Warrants and Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">For the purposes of this discussion, a &#8220;U.S. Holder&#8221; means a beneficial owner of our Common Stock, Pre-Funded Warrants or Common Warrants that is, (or other entity classified as a partnership for U.S. federal income tax purposes:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">(a) an individual who is a citizen or resident of the United States, (b) a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes), created or organized in or under the laws of the United States, any state thereof or the District of Columbia, (c) an estate the income of which is subject to U.S. federal income taxation regardless of its source, or (d) a trust if it (1) is subject to the primary supervision of a court within the United States and one or more U.S. persons (within the meaning of Section 7701(a)(30) of the Code) have the authority to control all substantial decisions of the trust or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">A &#8220;Non-U.S. Holder&#8221; is, for U.S. federal income tax purposes, a beneficial owner of Common Stock, Pre-Funded Warrants or Common Warrants that is not a U.S. Holder or an entity or arrangement treated as a partnership for U.S. federal income tax purposes.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>General Treatment of Pre-Funded Warrants</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Although the law in this area is not completely settled, the Pre-Funded Warrants are generally expected to be treated as shares of our Common Stock for U.S. federal income tax purposes and a holder of Pre-Funded Warrants should generally be taxed in the same manner as a holder of Common Stock as described below, and not as a holder of a Common Warrant as described below. Accordingly, no gain or loss should be recognized upon the exercise of a Pre-Funded Warrant and, upon exercise, the holding period of a Pre-Funded Warrant should carry over to the common shares received. Similarly, the tax basis of a Pre-Funded Warrant should carry over to the common share received upon exercise, increased by the exercise price (if applicable). Holders should discuss with their tax advisor the consequences of the acquisition, ownership and disposition of the Pre-Funded Warrants, as well as the exercise of, certain adjustments to, and any payments in respect of the Pre-Funded Warrants (including potential alternative characterizations). The balance of this discussion generally assumes that the characterization described above is respected for U.S. federal income tax purposes.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Allocation of Purchase Price</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">For U.S. federal income tax purposes, the shares of Common Stock and Common Warrants or Pre-Funded Warrants and Common Warrants acquired in this Offering will be treated as an &#8220;investment unit&#8221; consisting of one share of Common Stock and a Common Warrant to acquire one share of our Common Stock or one Pre-Funded Warrant and a Common Warrant to acquire one share of our Common Stock. The purchase price for each investment unit will be allocated between these two components in proportion to their relative fair market values at the time the unit is purchased by the holder. This allocation of the purchase price for each unit will establish the holder&#8217;s initial tax basis for U.S. federal income tax purposes in the share of Common Stock or Pre-Funded Warrant and the Common Warrant included in each unit. The separation of the share of Common Stock or Pre-Funded Warrant and the Common Warrant included in each unit should not be a taxable event for U.S. federal income tax purposes. Each holder should consult his, her or its own tax advisor regarding the allocation of the purchase price for a unit.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-19-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Tax Considerations Applicable to U.S. Holders</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Exercise and Expiration of Warrants</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In general, a U.S. Holder will not recognize gain or loss for U.S. federal income tax purposes upon exercise of a Common Warrant. The U.S. Holder will take a tax basis in the shares acquired on the exercise of a Common Warrant equal to the exercise price of the Common Warrant, increased by the U.S. Holder&#8217;s adjusted tax basis in the Common Warrant exercised (as determined pursuant to the rules discussed above). The U.S. Holder&#8217;s holding period in the shares of our Common Stock acquired on exercise of the Common Warrant will begin on the date of exercise of the Common Warrant, and will not include any period for which the U.S. Holder held the Common Warrant.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In certain limited circumstances, a U.S. Holder may be permitted to undertake a cashless exercise of Common Warrants into our Common Stock. The U.S. federal income tax treatment of a cashless exercise of Common Warrants into our Common Stock is unclear, and the tax consequences of a cashless exercise could differ from the consequences upon the exercise of a Common Warrant described in the preceding paragraph. U.S. Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of a cashless exercise of Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The lapse or expiration of a Common Warrant will be treated as if the U.S. Holder sold or exchanged the Common Warrant and recognized a capital loss equal to the U.S. Holder&#8217;s tax basis in the Common Warrant. The deductibility of capital losses is subject to limitations.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Certain Adjustments to and Distributions on Warrants</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Under Section 305 of the Code, an adjustment to the number of shares of Common Stock issued on the exercise of the Common Warrants or an adjustment to the exercise price of the Common Warrants may be treated as a constructive distribution to a U.S. Holder of the Common Warrants if, and to the extent that, such adjustment has the effect of increasing such U.S. Holder&#8217;s proportionate interest in our &#8220;earnings and profits&#8221; or assets, depending on the circumstances of such adjustment (for example, if such adjustment is to compensate for a distribution of cash or other property to our shareholders). An adjustment made pursuant to a bona fide reasonable adjustment formula that has the effect of preventing dilution should generally not be considered to result in a constructive distribution. Any such constructive distribution would be taxable whether or not there is an actual distribution of cash or other property to the holders of Common Warrants. In certain circumstances, if we were to make a distribution in cash or other property with respect to our Common Stock after the issuance of the Common Warrants, then we may make a corresponding distribution to the holders of the Common Warrants. The taxation of a distribution received with respect to a Common Warrant is unclear. It is possible such a distribution would be treated as a distribution (or constructive distribution), although other treatments are possible. For more information regarding the U.S. federal income tax considerations related to distributions, see the discussion below regarding &#8220;&#8212;Distributions.&#8221; U.S. Holders should consult their tax advisors regarding the proper treatment of any adjustments to the Common Warrants and any distributions with respect to the Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Distributions</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">As discussed above, we currently intend to retain any future earnings to invest in our business and do not expect to pay any dividends in the foreseeable future. In the event that we do make distributions on our Common Stock to a U.S. Holder, those distributions generally will constitute dividends for U.S. tax purposes to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that is applied against and reduces, but not below zero, a U.S. Holder&#8217;s adjusted tax basis in our Common Stock. Any remaining excess will be treated as gain realized on the sale or exchange of our Common Stock as described below under the section titled &#8220;&#8211;Disposition of Our Common Stock or Warrants.&#8221; Under current law, if certain requirements are met, a preferential U.S. federal income tax rate will apply to any dividends paid to the beneficial owner of our Common Stock who is an individual U.S. Holder and meets certain holding period requirements.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Distributions constituting dividends for U.S. federal income tax purposes that are made to U.S. Holders that are corporate shareholders may qualify for the dividends received deduction, or DRD, which is generally available to corporate shareholders. No assurance can be given that we will have sufficient earnings and profits (as determined for U.S. federal income tax purposes) to cause any distributions to be eligible for a DRD. In addition, a DRD is available only if certain holding periods and other taxable income requirements are satisfied.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-20-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The taxation of a distribution received with respect to a Pre-Funded Warrant is unclear. It is possible such a distribution would be treated as a distribution as described in this section, although other treatments may also be possible. Holders should consult their tax advisors regarding the proper treatment of any payments in respect of the Pre-Funded Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Disposition of Our Common Stock or Warrants</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Upon a sale or other taxable disposition of our Common Stock or Common Warrants, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the amount realized and the U.S. Holder&#8217;s adjusted tax basis in the Common Stock or Common Warrants. Capital gain or loss will constitute long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the Common Stock or Common Warrants exceeds one year. The deductibility of capital losses is subject to certain limitations. U.S. Holders who recognize losses with respect to a disposition of our Common Stock or Common Warrants should consult their own tax advisors regarding the tax treatment of such losses.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Information Reporting and Backup Withholding</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Information reporting requirements generally will apply to payments of dividends (including constructive dividends) on the Common Stock and Common Warrants and to the proceeds of a sale or other disposition of Common Stock and Common Warrants paid by us to a U.S. Holder unless such U.S. Holder is an exempt recipient, such as a corporation. Backup withholding will apply to those payments if the U.S. Holder fails to provide the holder&#8217;s taxpayer identification number, or certification of exempt status, or if the holder otherwise fails to comply with applicable requirements to establish an exemption.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Backup withholding is not an additional tax. Rather, any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against the U.S. Holder&#8217;s U.S. federal income tax liability provided the required information is timely furnished to the IRS. U.S. Holders should consult their own tax advisors regarding their qualification for exemption from information reporting and backup withholding and the procedure for obtaining such exemption.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Tax Considerations Applicable to Non-U.S. Holders</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Exercise and Expiration of Warrants</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In general, a Non-U.S. Holder will not recognize gain or loss for U.S. federal income tax purposes upon the exercise of Common Warrants into shares of Common Stock. The U.S. federal income tax treatment of a cashless exercise of Common Warrants into our Common Stock is unclear. A Non-U.S. Holder should consult his, her, or its own tax advisor regarding the U.S. federal income tax consequences of a cashless exercise of Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The expiration of a Common Warrant will be treated as if the Non-U.S. Holder sold or exchanged the Common Warrant and recognized a capital loss equal to the Non-U.S. Holder&#8217;s tax basis in the Common Warrant. However, a Non-U.S. Holder will not be able to utilize a loss recognized upon expiration of a Common Warrant against the Non-U.S. Holder&#8217;s U.S. federal income tax liability unless the loss is effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, if an income tax treaty applies, is attributable to a permanent establishment or fixed base in the United States) or is treated as a U.S.-source loss and the Non-U.S. Holder is present 183 days or more in the taxable year of disposition and certain other conditions are met.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Certain Adjustments to and Distributions on Warrants</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">As described under &#8220;&#8212;U.S. Holders &#8211;Certain Adjustments to and Distributions on Warrants,&#8221; an adjustment to the Common Warrants could result in a constructive distribution to a Non-U.S. Holder, which would be treated as described under &#8220;&#8212;Distributions&#8221; below, and the tax treatment of distributions on the Common Warrants is unclear. Any resulting withholding tax attributable to deemed dividends would be collected from other amounts payable or distributable to the Non-U.S. Holder. Non-U.S. Holders should consult their tax advisors regarding the proper treatment of any adjustments to and distributions on the Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-21-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Distributions</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">As discussed above, we currently intend to retain any future earnings to invest in our business and do not expect to pay any dividends in the foreseeable future. In the event that we do make distributions on our Common Stock to a Non-U.S. Holder, those distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as described in &#8220;&#8212;U.S. Holders &#8211; Distributions.&#8221;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Any distribution (including constructive distributions) on our Common Stock that is treated as a dividend paid to a Non-U.S. Holder that is not effectively connected with the holder&#8217;s conduct of a trade or business in the United States will generally be subject to withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and the Non-U.S. Holder&#8217;s country of residence. To obtain a reduced rate, of withholding under a treaty, a Non-U.S. Holder generally will be required to provide the applicable withholding agent with a properly executed IRS Form W-8BEN, IRS Form W-8BEN-E or other appropriate form, certifying the Non-U.S. Holder&#8217;s entitlement to benefits under that treaty. Such form must be provided prior to the payment of dividends and must be updated periodically. If a Non-U.S. Holder holds stock through a financial institution or other agent acting on the holder&#8217;s behalf, the holder will be required to provide appropriate documentation to such agent. The holder&#8217;s agent may then be required to provide certification to the applicable withholding agent, either directly or through other intermediaries. If you are eligible for a reduced rate of U.S. withholding tax under an income tax treaty, you should consult with your own tax advisor to determine if you are able to obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We generally are not required to withhold tax on dividends paid (or constructive dividends deemed paid) to a Non-U.S. Holder that are effectively connected with the holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base that the holder maintains in the United States) if a properly executed IRS Form W-8ECI, stating that the dividends are so connected, is furnished to us (or, if stock is held through a financial institution or other agent, to the applicable withholding agent). In general, such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated rates applicable to U.S. persons. A corporate Non-U.S. Holder receiving effectively connected dividends may also be subject to an additional &#8220;branch profits tax,&#8221; which is imposed, under certain circumstances, at a rate of 30% (or such lower rate as may be specified by an applicable treaty) on the corporate Non- U.S. Holder&#8217;s effectively connected earnings and profits, subject to certain adjustments.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The taxation of a distribution received with respect to a Pre-Funded Warrant is unclear. It is possible such a distribution would be treated as a distribution as described in this section, although other treatments may also be possible. Non-U.S. Holders should consult their own tax advisors regarding the proper treatment of any payments in respect of the Pre-Funded Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">See also the sections below titled &#8220;&#8212;Backup Withholding and Information Reporting&#8221; and &#8220;&#8212;Foreign Accounts&#8221; for additional withholding rules that may apply to dividends paid to certain foreign financial institutions or non-financial foreign entities.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Disposition of Our Common Stock or Warrants</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Subject to the discussions below under the sections titled &#8220;&#8212;Backup Withholding and Information Reporting&#8221; and &#8220;&#8212;Foreign Accounts&#8221; a Non-U.S. Holder generally will not be subject to U.S. federal income or withholding tax with respect to gain realized on a sale or other disposition of our Common Stock or Common Warrants unless:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the gain is effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business in the United States, and if an applicable income tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by the Non-U.S. Holder in the United States; in these cases, the Non-U.S. Holder will be taxed on a net income basis at the regular graduated rates and in the manner applicable to U.S. persons, and if the Non-U.S. Holder is a corporation, an additional branch profits tax at a rate of 30%, or a lower rate as may be specified by an applicable income tax treaty, may also apply;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-22-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">the Non-U.S. Holder is a nonresident alien present in the United States for 183 days or more in the taxable year of the disposition and certain other requirements are met, in which case the Non-U.S. Holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#8217;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S.-source capital losses of the Non- U.S. Holder, if any; or</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">our Common Stock constitutes a U.S. real property interest because we are, or have been at any time during the five-year period preceding such disposition (or the Non-U.S. Holder&#8217;s holding period for the Common Stock or Common Warrants, if shorter), a &#8220;U.S. real property holding corporation,&#8221;&#160;unless our Common Stock is regularly traded on an established securities market and the Non-U.S. Holder held no more than 5% of our outstanding Common Stock, directly or indirectly, during the shorter of the five-year period ending on the date of the disposition or the period that the Non-U.S. Holder held our Common Stock. Special rules may apply to the determination of the 5% threshold in the case of a holder of a Common Warrant. Non-U.S. Holders are urged to consult their own tax advisors regarding the effect of holding our Common Warrants on the calculation of such 5% threshold. Generally, a corporation is a &#8220;U.S. real property holding corporation&#8221;&#160;if the fair market value of its &#8220;U.S. real property interests&#8221;&#160;(as defined in the Code and applicable regulations) equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we believe that we are not currently, and we do not anticipate becoming, a &#8220;U.S. real property holding corporation&#8221;&#160;for U.S. federal income tax purposes. No assurance can be provided that our Common Stock will be regularly traded on an established securities market for purposes of the rules described above. Special rules may apply to non-U.S. holders of Pre-Funded Warrants, who should consult their tax advisors. Non-U.S. Holders are urged to consult their own tax advisors regarding the U.S. federal income tax considerations that could result if we are, or become, a &#8220;U.S. real property holding corporation.&#8221;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Backup Withholding and Information Reporting</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We must report annually to the IRS and to each Non-U.S. Holder the gross amount of the distributions (including constructive distributions) on our Common Stock or Common Warrants paid to such holder and the tax withheld, if any, with respect to such distributions. Non-U.S. Holders may have to comply with specific certification procedures to establish that the holder is not a U.S. person (as defined in the Code) in order to avoid backup withholding at the applicable rate, currently 24%, with respect to dividends (or constructive dividends) on our Common Stock or Common Warrants. Generally, a holder will comply with such procedures if it provides a properly executed IRS Form W-8BEN, IRS Form W-8BEN-E (or other applicable IRS Form W-8) or otherwise meets documentary evidence requirements for establishing that it is a Non-U.S. Holder, or otherwise establishes an exemption. Dividends paid to Non-U.S. Holders subject to withholding of U.S. federal income tax, as described above under the heading &#8220;&#8212;Dividends,&#8221; will generally be exempt from U.S. backup withholding.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Information reporting and backup withholding generally will apply to the proceeds of a disposition of our Common Stock or Common Warrants by a Non-U.S. Holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a Non-U.S. Holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a Non-U.S. Holder where the transaction is effected outside the United States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. Holders should consult their own tax advisors regarding the application of the information reporting and backup withholding rules to them.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Copies of information returns may be made available to the tax authorities of the country in which the Non-U.S. Holder resides or is incorporated under the provisions of a specific treaty or agreement.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-23-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a Non-U.S. Holder can be refunded or credited against the Non-U.S. Holder&#8217;s U.S. federal income tax liability, if any, provided that an appropriate claim is timely filed with the IRS.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Foreign Accounts</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Code Sections 1471-1474, commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, and the Treasury Regulations issued thereunder generally impose a U.S. federal withholding tax of 30% on dividends on, and, subject to the proposed Treasury Regulations discussed below, the gross proceeds from a sale or other disposition of, our Common Stock or Common Warrants such institution enters into an agreement with the U.S. government to, among other things, withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding the U.S. account holders of such institution (which include certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or otherwise establishes an exemption. FATCA also generally imposes a U.S. federal withholding tax of 30% on dividends on, and, subject to the proposed Treasury Regulations discussed below, the gross proceeds from a sale or other disposition of, our Common Stock or Common Warrants paid to a &#8220;non-financial foreign entity&#8221; (as defined under these rules) unless such entity provides the withholding agent with a certification identifying the direct and indirect U.S. owners of the entity, certifies that it does not have any substantial U.S. owners, or otherwise establishes an exemption. The withholding obligations under FATCA generally apply to dividends on our Common Stock or Common Warrants. The U.S. Department of the Treasury has issued proposed Treasury Regulations providing that, if finalized in their present form, the withholding obligations under FATCA would not apply with respect to payment of gross proceeds from a sale or other disposition of Common Stock or Common Warrants. The proposed Treasury Regulations may be relied upon until final Treasury Regulations are issued. Under certain circumstances, a non-U.S. holder might be eligible for refunds or credits of taxes withheld under FATCA. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. Non-U.S. Holders are encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their investment in our Common Stock or Common Warrants.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"><b>The preceding discussion of material U.S. federal tax considerations is for information only. It is not tax advice. Prospective investors should consult their own tax advisors regarding the particular U.S. federal, state, local and non-U.S. tax consequences of purchasing, holding and disposing of our Common Stock, Pre-Funded Warrants or Common Warrants, including the consequences of any proposed changes in applicable laws.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-24-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PLAN OF DISTRIBUTION </b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Placement Agent has agreed to act as our exclusive placement agent in connection with this offering. The Placement Agent is not purchasing or selling any of the securities offered by this prospectus, nor is it required to arrange the purchase or sale of any specific number or dollar amount of securities but has agreed to use its reasonable best efforts to arrange for the sale of all of the securities offered hereby. Therefore, we may not sell the entire number of securities offered pursuant to this prospectus. We will enter into a securities purchase agreement directly with certain investors, at the investor&#8217;s option, who purchases our securities in this offering. Investors who do not enter into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of our securities in this offering.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We will deliver the securities being issued to the investors upon receipt of such investor&#8217;s funds for the purchase of the securities offered pursuant to this prospectus. We expect to deliver the securities being offered pursuant to this prospectus on or about &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2024.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have agreed to indemnify the Placement Agent and specified other persons against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the Placement Agent may be required to make in respect thereof.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">In addition, certain members of our Board of Directors and a non-director executive officer, have indicated their preliminary interest in purchasing up to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;shares of our Common Stock and the&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; accompanying Common Warrants resulting in aggregate expected gross proceeds to us of approximately $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;million at the assumed combined public offering price per share of Common Stock and accompanying one-half Common Warrant.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Fees and Expenses </i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have engaged AGP as our exclusive placement agent in connection with this offering. This offering is being conducted on a &#8220;best efforts&#8221; basis and the Placement Agent has no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of securities. We have agreed to pay the Placement Agent a fee based on the aggregate proceeds as set forth in the table below:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 57%;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Per Share<br/>
			and<br/>
			One-Half Common<br/>
			Warrant</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
			<td colspan="2" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; text-align: center; width: 1%; border-bottom: 1px solid black;">
			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;"><b>Per Pre-Funded</b></div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;"><b>Warrant and One-</b></div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;"><b>Half Common </b></div>

			<div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt;"><b>Warrant</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 57%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Public offering price</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="nowrap: true; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 57%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Placement Agent Fees</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="nowrap: true; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 57%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Proceeds,&#160;before expenses, to us<sup style="vertical-align:top;line-height:120%;">(1)</sup></div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="nowrap: true; width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">&#160;</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">The amount of proceeds, before expenses, to us does not give effect to any exercise of the Pre-Funded Warrants or Common Warrants.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We have agreed to pay the Placement Agent the Cash Fee equal to 7.0% of the aggregate gross proceeds from the sale of the shares of Common Stock, or Pre-Funded Warrants in lieu thereof, together with the accompanying Common Warrants, sold in this offering; provided, however, that such commission percentage will be reduced to a fee of up to 3.5% for any proceeds to us from sales to our directors, our executive officers or other Identified Purchasers. Because there is no minimum offering amount required as a condition to closing in this offering, the actual aggregate Cash Fee, if any, is not presently determinable and may be substantially less than the maximum amount set forth above. No Cash Fee will be payable in respect of any Pre-Funded Warrant or Common Warrant exercises that may occur in the future. We have also agreed to reimburse the Placement Agent at closing (i) for legal and other expenses incurred by it in connection with the offering in an aggregate amount of up to $50,000, and (ii) non-accountable expenses payable to the Placement Agent of up to $10,000. We estimate the total expenses payable by us for this offering, excluding the Placement Agent fees and expenses, will be approximately $0.2 million.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-25-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Regulation M</i></b></div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Placement Agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the shares sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the Placement Agent would be required to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares by the Placement Agent acting as principal. Under these rules and regulations, the Placement Agent:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">may not engage in any stabilization activity in connection with our securities; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until it has completed its participation in the distribution.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Lock-Up Agreements</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Our directors and officers have entered into lock-up agreements. Under these agreements, these individuals agreed, subject to specified exceptions, not to sell or transfer any shares of Common Stock or securities convertible into, or exchangeable or exercisable for, Common Stock during a period ending &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;days after the completion of this offering, without first obtaining the written consent of the Placement Agent. Specifically, these individuals agreed, in part, subject to certain exceptions, not to:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">offer for sale, sell, pledge, or otherwise transfer or dispose of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common Stock;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of Common Stock; or</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tbody><tr style="vertical-align: top;">
			<td style="width: 18pt;">&#160;</td>
			<td style="width: 18pt;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="width: auto;">
			<div style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any of our securities.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>No Sales of Similar Securities</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We have agreed, subject to certain exceptions, not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of, any shares of Common Stock (or securities convertible into or exercisable for Common Stock) or, subject to certain exceptions, file any registration statement, including any amendments or supplements thereto (other than the prospectus supplement, registration statement or amendment to the registration statement relating to the securities offered hereunder and a registration statement on Form S-8), until &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;days after the completion of this offering.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Discretionary Accounts</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The Placement Agent does not intend to confirm sales of the securities offered hereby to any accounts over which it has discretionary authority.</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Listing </i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;BCDA.&#8221; We do not plan to list the Pre-Funded Warrants or Common Warrants on the Nasdaq or any other securities exchange or trading market.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
-26-

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">&#160;</div>
</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>LEGAL MATTERS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The validity of the securities offered hereby will be passed upon for us by Wilson Sonsini Goodrich &amp; Rosati, Professional Corporation, Palo Alto, California. Certain members of, and investment partnerships comprised of members of, and persons associated with, Wilson Sonsini Goodrich &amp; Rosati, P.C., own an interest representing less than one percent of the outstanding shares of Common Stock. The Placement Agent is being represented by Sullivan &amp; Worcester LLP, New York, New York in connection with this offering.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXPERTS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The financial statements incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December 31, 2023 have been so incorporated in reliance on the report of PKF San Diego, LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>WHERE YOU CAN FIND MORE INFORMATION</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">We have filed with the SEC a registration statement on Form&#160;S-1 under the Securities Act with respect to the securities offered by this prospectus.&#160; This prospectus, which constitutes a part of the registration statement, does not include all of the information contained in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC.&#160; You should refer to the registration statement and its exhibits for additional information.&#160; Whenever we make references in this prospectus to any of our contracts, agreements or other documents, such references are not necessarily complete and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">You can read our SEC filings, including the registration statement and its exhibits, over the Internet at the SEC&#8217;s web site at www.sec.gov.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We are subject to the information reporting requirements of the Exchange Act, and we will file annual, quarterly and special reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for inspection and copying at the website of the SEC referred to above. We also maintain a website at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that can be accessed through, our website is not a part of this prospectus.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The SEC allows us to &#8220;incorporate by reference&#8221; information from other documents that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or incorporated by reference in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below and any future filings we make with the SEC under Sections&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of those documents furnished rather than filed), until the offering of the securities under the registration statement of which this prospectus forms a part is terminated or completed:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our Annual Report on Form&#8239;10-K for the year ended December&#160;31, 2023, filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924009587/bcda20231231_10k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">March&#160;</span><span style="text-decoration: underline;">27, 2024</span></a>;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our Quarterly Reports on Form&#8239;10-Q for the quarters ended March&#160;31, 2024 and June 30, 2024, filed with the SEC on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924016611/bcda20240331_10q.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">May 14, 2024</span></a>&#160;and August&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2024, respectively;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-27-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the portions of our Definitive Proxy Statement on Schedule&#160;14A (other than information furnished rather than filed therein) filed on <a href="http://www.sec.gov/Archives/edgar/data/925741/000143774924012080/bcda20240410_def14a.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">April&#160;</span><span style="text-decoration: underline;">15, 2024</span></a>;</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our Current Reports on Form&#8239;8-K filed on <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924002611/bcda20240130_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">January&#160;</span><span style="text-decoration: underline;">31, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924003561/bcda20240208_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">February 9, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924007371/bcda20240312_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">March 12, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924007467/bcda20240312c_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">March 12, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924017856/bcda20240520_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">May 21, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924018654/bcda20240530_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">May 30, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924019535/bcda20240607_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">June 7, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924019813/bcda20240610_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">June&#160;</span><span style="text-decoration: underline;">10, 2024</span></a>, <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924022861/bcda20240716_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">July 17, 2024</span></a>, and <a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0000925741/000143774924023823/bcda20240730_8k.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">July 30, 2024</span></a>; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:36pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the description of our Common Stock contained in the Registration Statements on Form&#8239;8-A relating thereto, filed on <a href="http://www.sec.gov/Archives/edgar/data/925741/000143774919014460/bcda20190723_8a12b.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">July 23, 2019</span></a>, including any amendment or report filed for the purpose of updating such description.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We will furnish without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents. Any such request may be made by writing or telephoning us at the following address or phone number:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">BioCardia, Inc.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">320 Soquel Way</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Sunnyvale, California 94085</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Attn: Investor Relations</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(650) 226-0120</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We will not, however, send exhibits to those documents, unless the exhibits are specifically incorporated by reference in those documents.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We make available free of charge on our website our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and amendments to those reports, as soon as reasonably practicable after we electronically file or furnish such materials to the SEC. You may access these filings on our website at <i>www.biocardia.com</i>. We do not incorporate the information on our website into this prospectus and you should not consider any information on, or that can be accessed through, our website as part of this prospectus (other than those filings with the SEC that we specifically incorporate by reference into this prospectus).</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Any statement contained in a document incorporated in this prospectus will be deemed modified, superseded or replaced for purposes of this prospectus to the extent that a statement contained in this prospectus modifies, supersedes or replaces such statement.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">You should rely only on information contained in, or incorporated by reference into, this prospectus. We have not authorized anyone to provide you with information different from that contained in this prospectus or incorporated by reference therein. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
-28-
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="bcda20240808_s1img002.jpg" src="bcda20240808_s1img002.jpg" style="width:286;height:55;"/></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Prospectus</b></div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Up to</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b> Shares of Common Stock</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Up to</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b> Pre-Funded Warrants to Purchase Shares of Common Stock</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Up to</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b> Warrants to Purchase Shares of Common Stock</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Up to</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b> Shares of Common Stock issuable upon exercise of the Pre-Funded Warrants</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Up to</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<b> Shares of Common Stock issuable upon exercise of the Warrants</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><i>Sole Placement Agent</i></b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 18pt; font-variant: normal; text-align: center; margin: 0pt;"><b>A.G.P.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>, 2024</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&#160;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART II</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INFORMATION NOT REQUIRED IN PROSPECTUS</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 13. Other Expenses of Issuance and Distribution</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The following table sets forth all expenses, other than the selling commissions, payable by the registrant in connection with the securities being registered. All the amounts shown are estimates except the SEC registration fee, the Nasdaq Stock Market and the FINRA filing fee.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">

		<tbody><tr class="finHeading" style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Total</b></div>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">SEC registration fee</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,329</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">FINRA filing fee</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,850</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Legal fees and expenses</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">200,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounting fees and expenses</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Miscellaneous</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,000</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
		</tr>
		<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<div style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total</div>
			</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">216,179</td>
			<td style="nowrap: true; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 14. Indemnification of Directors and Officers</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Section 102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except for breaches of the director&#8217;s duty of loyalty to the corporation or its stockholders, acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of a law, authorizations of the payments of a dividend or approval of a stock repurchase or redemption in violation of Delaware corporate law or for any transactions from which the director derived an improper personal benefit.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Section 145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with a threatened, pending, or completed action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, indemnification is limited to expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with defense or settlement of such action or suit and no indemnification shall be made with respect to any claim, issue, or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. In addition, to the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise in defense of any action, suit, or proceeding described above (or claim, issue, or matter therein), such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith. Expenses (including attorneys&#8217; fees) incurred by an officer or director in defending any civil, criminal, administrative, or investigative action, suit, or proceeding may be advanced by the corporation upon receipt of an undertaking by such person to repay such amount if it is ultimately determined that such person is not entitled to indemnification by the corporation under Section 145 of the General Corporation Law of the State of Delaware.</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Section 174 of the General Corporation Law of the State of Delaware provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A director who was either absent when the unlawful actions were approved, or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
II-1
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Our amended and restated certificate of incorporation provides for the indemnification of our directors to the fullest extent permissible under Delaware General Corporation Law. Our amended and restated bylaws provide for the indemnification of our directors and officers to the maximum extent permitted by the Delaware General Corporation Law. In addition, we have entered into indemnification agreements with our directors and officers, and we maintain insurance policies insuring our directors and officers against certain liabilities that they may incur in their capacity as officers and directors of our company.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">These indemnification provisions and the indemnification agreements entered into between us and our officers and directors may be sufficiently broad to permit indemnification of our officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 15. Recent Sales of Unregistered Securities</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The following is a summary of all securities that we have sold during the past three years without registration under the Securities Act. On May 30, 2024, we executed a 1-for-15 reverse stock split of our Common Stock. Unless otherwise indicated, all per share amounts included in the summary below for transactions that occurred prior to such respective reverse stock splits are presented without giving effect to such reverse stock splits.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On February 9, 2024, we entered into a Securities Purchase and Registration Rights Agreement (the &#8220;2024 Purchase Agreement&#8221;) relating to a private placement (the &#8220;2024 Private Placement&#8221;) with certain qualified institutional buyers and institutional accredited investors, as well as Peter Altman, our President and Chief Executive Officer (each, a &#8220;2024 Investor&#8221;&#160;and, collectively, the &#8220;2024 Investors&#8221;). Pursuant to the 2024 Purchase Agreement, the Company sold to the 2024 Investors (i) an aggregate of 2,012,978 shares of the Company&#8217;s Common Stock (the &#8220;2024 Shares&#8221;), at an offering price of $0.4331 per 2024 Share, other than Dr. Altman, who paid $0.4625 per 2024 Share in compliance with Nasdaq rules, and (ii) warrants to purchase an aggregate of 1,006,488 shares of Common Stock (the &#8220;2024 Warrants&#8221;; the shares of Common Stock issuable upon exercise of or otherwise pursuant to the 2024 Warrants collectively are referred to herein as the &#8220;2024 Warrant Shares&#8221;; the 2024 Warrant Shares, together with the 2024 Shares and the 2024 Warrants, as applicable, the &#8220;2024 Securities&#8221;). Of the 2024 Securities, Dr. Altman purchased (i) 108,108 2024 Shares and (ii) a 2024 Warrant to purchase 54,054 2024 Warrant Shares.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On December 14, 2022, we entered into a Securities Purchase and Registration Rights Agreement (the &#8220;2022 Purchase Agreement&#8221;) relating to a private placement (the &#8220;2022 Private Placement&#8221;) with certain qualified institutional buyers and institutional accredited investors, as well as certain directors and officers of the Company (each, a &#8220;2022 Investor&#8221;&#160;and, collectively, the &#8220;2022 Investors&#8221;). Pursuant to the 2022 Purchase Agreement, the Company agreed to sell to the 2022 Investors an aggregate of 2,122,017 shares of the Company&#8217;s Common Stock (the &#8220;2022 Shares&#8221;), at an offering price of $1.68 per 2022 Share. Certain of the Company&#8217;s directors and executive officers purchased an aggregate of 499,997 of the 2022 Shares.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe the offers, sales and issuances of the above securities were exempt from registration under the Securities Act by virtue of Section 4(a)(2) of the Securities Act because the issuance of securities to the recipients did not involve a public offering. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
II-2
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b>Item 16. Exhibits and Financial Statement Schedules</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(a)</b>&#160;<b>Exhibits.</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">See the Exhibit Index immediately preceding the signature page hereto for a list of exhibits filed as part of this registration statement on Form&#160;S-1, which Exhibit Index is incorporated by reference.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(b)</b>&#160;<b>Financial Statement Schedules</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 17. Undertakings</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The undersigned registrant hereby undertakes:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">i.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To include any prospectus required by section 10(a)(3) of the Securities Act;</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ii.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221;&#160;table in the effective registration statement.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">iii.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; <i>provided, however</i>, that paragraphs&#160;(i), (ii)&#160;and (iii)&#160;above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act that are incorporated by reference in this Registration Statement or is contained in a form of prospectus filed pursuant to Rule&#160;424(b) that is part of the Registration Statement.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">i.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ii.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">iii.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
II-3
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:54pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">iv.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">That, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to section&#160;13(a) or section&#160;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to section&#160;15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">7.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule&#160;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&#160;424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</div>
			</td>
		</tr>

</tbody></table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tbody><tr>
			<td style="width:18pt;">&#160;</td>
			<td style="vertical-align:top;width:18pt;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">8.</div>
			</td>
			<td style="vertical-align:top;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For the purpose of determining any liability under the Securities Act of 1933, each post&#8209;effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <i>bona fide</i>&#160;offering thereof.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to section&#160;13(a) or section&#160;15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to section&#160;15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit Index</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit</b><br/>
			<b><span style="text-decoration: underline;">Number</span></b></div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline;">Description</span></b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">1.1&#8224;</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Placement Agency Agreement</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.1(1)</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000119312516691114/d242455dex21.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Agreement and Plan of Merger dated August 22, 2016</span>&#160;</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2.2(2)</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774916040470/ex2-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">First Amendment to Agreement and Plan of Merger dated October 21, 2016 </span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.1*</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_711385.htm" style="-sec-extract:exhibit;">Amended and Restated Certificate of Incorporation, as amended May 29, 2024, as currently in effect</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.2(3)</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774924018654/ex_681330.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Certificate of Amendment of Amended and Restated Certificate of Incorporation as filed on May 29, 2024 with the State of Delaware</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">3.3(4)</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774923011915/ex_508441.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Amended and Restated Bylaws </span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.1(5)</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774916040470/ex4-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Specimen common stock certificate</span></a>&#160;</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.2(6)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774916040470/ex10-1.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">BioCardia 2002 Stock Plan, as amended</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.3(7)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774917001935/ex4-3.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Stock Option Agreement under BioCardia 2002 Stock Plan</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.4*</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_711393.htm" style="-sec-extract:exhibit;">BioCardia 2016 Equity Incentive Plan, as amended</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.5(8)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774917001935/ex4-7.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Stock Option Agreement under BioCardia 2016 Equity Incentive Plan</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.6(9)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774917001935/ex4-8.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Restricted Stock Unit Agreement under BioCardia 2016 Equity Inventive Plan</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%; text-align: center;">4.7&#8224;</td>
			<td style="vertical-align: top; width: 90%;">Form of Pre-Funded Warrant in connection with this offering</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.8&#8224;</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Common Warrant in connection with this offering</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.9(10)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774920010860/ex_186905.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Director Restricted Stock Unit Agreement under the BioCardia 2016 Equity Incentive Plan</span></a></div>
			</td>
		</tr>

</tbody></table>

<div style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
II-4
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 10%;"><b>Exhibit</b><br/>
			<b><span style="text-decoration: underline;">Number</span></b></td>
			<td style="vertical-align: bottom; width: 90%;"><b><span style="text-decoration: underline;">Description</span></b></td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.10(11)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774922029106/ex_456742.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Securities Purchase and Registration Rights Agreement, dated December 14, 2022, between the Company and certain qualified institutional buyers and institutional accredited investors</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">4.11(12)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774924003561/ex_624462.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Securities Purchase and Registration Rights Agreement, dated February 9, 2024, by and among the Company and certain qualified institutional buyers and institutional accredited investors (including the Form of Warrant attached as Exhibit A thereto)</span></a>&#160;</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">5.1&#8224;</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Opinion of Wilson Sonsini Goodrich &amp; Rosati, P.C.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.1(13)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774916040470/ex10-4.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Indemnification Agreement for directors and executive officers</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.2(14)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774917005643/ex10-2.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Form of Change of Control and Severance Agreement with each executive officer</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.3(15)**</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774916040470/ex10-8.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">License and Distribution Agreement, dated October 30, 2012, by and between the Company and Biomet Biologics, LLC, as amended</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.4(16)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774923008312/ex_492010.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Second Amendment to License and Distribution Agreement, dated September 22, 2022, by and between Biomet Biologics, LLC</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.5(17)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774920007637/ex_181285.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Litigation Funding Agreement dated April 9, 2020, between BSLF, LLC and the Company</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.6(18)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774922007544/ex_340237.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Lease agreement, dated December 14, 2021 between the Company and the Irvine Company LLC</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.7(19)</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774922008717/ex_356846.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">Controlled Equity Offering Sales Agreement dated April 12, 2022 between the Company and Cantor Fitzgerald &amp; Co.</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.8(20)</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774923033718/ex_602831.htm" style="-sec-extract:exhibit;"><span style="text-decoration: underline;">At The Market Offering Agreement, dated December 6, 2023, by and between BioCardia, Inc. and H.C. Wainwright &amp; Co., LLC</span></a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.9&#8224;</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Form of Securities Purchase Agreement</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.10*</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_711394.htm" style="-sec-extract:exhibit;">Amendment to Change of Control and Severance Agreement, dated May 30, 2024, by and between BioCardia, Inc. and Peter Altman</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">10.11*</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_711395.htm" style="-sec-extract:exhibit;">Amendment to Change of Control and Severance Agreement, dated May 30, 2024, by and between BioCardia, Inc. and David McClung</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">21.1(21)</div>
			</td>
			<td style="vertical-align: top; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/925741/000143774924009587/ex_642178.htm" style="-sec-extract:exhibit;">Subsidiaries of the Company</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">23.1*</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_711422.htm" style="-sec-extract:exhibit;">Consent of PKF San Diego, LLP, Independent Registered Public Accounting Firm</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">23.2&#8224;</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consent of Wilson Sonsini Goodrich &amp; Rosati, P.C. (included in the opinion filed as Exhibit&#8239;5.1 to this registration statement)</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">24.1</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="#poa" style="-sec-extract:exhibit;">Power of attorney (included on signature page of this report)</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">107*</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_711396.htm" style="-sec-extract:exhibit;">Filing Fee Table</a></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">*</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filed herewith.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">**</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Confidential Treatment portions of this exhibit have been omitted as permitted by applicable regulations.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 10%;">
			<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8224;</div>
			</td>
			<td style="vertical-align: bottom; width: 90%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To be filed by amendment.</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
II-5
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(1)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 2.1 to the Current Report on Form 8-K filed by us on August 25, 2016.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(2)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 2.2 to the Current Report on Form 8-K filed by us on October 27, 2016.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(3)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 3.1 to the Current Report on Form 8-K filed by us on May 30, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(4)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 3.1 to the Current Report on Form 8-K filed by us on May 1, 2023.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(5)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed by us on October 27, 2016.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(6)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 10.1 to the Current Report on Form 8-K filed by us on October 27, 2016.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(7)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 4.3 to the registration statement on Form S-8 filed by us on February 8, 2017.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(8)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 4.7 to the registration statement on Form S-8 filed by us on February 8, 2017.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(9)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 4.8 to the registration statement on Form S-8 filed by us on February 8, 2017.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(10)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed by us on May 15, 2020.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(11)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed by us on December 15, 2022.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(12)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed by us on February 9, 2024.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(13)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 10.4 to the Current Report on Form 8-K filed by us on October 27, 2016.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(14)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 10.2 to the Annual Report on Form 10-K filed by us on March 30, 2017.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(15)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 10.8 to the Current Report on Form 8-K filed by us on October 27, 2016.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(16)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 10.4 to the Annual Report on 10-K filed by us on March 29, 2023.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(17)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 10.1 to the Current Report on Form 8-K filed by us on April 14, 2020.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(18)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 10.14 to the Annual Report on 10-K filed by us on March 29, 2022.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(19)</div>
			</td>
			<td style="vertical-align: top; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 1.1 to the Current Report on Form 8-K filed by us on April 12, 2022.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(20)</div>
			</td>
			<td style="vertical-align: middle; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously filed as Exhibit 1.1 to the Current Report on Form 8-K filed by us on December 6, 2023.</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 8%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(21)</div>
			</td>
			<td style="vertical-align: middle; width: 92%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Previously Filed as Exhibit 21.1 to the Annual Report on Form 10-K filed on March 27, 2024</div>
			</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
II-6
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000"/>
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&#160;</div>
</div>
</div>
</div>

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form&#8239;S-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Sunnyvale, State of California, on August 9, 2024.</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tbody><tr>
			<td colspan="2" rowspan="1" style="width: 5%;"><b>BIOCARDIA,</b>&#8239;<b>INC.</b></td>
			<td style="width: 55%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&#160;</td>
			<td style="width: 40%;">&#160;</td>
			<td style="width: 55%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 5%;">By:</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 40%;">/s/ Peter Altman, Ph.D.</td>
			<td style="width: 55%;">&#160;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&#160;</td>
			<td style="width: 40%;">
			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Peter Altman, Ph.D.</div>

			<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">President and Chief Executive Officer</div>
			</td>
			<td style="width: 55%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>POWER OF ATTORNEY</b></div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Peter Altman and David McClung as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and substitution, for him or her and in his or her name, place, and stead, in any and all capacities (including his or her capacity as a director and/or officer of BioCardia, Inc.) to sign any or all amendments (including post-effective amendments) to this registration statement and any and all additional registration statements pursuant to Rule&#160;462(b) of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents or any of them, or their, his, or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.&#8239;Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:</div>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tbody><tr>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Signature</b></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Title</b></div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%; border-bottom: 1px solid rgb(0, 0, 0);">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Date</b></div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">/s/ Peter Altman, Ph.D.</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer and Director</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 9, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Peter Altman, Ph.D.</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Executive Officer)</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">/s/ David McClung</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 9, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">David McClung</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Financial and Accounting Officer)</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">/s/ Andrew Blank</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 9, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Andrew Blank</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">/s/ Jim Allen</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 9, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Jim Allen</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">/s/ Bill Facteau</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 9, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Bill Facteau</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">/s/ Richard Krasno, Ph.D.</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 9, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Richard Krasno, Ph.D.</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35%; text-align: center;">/s/ Jay M. Moyes</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 9, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Jay M. Moyes</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 35%; text-align: center;">/s/ Simon Stertzer, M.D.</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 9, 2024</div>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 35%;">
			<div style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Simon Stertzer, M.D.</div>
			</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 45%;">&#160;</td>
			<td style="vertical-align: bottom; width: 1%;">&#160;</td>
			<td style="vertical-align: bottom; width: 18%;">&#160;</td>
		</tr>

</tbody></table>

<div style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
II-7
</div>
</div>
</div>


</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex_711385.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<html><head>
	<title>ex_711385.htm</title>

	<!-- Generated by ThunderDome Portal - 8/8/2024 7:28:48 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt 0pt 0pt 15pt;"><b>Exhibit 3.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ARTICLE I</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The name of the Corporation is BioCardia, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ARTICLE II</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The purpose of this Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of Delaware (the &#8220;DGCL&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ARTICLE III</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The address of the Corporation&#8217;s registered office in the State of Delaware is 1209 Orange Street, City of Wilmington, County of New Castle, 19801. The name of its registered agent at such address is The Corporation Trust Company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ARTICLE IV</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 72pt;">4.1 <u>Authorized Capital Stock</u>. Effectively immediately on May 7, 2019, at 12:01 a.m., Eastern Time, each nine outstanding shares of Common Stock and Preferred Stock will be exchanged and combined, automatically and without further action, into one (1) share of Common Stock or Preferred Stock, respectively (the &#8220;Reverse Stock Split&#8221;). The Reverse Stock Split shall also apply to any outstanding securities or rights convertible into, or exchangeable or exercisable for, Common Stock or Preferred Stock of the Corporation. The Reverse Stock Split shall be effected on a certificate-by-certificate basis and no fractional shares shall be issued upon the exchange and combination. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay an amount of cash equal to the product of (i) the fractional share to which the holder would otherwise be entitled and (ii) the then fair value of a share as determined in good faith by the Board of Directors of the Corporation. All other rights, preferences and privileges of the Company&#8217;s Common Stock and Preferred Stock, shall be adjusted to reflect the Reverse Stock Split pursuant to the terms of the Amended and Restated Certificate of Incorporation in existence as of immediately prior to the filing of the Certificate of Amendment. After giving effect to the Reverse Stock Split, the total number of shares of all classes of capital stock that the Corporation is authorized to issue is 125,000,000 shares, consisting of 100,000,000 shares of Common Stock, having par value of $0.001 (the &#8220;Common Stock&#8221;), and 25,000,000 shares of Preferred Stock, having a par value of $0.001 (the &#8220;Preferred Stock&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 72pt;">4.2 <u>Increase or Decrease in Authorized Capital Stock</u>. The number of authorized shares of Preferred Stock or Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock of the Corporation entitled to vote generally in the election of directors, irrespective of the provisions of Section 242(b)(2) of the DGCL (or any successor provision thereto), voting together as a single class, without a separate vote of the holders of the class or classes the number of authorized shares of which are being increased or decreased.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 72pt;">4.3 <u>Common Stock</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 99pt;">(a) The holders of shares of Common Stock shall be entitled to one vote for each such share on each matter on which the holders of shares of Common Stock are entitled to vote. Except as otherwise required by law or this certificate of incorporation (this &#8220;<b>Certificate of Incorporation</b>&#8221; which term, as used herein, shall mean the certificate of incorporation of the Corporation, as amended from time to time, including the terms of any certificate of designations of any series of Preferred Stock), and subject to the rights of the holders of Preferred Stock, at any annual or special meeting of the stockholders the holders of shares of Common Stock shall have the right to vote for the election of directors and on all other matters submitted to a vote of the stockholders; provided, however, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation that relates solely to the terms, number of shares, powers, designations, preferences, or relative participating, optional or other special rights (including, without limitation, voting rights), or to qualifications, limitations or restrictions thereon, of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one more other such series, to vote thereon pursuant to this Certificate of Incorporation (including, without limitation, by any certificate of designations relating to any series of Preferred Stock) or pursuant to the DGCL.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 99pt;">(b) Subject to the rights of the holders of Preferred Stock, the holders of shares of Common Stock shall be entitled to receive such dividends and other distributions (payable in cash, property or capital stock of the Corporation) when, as and if declared thereon by the Board of Directors from time to time out of any assets or funds of the Corporation legally available therefor and shall share equally on a per share basis in such dividends and distributions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:99pt;">(c) In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Corporation, after payment or provision for payment of the debts and other liabilities of the Corporation, and subject to the rights of the holders of Preferred Stock in respect thereof, the holders of shares of Common Stock shall be entitled to receive all the remaining assets of the Corporation available for distribution to its stockholders, ratably in proportion to the number of shares of Common Stock held by them.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 72pt;">4.4 <u>Preferred Stock</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 99pt;">(a) The Preferred Stock may be issued from time to time in one or more series pursuant to a resolution or resolutions providing for such issue duly adopted by the Board of Directors (authority to do so being hereby expressly vested in the Board of Directors). The Board of Directors is further authorized, subject to limitations prescribed by law, to fix by resolution or resolutions and to set forth in a certification of designations filed pursuant to the DGCL the powers, designations, preferences and relative, participation, optional or other rights, if any, and the qualifications, limitations or restrictions thereof, if any, of any wholly unissued series of Preferred Stock, including without limitation authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices, and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 99pt;">(b) The Board of Directors is further authorized to increase (but not above the total number of authorized shares of the class) or decrease (but not below the number of shares of any such series then outstanding) the number of shares of any series, the number of which was fixed by it, subsequent to the issuance of shares of such series then outstanding, subject to the powers, preferences and rights, and the qualifications, limitations and restrictions thereof stated in the Certificate of Incorporation or the resolution of the Board of Directors originally fixing the number of shares of such series. If the number of shares of any series is so decreased, then the shares constituting such decrease shall resume the status which they had prior to the adoption of the resolution originally fixing the number of shares of such series.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ARTICLE V</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 72pt;">5.1 <u>General Powers</u>. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 72pt;">5.2 <u>Number of Directors; Election; Term</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 99pt;">(a) Subject to the rights of holders of any series of Preferred Stock with respect to the election of directors, the number of directors that constitutes the entire Board of Directors of the Corporation shall be fixed solely by resolution of the majority of the Whole Board. For purposes of this Certificate of Incorporation, the term &#8220;<b>Whole Board</b>&#8221; will mean the total number of authorized directors whether or not there exist any vacancies in previously authorized directorships.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 99pt;">(b) Subject to the rights of holders of any series of Preferred Stock with respect to the election of directors, effective upon the filing of this Certificate of Incorporation (the &#8220;<b>Effective Date</b>&#8221;), the directors of the Corporation shall be divided into three classes as nearly equal in size as is practicable, hereby designated Class I, Class II and Class III. The initial assignment of members of the Board of Directors to each such class shall be made by the Board of Directors. The term of office of the initial Class I directors shall expire at the first regularly-scheduled annual meeting of the stockholders following the Effective Date, the term of office of the initial Class II directors shall expire at the second annual meeting of the stockholders following the Effective Date and the term of office of the initial Class III directors shall expire at the third annual meeting of the stockholders following the Effective Date. At each annual meeting of stockholders, commencing with the first regularly-scheduled annual meeting of stockholders following the Effective Date, each of the successors elected to replace the directors of a Class whose term shall have expired at such annual meeting shall be elected to hold office until the third annual meeting next succeeding his or her election and until his or her respective successor shall have been duly elected and qualified. Subject to the rights of holders of any series of Preferred Stock with respect to the election of directors, if the number of directors that constitutes the Board of Directors is changed, any newly created directorships or decrease in directorships shall be so apportioned by the Board of Directors among the classes as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 99pt;">(c) Notwithstanding the foregoing provisions of this Section 5.2, and subject to the rights of holders of any series of Preferred Stock with respect to the election of directors, each director shall serve until his or her successor is duly elected and qualified or until his or her earlier death, resignation, or removal.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 99pt;">(d) Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 72pt;">5.3 <u>Removal</u>. Subject to the rights of holders of any series of Preferred Stock with respect to the election of directors, a director may be removed from office by the stockholders of the Corporation only for cause and only by the affirmative vote of the holders of at least 66&#8532;% in voting power of the stock of the Corporation entitled to vote thereon.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 72pt;">5.4 <u>Vacancies and Newly Created Directorships</u>. Subject to the rights of holders of any series of Preferred Stock with respect to the election of directors, and except as otherwise provided in the DGCL, vacancies occurring on the Board of Directors for any reason and newly created directorships resulting from an increase in the authorized number of directors may be filled only by vote of a majority of the remaining members of the Board of Directors, although less than a quorum, or by a sole remaining director, at any meeting of the Board of Directors. A person so elected by the Board of Directors to fill a vacancy or newly created directorship shall hold office until the next election of the class for which such director shall have been assigned by the Board of Directors and until his or her successor shall be duly elected and qualified.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ARTICLE VI</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In furtherance and not in limitation of the powers conferred by statute, the Board of Directors of the Corporation is expressly authorized to adopt, amend or repeal the Bylaws of the Corporation by the affirmative vote of a majority of the Whole Board. Notwithstanding any other provision of this Certificate of Incorporation or any provision of law that might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any series of Preferred Stock required by law, by this Certificate of Incorporation or by any Preferred Stock Designation, the affirmative vote of the holders of at least 66&#8532;% of the voting power of the stock of the Corporation entitled to vote thereon shall be required for the stockholders of the Corporation to amend, alter or repeal the Bylaws or adopt new Bylaws.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ARTICLE VII</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 72pt;">7.1 <u>No Action by Written Consent of Stockholders</u>. Except (i) with respect to the approval of stock splits or reverse stock splits, or (ii) as otherwise expressly provided by the terms of any series of Preferred Stock permitting the holders of such series of Preferred Stock to act by written consent, any action required or permitted to be taken by stockholders of the Corporation must be effected at a duly called annual or special meeting of the stockholders and may not be effected by written consent in lieu of a meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 72pt;">7.2 <u>Special Meetings</u>. Except as otherwise expressly provided by the terms of any series of Preferred Stock permitting the holders of such series of Preferred Stock to call a special meeting of the holders of such series, special meetings of stockholders of the Corporation may be called only by the affirmative vote of a majority of the Whole Board, the chairperson of the Board of Directors, the chief executive officer or the president (in the absence of a chief executive officer), and the ability of the stockholders to call a special meeting is hereby specifically denied. The Board of Directors, by the affirmative vote of a majority of the Whole Board, may cancel, postpone or reschedule any previously scheduled special meeting at any time, before or after the notice for such meeting has been sent to the stockholders.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 72pt;">7.3 <u>Advance Notice</u>. Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders of the Corporation shall be given in the manner provided in the Bylaws of the Corporation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ARTICLE VIII</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 72pt;">8.1 <u>Limitation of Personal Liability</u>. To the fullest extent permitted by the DGCL, as it presently exists or may hereafter be amended from time to time, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 72pt;">8.2 <u>Indemnification</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Corporation shall indemnify, to the fullest extent permitted by applicable law, any director or officer of the Corporation who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#8220;<b>Proceeding</b>&#8221;) by reason of the fact that he or she is or was a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding. The Corporation shall be required to indemnify a person in connection with a Proceeding initiated by such person only if the Proceeding was authorized by the Board.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Corporation shall have the power to indemnify, to the extent permitted by the DGCL, as it presently exists or may hereafter be amended from time to time, any employee or agent of the Corporation who was or is a party or is threatened to be made a party to any Proceeding by reason of the fact that he or she is or was a director, officer, employee or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Any repeal or amendment of this Article VIII by the stockholders of the Corporation or by changes in law, or the adoption of any other provision of this Certificate of Incorporation inconsistent with this Article VIII will, unless otherwise required by law, be prospective only (except to the extent such amendment or change in law permits the Corporation to further limit or eliminate the liability of directors) and shall not adversely affect any right or protection of a director of the Corporation existing at the time of such repeal or amendment or adoption of such inconsistent provision with respect to acts or omissions occurring prior to such repeal or amendment or adoption of such inconsistent provision.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>ARTICLE IX</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">If any provision or provisions of this Certificate of Incorporation shall be held to be invalid, illegal or unenforceable as applied to any circumstance for any reason whatsoever: (i) the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Certificate of Incorporation (including, without limitation, each portion of any paragraph of this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and (ii) to the fullest extent possible, the provisions of this Certificate of Incorporation (including, without limitation, each such portion of any paragraph of this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to permit the Corporation to protect its directors, officers, employees and agents from personal liability in respect of their good faith service or for the benefit of the Corporation to the fullest extent permitted by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation (including any rights, preferences or other designations of Preferred Stock), in the manner now or hereafter prescribed by this Certificate of Incorporation and the DGCL; and all rights, preferences and privileges herein conferred upon stockholders by and pursuant to this Certificate of Incorporation in its present form or as hereafter amended are granted subject to the right reserved in this Article IX. Notwithstanding any other provision of this Certificate of Incorporation, and in addition to any other vote that may be required by law or the terms of any series of Preferred Stock, the affirmative vote of the holders of at least 66&#8532;% of the voting power of all then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend, alter or repeal, or adopt any provision as part of this Certificate of Incorporation inconsistent with the purpose and intent of, Article V, Article VI, Article VII, Article VIII or this Article IX (including, without limitation, any such Article as renumbered as a result of any amendment, alteration, change, repeal or adoption of any other Article).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>CERTIFICATE OF AMENDMENT</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>TO THE </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>OF</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>BIOCARDIA, INC.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">BioCardia, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;<u>Corporation</u>&#8221;), certifies that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">1. The name of the Corporation is BioCardia, Inc. The Corporation was originally incorporated under the name &#8220;NAM Corporation&#8221; and the Corporation&#8217;s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on January 12, 1994.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">2. The Corporation&#8217;s Amended and Restated Certificate of Incorporation is hereby amended as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">a.</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;">Article IV, Section 4.1 of the Corporation&#8217;s Certificate of Incorporation is hereby amended and restated in its entirety to read as follows:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&#8220;<u>Authorized Capital Stock</u>. Effective upon the filing of the Certificate of Amendment to the Amended and Restated Certificate of Incorporation amending this paragraph (the &#8220;<u>Effective Time</u>&#8221;), each two (2) to twenty (20) shares of Common Stock shall automatically be exchanged and combined into one (1) validly issued, fully paid and non-assessable share of Common Stock, in each case without any further action by the Corporation or any holder thereof, the exact ratio within the two to twenty range to be determined by the Board of Directors of the Corporation prior to the Effective Time and publicly announced by the Corporation, subject to the treatment of fractional share interests as described below (the &#8220;<u>Reverse Stock Split</u>&#8221;). No fractional shares of Common Stock shall be issued in connection with the Reverse Stock Split. The Reverse Stock Split shall be effected on a certificate-by-certificate basis and no fractional shares shall be issued upon the exchange and combination. Each certificate that immediately prior to the Effective Time represented shares of Common Stock (the &#8220;<u>Old Certificates</u>&#8221;) shall, until surrendered to the Corporation in exchange for a certificate representing such new number of shares of Common Stock, automatically represent that number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above and subject to prior combinations of Common Stock by the Corporation. The total number of shares of all classes of capital stock that the Corporation is authorized to issue is 75,000,000 shares, consisting of 50,000,000 shares of Common Stock, having par value of $0.001 (the &#8220;<u>Common Stock</u>&#8221;), and 25,000,000 shares of Preferred Stock, having a par value of $0.001 (the &#8220;<u>Preferred Stock</u>&#8221;).&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">3. On May 20, 2024, the Board of Directors of the Corporation determined that each fifteen (15) shares of the Corporation&#8217;s Common Stock issued immediately prior to the Effective Time shall automatically be combined into one (1) validly issued, fully paid and non-assessable share of Common Stock. The Corporation publicly announced this ratio on May 21, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">4. This Certificate of Amendment was duly adopted in accordance with Section 242 of the General Corporation Law of the State of Delaware, and amends the provisions of the Corporation&#8217;s Amended and Restated Certificate of Incorporation.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">5. This Certificate of Amendment shall become effective on May 30, 2024 at 12:01 a.m. Eastern Time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">[<i>Signature Page Follows</i>]</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><b>IN WITNESS WHEREOF</b>, this Certificate of Amendment is duly executed by the undersigned officer of the Corporation on May 29, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">By: <u>/s/ Peter Altman</u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Name: Peter Altman</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Title: President and Chief Executive Officer</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>3
<FILENAME>ex_711393.htm
<DESCRIPTION>EXHIBIT 4.4
<TEXT>
<html><head>
	<title>ex_711393.htm</title>

	<!-- Generated by ThunderDome Portal - 8/8/2024 10:03:22 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 4.4</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>BIOCARDIA, INC.</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>2016 EQUITY INCENTIVE PLAN</u></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(as amended effective May 30, 2024 (the &#8220;Effective Date&#8221;)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">1.<u> </u></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;"><u>Purposes of the Plan</u>. The purposes of this Plan are:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt; text-align: justify;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">to attract and retain the best available personnel for positions of substantial responsibility,</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt; text-align: justify;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">to provide additional incentive to Employees, Directors and Consultants, and</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 72pt; text-align: justify;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#9679;</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">to promote the success of the Company&#8217;s business.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">The Plan permits the grant of Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares.</p>

<p style="text-align: justify; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt; text-align: justify;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">2.<u> </u></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;"><u>Definitions</u>. As used herein, the following definitions will apply:</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<u>Administrator</u>&#8221; means the Board or any of its Committees as will be administering the Plan, in accordance with Section 4 of the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(b)&nbsp; &nbsp;&nbsp;&#8220;<u>Applicable Laws</u>&#8221; means the requirements relating to the administration of equity-based awards under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws of any foreign country or jurisdiction where Awards are, or will be, granted under the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(c)&nbsp; &nbsp;&nbsp;&#8220;<u>Award</u>&#8221; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(d)&nbsp; &nbsp;&nbsp;&#8220;<u>Award Agreement</u>&#8221; means the written or electronic agreement setting forth the terms and provisions applicable to each Award granted under the Plan. The Award Agreement is subject to the terms and conditions of the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(e)&nbsp; &nbsp;&nbsp;&#8220;<u>Board</u>&#8221; means the Board of Directors of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(f)&nbsp; &nbsp;&nbsp;&#8220;<u>Change in Control</u>&#8221; means the occurrence of any of the following events:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 99pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;A change in the ownership of the Company<i> </i>which occurs on the date that any one person, or more than one person acting as a group (&#8220;<u>Person</u>&#8221;), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than fifty percent (50%)&nbsp;of the total voting power of the stock of the Company; provided, however, that for purposes of this subsection, the acquisition of additional stock by any one Person, who is considered to own more than fifty percent (50%)&nbsp;of the total voting power of the stock of the Company will not be considered a Change in Control; or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 99pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="-" data-startnum="2" data-suffix="-" data-textalign="center">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 99pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;A change in the effective control of the Company which occurs on the date that a majority of members of the Board is replaced during any twelve (12)&nbsp;month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purposes of this clause (ii), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control; or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 99pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 99pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;A change in the ownership of a substantial portion of the Company&#8217;s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12)&nbsp;month period ending on the date of the most recent acquisition by such person or persons)&nbsp;assets from the Company that have a total gross fair market value equal to or more than fifty percent (50%)&nbsp;of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions; provided, however, that for purposes of this subsection (iii), the following will not constitute a change in the ownership of a substantial portion of the Company&#8217;s assets: (A)&nbsp;a transfer to an entity that is controlled by the Company&#8217;s stockholders immediately after the transfer, or (B)&nbsp;a transfer of assets by the Company to: (1)&nbsp;a stockholder of the Company (immediately before the asset transfer)&nbsp;in exchange for or with respect to the Company&#8217;s stock, (2)&nbsp;an entity, fifty percent (50%)&nbsp;or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (3)&nbsp;a Person, that owns, directly or indirectly, fifty percent (50%)&nbsp;or more of the total value or voting power of all the outstanding stock of the Company, or (4)&nbsp;an entity, at least fifty percent (50%)&nbsp;of the total value or voting power of which is owned, directly or indirectly, by a Person described in this subsection (iii)(B)(3). For purposes of this subsection (iii), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">For purposes of this definition, persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in control event within the meaning of Code Section&nbsp;409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and Internal Revenue Service guidance that has been promulgated or may be promulgated thereunder from time to time.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">Further and for the avoidance of doubt, a transaction will not constitute a Change in Control if: (i)&nbsp;its sole purpose is to change the state of the Company&#8217;s incorporation, or (ii)&nbsp;its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#8217;s securities immediately before such transaction.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&#8220;<u>Code</u>&#8221; means the Internal Revenue Code of 1986, as amended. Reference to a specific section of the Code or regulation thereunder will include such section or regulation, any valid regulation promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(h)&nbsp; &nbsp; &#8220;<u>Committee</u>&#8221; means a committee of Directors or of other individuals satisfying Applicable Laws appointed by the Board, or a duly authorized committee of the Board, in accordance with Section 4 hereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(i)&nbsp; &nbsp; &#8220;<u>Common Stock</u>&#8221; means the common stock of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="-" data-suffix="-" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-2-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(j)&nbsp; &nbsp; &#8220;<u>Company</u>&#8221; means BioCardia, Inc., a Delaware corporation, or any successor thereto.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(k)&nbsp; &nbsp;&nbsp;&#8220;<u>Consultant</u>&#8221; means any natural person, including an advisor, engaged by the Company or a Parent or Subsidiary to render bona fide services to such entity, provided the services (i)&nbsp;are not in connection with the offer or sale of securities in a capital-raising transaction, and (ii)&nbsp;do not directly promote or maintain a market for the Company&#8217;s securities.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(l)&nbsp; &nbsp;&nbsp;&#8220;<u>Director</u>&#8221; means a member of the Board.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(m)&nbsp; &nbsp;&nbsp;&#8220;<u>Disability</u>&#8221; means total and permanent disability as defined in Section&nbsp;22(e)(3)&nbsp;of the Code, provided that in the case of Awards other than Incentive Stock Options, the Administrator in its discretion may determine whether a permanent and total disability exists in accordance with uniform and non-discriminatory standards adopted by the Administrator from time to time.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(n)&nbsp; &nbsp;&nbsp;&#8220;<u>Employee</u>&#8221; means any person, including Officers and Directors, employed by the Company or any Parent or Subsidiary of the Company. Neither service as a Director nor payment of a director&#8217;s fee by the Company will be sufficient to constitute &#8220;employment&#8221; by the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(o)&nbsp; &nbsp;&nbsp;&#8220;<u>Exchange Act</u>&#8221; means the Securities Exchange Act of 1934, as amended.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(p)&nbsp; &nbsp;&nbsp;&#8220;<u>Exchange Program</u>&#8221; means a program under which (i)&nbsp;outstanding Awards are surrendered or cancelled in exchange for awards of the same type (which may have higher or lower exercise prices and different terms), awards of a different type, and/or cash, (ii)&nbsp;Participants would have the opportunity to transfer any outstanding Awards to a financial institution or other person or entity selected by the Administrator, and/or (iii)&nbsp;the exercise price of an outstanding Award is increased or reduced. The Administrator will determine the terms and conditions of any Exchange Program in its sole discretion.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(q)&nbsp; &nbsp;&nbsp;&#8220;<u>Fair Market Value</u>&#8221; means, as of any date, the value of Common Stock determined as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;If the Common Stock is listed on any established stock exchange or a national market system, including without limitation the New York Stock Exchange, the NASDAQ Global Select Market, the NASDAQ Global Market or the NASDAQ Capital Market of The NASDAQ Stock Market, its Fair Market Value will be the closing sales price for such stock (or the closing bid, if no sales were reported)&nbsp;as quoted on such exchange or system on the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value of a Share will be the mean between the high bid and low asked prices for the Common Stock on the date of determination (or, if no bids and asks were reported on that date, as applicable, on the last trading date such bids and asks were reported), as reported in The Wall Street Journal or such other source as the Administrator deems reliable; or</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;In the absence of an established market for the Common Stock, the Fair Market Value will be determined in good faith by the Administrator.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(r)&nbsp; &nbsp; &#8220;<u>Fiscal Year</u>&#8221; means the fiscal year of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(s)&nbsp; &nbsp;&nbsp;&#8220;<u>Incentive Stock Option</u>&#8221; means an Option that by its terms qualifies and is intended to qualify as an incentive stock option within the meaning of Section&nbsp;422 of the Code.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="-" data-suffix="-" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-3-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(t)&nbsp; &nbsp;&nbsp;&#8220;<u>Inside Director</u>&#8221; means a Director who is an Employee.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(u)&nbsp; &nbsp;&nbsp;&#8220;<u>Nonstatutory Stock Option</u>&#8221; means an Option that by its terms does not qualify or is not intended to qualify as an Incentive Stock Option.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(v)&nbsp; &nbsp;&nbsp;&#8220;<u>Officer</u>&#8221; means a person who is an officer of the Company within the meaning of Section&nbsp;16 of the Exchange Act and the rules and regulations promulgated thereunder.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(w)&nbsp; &nbsp;&nbsp;&#8220;<u>Option</u>&#8221; means a stock option granted pursuant to the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(x)&nbsp; &nbsp;&nbsp;&#8220;<u>Outside Director</u>&#8221; means a Director who is not an Employee.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(y)&nbsp; &nbsp;&nbsp;&#8220;<u>Parent</u>&#8221; means a &#8220;parent corporation,&#8221; whether now or hereafter existing, as defined in Section&nbsp;424(e)&nbsp;of the Code.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(z)&nbsp; &nbsp;&nbsp;&#8220;<u>Participant</u>&#8221; means the holder of an outstanding Award.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(aa)&nbsp; &nbsp;&nbsp;&#8220;<u>Performance Share</u>&#8221; means an Award denominated in Shares which may be earned in whole or in part upon attainment of performance goals or other vesting criteria as the Administrator may determine pursuant to Section 10.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(bb)&nbsp; &nbsp;&nbsp;&#8220;<u>Performance Unit</u>&#8221; means an Award which may be earned in whole or in part upon attainment of performance goals or other vesting criteria as the Administrator may determine and which may be settled for cash, Shares or other securities or a combination of the foregoing pursuant to Section 10.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(cc)&nbsp; &nbsp;&nbsp;&#8220;<u>Period of Restriction</u>&#8221; means the period during which the transfer of Shares of Restricted Stock are subject to restrictions and therefore, the Shares are subject to a substantial risk of forfeiture. Such restrictions may be based on the passage of time, the achievement of target levels of performance, or the occurrence of other events as determined by the Administrator.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(dd)&nbsp; &nbsp;&nbsp;&#8220;<u>Plan</u>&#8221; means this 2016 Equity Incentive Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(ee)&nbsp; &nbsp;&nbsp;&#8220;<u>Restricted Stock</u>&#8221; means Shares issued pursuant to a Restricted Stock award under Section 7 of the Plan, or issued pursuant to the early exercise of an Option.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(ff)&nbsp; &nbsp;&nbsp;&#8220;<u>Restricted Stock Unit</u>&#8221; means a bookkeeping entry representing an amount equal to the Fair Market Value of one Share, granted pursuant to Section 8. Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(gg)&nbsp; &nbsp;&nbsp;&#8220;<u>Rule 16b-3</u>&#8221; means Rule 16b-3 of the Exchange Act or any successor to Rule 16b-3, as in effect when discretion is being exercised with respect to the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(hh)&nbsp; &nbsp;&nbsp;&#8220;<u>Section&nbsp;</u><u>16(b)</u>&#8221; means Section&nbsp;16(b)&nbsp;of the Exchange Act.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(ii)&nbsp; &nbsp;&nbsp;&#8220;<u>Service Provider</u>&#8221; means an Employee, Director or Consultant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(jj)&nbsp; &nbsp;&nbsp;&#8220;<u>Share</u>&#8221; means a share of the Common Stock, as adjusted in accordance with Section 14 of the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(kk)&nbsp; &nbsp;&nbsp;&#8220;<u>Stock Appreciation Right</u>&#8221; means an Award, granted alone or in connection with an Option, that pursuant to Section&nbsp;9 is designated as a Stock Appreciation Right.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="-" data-suffix="-" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-4-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(ll)&nbsp; &nbsp;&nbsp;&#8220;<u>Subsidiary</u>&#8221; means a &#8220;subsidiary corporation,&#8221; whether now or hereafter exist&#8208;ing, as defined in Section&nbsp;424(f)&nbsp;of the Code.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Stock</u><u> </u><u>Subject</u><u> </u><u>to</u><u> </u><u>the</u><u> </u><u>Plan</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock</u><u>&nbsp;</u><u>Subject</u><u>&nbsp;</u><u>to</u><u>&nbsp;</u><u>the</u><u>&nbsp;</u><u>Plan</u>. Subject to the provisions of Section 14 of the Plan, the maximum aggregate number of Shares that may be issued under the Plan is 245,509 Shares, plus any Shares subject to stock options or similar awards granted under the Company&#8217;s 2002&nbsp;Stock Option Plan (the &#8220;Prior Plan&#8221;) that, on or after the Effective Date, expire or otherwise terminate without having been exercised in full and Shares issued pursuant to awards granted under the Prior Plan that are forfeited to or repurchased by the Company, with the maximum number of Shares to be added to the Plan from previously granted awards under the Prior Plan equal to 4,353. The Shares may be authorized, but unissued, or reacquired Common Stock.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Automatic Share Reserve Increase</u>. Subject to the provisions of Section&nbsp;14 of the Plan, the number of Shares available for issuance under the Plan will be increased on the first day of each Fiscal Year beginning with the 2025 Fiscal Year, in an amount equal to the least of (i)&nbsp;66,666 Shares, (ii)&nbsp;four percent (4.0%) of the outstanding Shares on the last day of the immediately preceding Fiscal Year or (iii)&nbsp;such number of Shares determined by the Board; provided, however, that such determination under clause&nbsp;(iii) will be made no later than the last day of the immediately preceding Fiscal Year.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Lapsed Awards</u>. If an Award expires or becomes unexercisable without having been exercised in full, is surrendered pursuant to an Exchange Program, or, with respect to Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares, is forfeited to, or repurchased by, the Company due to failure to vest, then the unpurchased Shares (or for Awards other than Options or Stock Appreciation Rights the forfeited or repurchased Shares), which were subject thereto will become available for future grant or sale under the Plan (unless the Plan has terminated). With respect to Stock Appreciation Rights, only Shares actually issued (i.e., the net Shares issued)&nbsp;pursuant to a Stock Appreciation Right will cease to be available under the Plan; all remaining Shares under Stock Appreciation Rights will remain available for future grant or sale under the Plan (unless the Plan has terminated). Shares that actually have been issued under the Plan under any Award will not be returned to the Plan and will not become available for future distribution under the Plan; provided, however, that if Shares issued pursuant to Awards of Restricted Stock, Restricted Stock Units, Performance Shares or Performance Units are repurchased by the Company or are forfeited to the Company, such Shares will become available for future grant under the Plan. Shares used to pay the exercise price of an Award or to satisfy the tax withholding obligations related to an Award will become available for future grant or sale under the Plan. To the extent an Award under the Plan is paid out in cash rather than Shares, such cash payment will not result in reducing the number of Shares available for issuance under the Plan. Notwithstanding the foregoing and, subject to adjustment as provided in Section 14, the maximum number of Shares that may be issued upon the exercise of Incentive Stock Options will equal the aggregate Share number stated in Section&nbsp;3(a), plus, to the extent allowable under Section 422 of the Code, any Shares that become available for issuance under the Plan pursuant to Sections 3(b)&nbsp;and 3(c).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Share Reserve</u>. The Company, during the term of this Plan, will at all times reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="5" data-prefix="-" data-suffix="-" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-5-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.<u> </u></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Administration of the Plan</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(a)&nbsp; &nbsp; &nbsp;&nbsp;<u>Procedure</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Multiple Administrative Bodies</u>. Different Committees with respect to different groups of Service Providers may administer the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Section</u><u>&nbsp;</u><u>162(m)</u>. To the extent that the Administrator determines it to be desirable to qualify Awards granted hereunder as &#8220;performance-based compensation&#8221; within the meaning of Section&nbsp;162(m)&nbsp;of the Code, the Plan will be administered by a Committee of two (2)&nbsp;or more &#8220;outside directors&#8221; within the meaning of Section&nbsp;162(m)&nbsp;of the Code.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Rule 16b-3</u>. To the extent desirable to qualify transactions hereunder as exempt under Rule 16b-3, the transactions contemplated hereunder will be structured to satisfy the requirements for exemption under Rule 16b-3.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Administration</u>. Other than as provided above, the Plan will be administered by (A)&nbsp;the Board or (B)&nbsp;a Committee, which committee will be constituted to satisfy Applicable Laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(b)&nbsp; &nbsp; &nbsp; <u>Powers of the Administrator</u>. Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific duties delegated by the Board to such Committee, the Administrator will have the authority, in its discretion:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;to determine the Fair Market Value;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;to select the Service Providers to whom Awards may be granted hereunder;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;to determine the number of Shares to be covered by each Award granted hereunder;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;to approve forms of Award Agreements for use under the Plan;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(v)&nbsp;&nbsp;&nbsp;&nbsp;to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and conditions include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Administrator will determine;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;to institute and determine the terms and conditions of an Exchange Program;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;to construe and interpret the terms of the Plan and Awards granted pursuant to the Plan;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(viii)&nbsp;&nbsp;&nbsp;&nbsp;to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans established for the purpose of satisfying applicable foreign laws or for qualifying for favorable tax treatment under applicable foreign laws;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="6" data-prefix="-" data-suffix="-" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-6-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;to modify or amend each Award (subject to Section&nbsp;19 of the Plan), including but not limited to the discretionary authority to extend the post-termination exercisability period of Awards and to extend the maximum term of an Option (subject to Section 6(b)&nbsp;of the Plan regarding Incentive Stock Options);</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(x)&nbsp;&nbsp;&nbsp;&nbsp;to allow Participants to satisfy tax withholding obligations in such manner as prescribed in Section 15 of the Plan;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(xi)&nbsp;&nbsp;&nbsp;&nbsp;to authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously granted by the Administrator;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 126pt; text-align: justify;">(xii)&nbsp;&nbsp;&nbsp;&nbsp;to allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that otherwise would be due to such Participant under an Award; and</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 126pt; text-align: justify;">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;to make all other determinations deemed necessary or advisable for administering the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(c)<u>&nbsp;&nbsp;&nbsp;&nbsp;Effect of Administrator</u><u>&#8217;</u><u>s</u><u>&nbsp;</u><u>Decision</u>. The Administrator&#8217;s decisions, determinations and interpretations will be final and binding on all Participants and any other holders of Awards.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; <u>Eligibility</u>. Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Shares and Performance Units may be granted to Service Providers. Incentive Stock Options may be granted only to Employees.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6.<u> </u></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Stock Options</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitations</u>. Each Option will be designated in the Award Agreement as either an Incentive Stock Option or a Nonstatutory Stock Option. However, notwithstanding such designation, to the extent that the aggregate Fair Market Value of the Shares with respect to which Incentive Stock Options are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary)&nbsp;exceeds one hundred thousand dollars ($100,000), such Options will be treated as Nonstatutory Stock Options. For purposes of this Section&nbsp;6(a), Incentive Stock Options will be taken into account in the order in which they were granted. The Fair Market Value of the Shares will be determined as of the time the Option with respect to such Shares is granted.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Term of Option</u>. The term of each Option will be stated in the Award Agreement. In the case of an Incentive Stock Option, the term will be ten (10)&nbsp;years from the date of grant or such shorter term as may be provided in the Award Agreement. Moreover, in the case of an Incentive Stock Option granted to a Participant who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent (10%)&nbsp;of the total combined voting power of all classes of stock of the Company or any Parent or Subsidiary, the term of the Incentive Stock Option will be five (5)&nbsp;years from the date of grant or such shorter term as may be provided in the Award Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Option Exercise Price and Consideration</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(i)&nbsp; &nbsp; &nbsp; &nbsp;<u>Exercise Price</u>. The per share exercise price for the Shares to be issued pursuant to exercise of an Option will be determined by the Administrator, subject to the following:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 126pt; text-align: justify;">(1)&nbsp; &nbsp; &nbsp; In the case of an Incentive Stock Option</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 153pt; text-align: justify;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;granted to an Employee who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent (10%)&nbsp;of the voting power of all classes of stock of the Company or any Parent or Subsidiary, the per Share exercise price will be no less than one hundred ten percent (110%)&nbsp;of the Fair Market Value per Share on the date of grant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="7" data-prefix="-" data-suffix="-" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-7-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 153pt; text-align: justify;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;granted to any Employee other than an Employee described in paragraph (A)&nbsp;immediately above, the per Share exercise price will be no less than one hundred percent (100%)&nbsp;of the Fair Market Value per Share on the date of grant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 126pt; text-align: justify;">(2)&nbsp; &nbsp; &nbsp; In the case of a Nonstatutory Stock Option, the per Share exercise price will be no less than one hundred percent (100%)&nbsp;of the Fair Market Value per Share on the date of grant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 126pt; text-align: justify;">(3)&nbsp; &nbsp; &nbsp; Notwithstanding the foregoing, Options may be granted with a per Share exercise price of less than one hundred percent (100%)&nbsp;of the Fair Market Value per Share on the date of grant pursuant to a transaction described in, and in a manner consistent with, Section&nbsp;424(a)&nbsp;of the Code.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(ii)&nbsp; &nbsp; &nbsp; <u>Waiting Period and Exercise Dates</u>. At the time an Option is granted, the Administrator will fix the period within which the Option may be exercised and will determine any conditions that must be satisfied before the Option may be exercised.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Form of Consideration</u>. The Administrator will determine the acceptable form of consideration for exercising an Option, including the method of payment. In the case of an Incentive Stock Option, the Administrator will determine the acceptable form of consideration at the time of grant. Such consideration may consist entirely of: (1)&nbsp;cash; (2)&nbsp;check; (3)&nbsp;promissory note, to the extent permitted by Applicable Laws, (4)&nbsp;other Shares, provided that such Shares have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which such Option will be exercised and provided that accepting such Shares will not result in any adverse accounting consequences to the Company, as the Administrator determines in its sole discretion; (5)&nbsp;consideration received by the Company under a broker-assisted (or other)&nbsp;cashless exercise program (whether through a broker or otherwise)&nbsp;implemented by the Company in connection with the Plan; (6)&nbsp;by net exercise; (7)&nbsp;such other consideration and method of payment for the issuance of Shares to the extent permitted by Applicable Laws; or (8)&nbsp;any combination of the foregoing methods of payment.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(d)<u> </u></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Exercise of Option</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;<u>Procedure for Exercise; Rights as a Stockholder</u>. Any Option granted hereunder will be exercisable according to the terms of the Plan and at such times and under such conditions as determined by the Administrator and set forth in the Award Agreement. An Option may not be exercised for a fraction of a Share.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 117pt; text-align: justify;">An Option will be deemed exercised when the Company receives: (i)&nbsp;a notice of exercise (in such form as the Administrator may specify from time to time)&nbsp;from the person entitled to exercise the Option, and (ii)&nbsp;full payment for the Shares with respect to which the Option is exercised (together with applicable withholding taxes). Full payment may consist of any consideration and method of payment authorized by the Administrator and permitted by the Award Agreement and the Plan. Shares issued upon exercise of an Option will be issued in the name of the Participant or, if requested by the Participant, in the name of the Participant and his or her spouse. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder will exist with respect to the Shares subject to an Option, notwithstanding the exercise of the Option. The Company will issue (or cause to be issued)&nbsp;such Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 14 of the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="8" data-prefix="-" data-suffix="-" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-8-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under the Option, by the number of Shares as to which the Option is exercised.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination of Relationship as a Service Provider</u>. If a Participant ceases to be a Service Provider, other than upon the Participant&#8217;s termination as the result of the Participant&#8217;s death or Disability, the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement). In the absence of a specified time in the Award Agreement, the Option will remain exercisable for three (3)&nbsp;months following the Participant&#8217;s termination. Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan. If after termination the Participant does not exercise his or her Option within the time specified by the Administrator, the Option will terminate, and the Shares covered by such Option will revert to the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<u>Disability of Participant</u>. If a Participant ceases to be a Service Provider as a result of the Participant&#8217;s Disability, the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement). In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12)&nbsp;months following the Participant&#8217;s termination. Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan. If after termination the Participant does not exercise his or her Option within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;<u>Death of Participant</u>. If a Participant dies while a Service Provider, the Option may be exercised following the Participant&#8217;s death within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of death (but in no event may the option be exercised later than the expiration of the term of such Option as set forth in the Award Agreement), by the Participant&#8217;s designated beneficiary, provided such beneficiary has been designated prior to Participant&#8217;s death in a form acceptable to the Administrator. If no such beneficiary has been designated by the Participant, then such Option may be exercised by the personal representative of the Participant&#8217;s estate or by the person(s)&nbsp;to whom the Option is transferred pursuant to the Participant&#8217;s will or in accordance with the laws of descent and distribution. In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12)&nbsp;months following Participant&#8217;s death. Unless otherwise provided by the Administrator, if at the time of death Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will immediately revert to the Plan. If the Option is not so exercised within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="9" data-prefix="-" data-suffix="-" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-9-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7.<u> </u></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Restricted Stock</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Grant of Restricted Stock</u>. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time, may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Restricted Stock Agreement</u>. Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of Restriction, the number of Shares granted, and such other terms and conditions as the Administrator, in its sole discretion, will determine. Unless the Administrator determines otherwise, the Company as escrow agent will hold Shares of Restricted Stock until the restrictions on such Shares have lapsed.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Transferability</u>. Except as provided in this Section 7 or the Award Agreement, Shares of Restricted Stock may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated until the end of the applicable Period of Restriction.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Restrictions</u>. The Administrator, in its sole discretion, may impose such other restrictions on Shares of Restricted Stock as it may deem advisable or appropriate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Removal of Restrictions</u>. Except as otherwise provided in this Section 7, Shares of Restricted Stock covered by each Restricted Stock grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction or at such other time as the Administrator may determine. The Administrator, in its discretion, may accelerate the time at which any restrictions will lapse or be removed.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Voting Rights</u>. During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder may exercise full voting rights with respect to those Shares, unless the Administrator determines otherwise.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(g)&nbsp;&nbsp;&nbsp;&nbsp;<u>Dividends and Other Distributions</u>. During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be entitled to receive all dividends and other distributions paid with respect to such Shares, unless the Administrator provides otherwise. If any such dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were paid.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(h)&nbsp;&nbsp;&nbsp;&nbsp;<u>Return of Restricted Stock to Company</u>. On the date set forth in the Award Agreement, the Restricted Stock for which restrictions have not lapsed will revert to the Company and again will become available for grant under the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8.<u> </u></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Restricted Stock Units</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Grant</u>. Restricted Stock Units may be granted at any time and from time to time as determined by the Administrator. After the Administrator determines that it will grant Restricted Stock Units under the Plan, it will advise the Participant in an Award Agreement of the terms, conditions, and restrictions related to the grant, including the number of Restricted Stock Units.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Vesting Criteria and Other Terms</u>. The Administrator will set vesting criteria in its discretion, which, depending on the extent to which the criteria are met, will determine the number of Restricted Stock Units that will be paid out to the Participant. The Administrator may set vesting criteria based upon the achievement of Company-wide, divisional, business unit, or individual goals (including, but not limited to, continued employment or service), applicable federal or state securities laws or any other basis determined by the Administrator in its discretion.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="10" data-prefix="-" data-suffix="-" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-10-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Earning Restricted Stock Units</u>. Upon meeting the applicable vesting criteria, the Participant will be entitled to receive a payout as determined by the Administrator. Notwithstanding the foregoing, at any time after the grant of Restricted Stock Units, the Administrator, in its sole discretion, may reduce or waive any vesting criteria that must be met to receive a payout.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Form and Timing of Payment</u>. Payment of earned Restricted Stock Units will be made as soon as practicable after the date(s)&nbsp;determined by the Administrator and set forth in the Award Agreement. The Administrator, in its sole discretion, may only settle earned Restricted Stock Units in cash, Shares, or a combination of both.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cancellation</u>. On the date set forth in the Award Agreement, all unearned Restricted Stock Units will be forfeited to the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">9.<u> </u></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Stock Appreciation Rights</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(a)&nbsp; &nbsp; &nbsp;&nbsp;<u>Grant of Stock Appreciation Rights</u>. Subject to the terms and conditions of the Plan, a Stock Appreciation Right may be granted to Service Providers at any time and from time to time as will be determined by the Administrator, in its sole discretion.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(b)&nbsp; &nbsp; &nbsp;&nbsp;<u>Number of Shares</u>. The Administrator will have complete discretion to determine the number of Stock Appreciation Rights granted to any Service Provider.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(c)&nbsp; &nbsp; &nbsp;&nbsp;<u>Exercise Price and Other Terms</u>. The per share exercise price for the Shares to be issued pursuant to exercise of a Stock Appreciation Right will be determined by the Administrator and will be no less than one hundred percent (100%)&nbsp;of the Fair Market Value per Share on the date of grant. Otherwise, the Administrator, subject to the provisions of the Plan, will have complete discretion to determine the terms and conditions of Stock Appreciation Rights granted under the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(d)&nbsp; &nbsp; &nbsp;&nbsp;<u>Stock Appreciation Right Agreement</u>. Each Stock Appreciation Right grant will be evidenced by an Award Agreement that will specify the exercise price, the term of the Stock Appreciation Right, the conditions of exercise, and such other terms and conditions as the Administrator, in its sole discretion, will determine.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(e)&nbsp; &nbsp; &nbsp;&nbsp;<u>Expiration of Stock Appreciation Rights</u>. A Stock Appreciation Right granted under the Plan will expire ten (10)&nbsp;years from the date of grant or such shorter term as may be provided in the Award Agreement, as determined by the Administrator, in its sole discretion. Notwithstanding the foregoing, the rules of Section 6(d)&nbsp;relating to exercise also will apply to Stock Appreciation Rights.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(f)&nbsp; &nbsp; &nbsp;&nbsp;<u>Payment of Stock Appreciation Right Amount</u>. Upon exercise of a Stock Appreciation Right, a Participant will be entitled to receive payment from the Company in an amount determined by multiplying:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;The difference between the Fair Market Value of a Share on the date of exercise over the exercise price; times</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 99pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The number of Shares with respect to which the Stock Appreciation Right is exercised.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="11" data-prefix="-" data-suffix="-" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-11-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">At the discretion of the Administrator, the payment upon Stock Appreciation Right exercise may be in cash, in Shares of equivalent value, or in some combination thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Performance Units and Performance Shares</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Grant of Performance Units/Shares</u>. Performance Units and Performance Shares may be granted to Service Providers at any time and from time to time, as will be determined by the Administrator, in its sole discretion. The Administrator will have complete discretion in determining the number of Performance Units and Performance Shares granted to each Participant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Value of Performance Units/Shares</u>. Each Performance Unit will have an initial value that is established by the Administrator on or before the date of grant. Each Performance Share will have an initial value equal to the Fair Market Value of a Share on the date of grant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Performance Objectives and Other Terms</u>. The Administrator will set performance objectives or other vesting provisions (including, without limitation, continued status as a Service Provider)&nbsp;in its discretion which, depending on the extent to which they are met, will determine the number or value of Performance Units/Shares that will be paid out to the Service Providers. The time period during which the performance objectives or other vesting provisions must be met will be called the &#8220;<u>Performance Period</u>.&#8221; Each Award of Performance Units/Shares will be evidenced by an Award Agreement that will specify the Performance Period, and such other terms and conditions as the Administrator, in its sole discretion, will determine. The Administrator may set performance objectives based upon the achievement of Company-wide, divisional, business unit or individual goals (including, but not limited to, continued employment or service), applicable federal or state securities laws, or any other basis determined by the Administrator in its discretion.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Earning of Performance Units/Shares</u>. After the applicable Performance Period has ended, the holder of Performance Units/Shares will be entitled to receive a payout of the number of Performance Units/Shares earned by the Participant over the Performance Period, to be determined as a function of the extent to which the corresponding performance objectives or other vesting provisions have been achieved. After the grant of a Performance Unit/Share, the Administrator, in its sole discretion, may reduce or waive any performance objectives or other vesting provisions for such Performance Unit/Share.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;<u>Form and Timing of Payment of Performance Units/Shares</u>. Payment of earned Performance Units/Shares will be made as soon as practicable after the expiration of the applicable Performance Period. The Administrator, in its sole discretion, may pay earned Performance Units/Shares in the form of cash, in Shares (which have an aggregate Fair Market Value equal to the value of the earned Performance Units/Shares at the close of the applicable Performance Period)&nbsp;or in a combination thereof.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cancellation of Performance Units/Shares</u>. On the date set forth in the Award Agreement, all unearned or unvested Performance Units/Shares will be forfeited to the Company, and again will be available for grant under the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">11.<u> </u></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Outside Director Limitations</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Cash-settled Awards</u>. No Outside Director may be granted, in any Fiscal Year, cash&#8209;settled Awards with a grant date fair value (determined in accordance with U.S. generally accepted accounting principles) of greater than $300,000, increased to $500,000 in the Fiscal Year of his or her initial service as an Outside Director.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="12" data-prefix="-" data-suffix="-" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-12-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stock-settled Awards</u>. Subject to the provisions of Section 14 of the Plan, no Outside Director may be granted, in any Fiscal Year, Awards covering more than 33,333 Shares, increased to 50,000 Shares in the Fiscal Year of his or her initial service as an Outside Director.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any Awards granted to an individual while he or she was an Employee, or while he or she was a Consultant but not an Outside Director, will not count for purposes of the limitations under this Section&nbsp;11.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">12.&nbsp; &nbsp; &nbsp; &nbsp;<u>Leaves of Absence/Transfer Between Locations</u>. Unless the Administrator provides otherwise, vesting of Awards granted hereunder will be suspended during any unpaid leave of absence. A Participant will not cease to be an Employee in the case of (i)&nbsp;any leave of absence approved by the Company or (ii)&nbsp;transfers between locations of the Company or between the Company, its Parent, or any Subsidiary. For purposes of Incentive Stock Options, no such leave may exceed three (3)&nbsp;months, unless reemployment upon expiration of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence approved by the Company is not so guaranteed, then six (6)&nbsp;months following the first (1st)&nbsp;day of such leave any Incentive Stock Option held by the Participant will cease to be treated as an Incentive Stock Option and will be treated for tax purposes as a Nonstatutory Stock Option.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">13.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Transferability of Awards</u>. Unless determined otherwise by the Administrator, an Award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Participant, only by the Participant. If the Administrator makes an Award transferable, such Award will contain such additional terms and conditions as the Administrator deems appropriate.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">14.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Adjustments; Dissolution or Liquidation; Change in Control</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustments</u>. In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, will adjust the number and class of Shares that may be delivered under the Plan and/or the number, class, and price of Shares covered by each outstanding Award, and the numerical Share limits in Sections&nbsp;3 and 11(b) of the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Dissolution or Liquidation</u>. In the event of the proposed dissolution or liquidation of the Company, the Administrator will notify each Participant as soon as practicable prior to the effective date of such proposed transaction. To the extent it previously has not been exercised, an Award will terminate immediately prior to the consummation of such proposed action.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Change in Control</u>. In the event of a Change in Control, each outstanding Award will be treated as the Administrator determines, including, without limitation, that (i)&nbsp;Awards may be assumed, or substantially equivalent Awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof) with appropriate adjustments as to the number and kind of shares and prices; (ii) upon written notice to a Participant, that the Participant&#8217;s Awards will terminate upon or immediately prior to the consummation of such Change in Control; (iii) outstanding Awards will vest and become exercisable, realizable, or payable, or restrictions applicable to an Award will lapse, in whole or in part prior to or upon consummation of such Change in Control, and, to the extent the Administrator determines, terminate upon or immediately prior to the effectiveness of such merger or Change in Control; (iv)&nbsp;(A)&nbsp;the termination of an Award in exchange for an amount of cash and/or property, if any, equal to the amount that would have been attained upon the exercise of such Award or realization of the Participant&#8217;s rights as of the date of the occurrence of the transaction (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction the Administrator determines in good faith that no amount would have been attained upon the exercise of such Award or realization of the Participant&#8217;s rights, then such Award may be terminated by the Company without payment), or (B)&nbsp;the replacement of such Award with other rights or property selected by the Administrator in its sole discretion; or (v) any combination of the foregoing. In taking any of the actions permitted under this Section&nbsp;14(c), the Administrator will not be required to treat all Awards similarly in the transaction.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="13" data-prefix="-" data-suffix="-" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-13-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">In the event that the successor corporation does not assume or substitute for the Award, the Participant will fully vest in and have the right to exercise all of his or her outstanding Options and Stock Appreciation Rights, including Shares as to which such Awards would not otherwise be vested or exercisable, all restrictions on Restricted Stock and Restricted Stock Units will lapse, and, with respect to Awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%)&nbsp;of target levels and all other terms and conditions met. In addition, if an Option or Stock Appreciation Right is not assumed or substituted in the event of a Change in Control, the Administrator will notify the Participant in writing or electronically that the Option or Stock Appreciation Right will be exercisable for a period of time determined by the Administrator in its sole discretion, and the Option or Stock Appreciation Right will terminate upon the expiration of such period.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">For the purposes of this subsection (c), an Award will be considered assumed if, following the Change in Control, the Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the Change in Control, the consideration (whether stock, cash, or other securities or property)&nbsp;received in the Change in Control by holders of Common Stock for each Share held on the effective date of the transaction (and if holders were offered a choice of consideration, thes type of consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that if such consideration received in the Change in Control is not solely common stock of the successor corporation or its Parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise of an Option or Stock Appreciation Right or upon the payout of a Restricted Stock Unit, Performance Unit or Performance Share, for each Share subject to such Award, to be solely common stock of the successor corporation or its Parent equal in fair market value to the per share consideration received by holders of Common Stock in the Change in Control.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">Notwithstanding anything in this Section 14(c)&nbsp;to the contrary, an Award that vests, is earned or paid-out upon the satisfaction of one or more performance goals will not be considered assumed if the Company or its successor modifies any of such performance goals without the Participant&#8217;s consent; provided, however, a modification to such performance goals only to reflect the successor corporation&#8217;s post-Change in Control corporate structure will not be deemed to invalidate an otherwise valid Award assumption.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;<u>Outside Director Awards</u>. With respect to Awards granted to an Outside Director, in the event of a Change in Control, the Participant will fully vest in and have the right to exercise Options and/or Stock Appreciation Rights as to all of the Shares underlying such Award, including those Shares which otherwise would not be vested or exercisable, all restrictions on Restricted Stock and Restricted Stock Units will lapse, and, with respect to Awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%)&nbsp;of target levels and all other terms and conditions met.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="14" data-prefix="-" data-suffix="-" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-14-</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">15.<u> </u></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Tax</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Withholding Requirements</u>. Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof)&nbsp;or such earlier time as any tax withholding obligations are due, the Company will have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy federal, state, local, foreign or other taxes (including the Participant&#8217;s FICA obligation)&nbsp;required to be withheld with respect to such Award (or exercise thereof).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Withholding Arrangements</u>. The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit a Participant to satisfy such tax withholding obligation, in whole or in part by (without limitation)&nbsp;(a)&nbsp;paying cash, (b)&nbsp;electing to have the Company withhold otherwise deliverable cash or Shares having a Fair Market Value equal to the minimum statutory amount required to be withheld, or (c)&nbsp;delivering to the Company already-owned Shares having a Fair Market Value equal to the minimum statutory amount required to be withheld. The Fair Market Value of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to be withheld.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance With Code Section</u><u>&nbsp;</u><u>409A</u>. Awards will be designed and operated in such a manner that they are either exempt from the application of, or comply with, the requirements of Code Section&nbsp;409A such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Code Section&nbsp;409A, except as otherwise determined in the sole discretion of the Administrator. The Plan and each Award Agreement under the Plan is intended to meet the&nbsp;requirements of Code Section&nbsp;409A and will be construed and interpreted in accordance with such intent, except as otherwise determined in the sole discretion of the Administrator. To the extent that an Award or payment, or the settlement or deferral thereof, is subject to Code Section&nbsp;409A, the Award will be granted, paid, settled or deferred in a manner that will meet the requirements of Code Section&nbsp;409A, such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Code Section&nbsp;409A.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">16.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>No Effect on Employment or Service</u>. Neither the Plan nor any Award will confer upon a Participant any right with respect to continuing the Participant&#8217;s relationship as a Service Provider with the Company, nor will they interfere in any way with the Participant&#8217;s right or the Company&#8217;s right to terminate such relationship at any time, with or without cause, to the extent permitted by Applicable Laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">17.&nbsp; &nbsp; &nbsp; &nbsp; <u>Date of Grant</u>. The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the determination granting such Award, or such other later date as is determined by the Administrator. Notice of the determination will be provided to each Participant within a reasonable time after the date of such grant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">18.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Term of Plan</u>. Subject to Section 22<b> </b>of the Plan, the Plan will become effective upon the date of its adoption by the Board. It will continue in effect for a term of ten (10)&nbsp;years from the date adopted by the Board, unless terminated earlier under Section 19<b> </b>of the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">19.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Amendment and Termination of the Plan</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment and Termination</u>. The Administrator may at any time amend, alter, suspend or terminate the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Stockholder Approval</u>. The Company will obtain stockholder approval of any Plan amendment to the extent necessary and desirable to comply with Applicable Laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;<u>Effect of Amendment or Termination</u>. No amendment, alteration, suspension or termination of the Plan will materially impair the rights of any Participant, unless mutually agreed otherwise between the Participant and the Administrator, which agreement must be in writing and signed by the Participant and the Company. Termination of the Plan will not affect the Administrator&#8217;s ability to exercise the powers granted to it hereunder with respect to Awards granted under the Plan prior to the date of such termination.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">20.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<u>Conditions Upon Issuance of Shares</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;<u>Legal Compliance</u>. Shares will not be issued pursuant to the exercise of an Award unless the exercise of such Award and the issuance and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company with respect to such compliance.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;<u>Investment Representations</u>. As a condition to the exercise of an Award, the Company may require the person exercising such Award to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">21.&nbsp;&nbsp;&nbsp;&nbsp;<u>Inability to Obtain Authority</u>. The inability of the Company to obtain authority from any regulatory body having jurisdiction or to complete or comply with the requirements of any registration or other qualification of the Shares under any state, federal or foreign law or under the rules and regulations of the Securities and Exchange Commission, the stock exchange on which Shares of the same class are then listed, or any other governmental or regulatory body, which authority, registration, qualification or rule compliance is deemed by the Company&#8217;s counsel to be necessary or advisable for the issuance and sale of any Shares hereunder, will relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority, registration, qualification or rule compliance will not have been obtained.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">22.&nbsp;&nbsp;&nbsp;&nbsp;<u>Stockholder Approval</u>. The Plan will be subject to approval by the stockholders of the Company within twelve (12)&nbsp;months after the date the Plan is adopted by the Board. Such stockholder approval will be obtained in the manner and to the degree required under Applicable Laws.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="15" data-prefix="-" data-suffix="-" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">-15-</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>4
<FILENAME>ex_711394.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<html><head>
	<title>ex_711394.htm</title>

	<!-- Generated by ThunderDome Portal - 8/9/2024 6:04:49 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.10</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>AMENDMENT TO CHANGE OF CONTROL AND SEVERANCE AGREEMENT</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">This Amendment to the Change in Control and Severance Agreement (the &#8220;Amendment&#8221;) is entered into by and between BioCardia, Inc. (the &#8220;Company&#8221;) and Peter Altman (&#8220;Executive&#8221;) (together, the &#8220;Parties,&#8221; or individually, a &#8220;Party&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>RECITALS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">WHEREAS, Executive signed the Change in Control and Severance Agreement with the Company on August 22, 2016 (the &#8220;Agreement&#8221;); and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">WHEREAS, the Parties desire to amend the Agreement as set forth in this Amendment.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">NOW, THEREFORE, the Parties hereby agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">1.&nbsp; &nbsp; &nbsp; &nbsp;<u>Severance Entitlement(s)</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt;">a.&nbsp; &nbsp; &nbsp; &nbsp;Section 3(b) of the Agreement shall be amended to include the following subsection (iv):</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 90pt;">Notwithstanding any other provision set forth in this Agreement, so long as a good faith effort is made to pay executive severance that is due as if the severance were a board liability, for any termination of Executive without Cause under this provision which results due to a winding up of the business of BioCardia, which is followed by disposition of BioCardia assets, Executive agrees that personal resources that are unrelated to the disposition of BioCardia assets resulting from the winding up of the business of BioCardia of any BioCardia officers or BioCardia directors will not be pursued to cover the severance payments Executive is to receive under this agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;">2.&nbsp; &nbsp; &nbsp; &nbsp;<u>Notice. </u></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 63pt;">a.&nbsp; &nbsp; &nbsp; &nbsp; Section 9 (iv) (B) will be updated with the following:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 90pt;"><u>(</u>B) if to the Company, at the following address:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 90pt;">BioCardia, Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 90pt;">320 Soquel Way</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 90pt;">Sunnyvale, California 94085</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 90pt;">Attention: Chief Executive Officer</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">3.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Full Force and Effect</u>. To the extent not expressly amended hereby, the Agreement shall remain in full force and effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">4.&nbsp; &nbsp; &nbsp; &nbsp; <u>Effective Date</u>. This Amendment is effective as of May 30, 2024 (the &#8220;Effective Date&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">5.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Entire Agreement; No Oral Modification</u>. This Amendment constitute the full and entire understanding and agreement between the Company and Executive with regard to the amendment of the Agreement. This Amendment supersedes any prior promises, agreements, or understandings related to the subject matter hereof and may be amended only in writing signed by the Company&#8217;s Board of Directors.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">6.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Counterparts</u>. This Amendment may be executed in counterparts, each of which shall be deemed to be an original, and all such counterparts shall constitute but one instrument.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>[intentionally blank; signature page follows]</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">IN WITNESS WHEREOF, the Parties have executed this Amendment as of the date set forth below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">EXECUTIVE</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Dated:&nbsp; <u>&nbsp; &nbsp;</u><b><u>5/30/2024&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></b></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">/s/&nbsp;Peter Altman</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt 0px 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Peter Altman</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt 0px 18pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">President and CEO</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td valign="top" width="35%">&nbsp;</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td valign="top" width="35%">&nbsp;</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td valign="top" width="35%">&nbsp;</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td colspan="2" rowspan="1" valign="top" width="3%">COMPANY</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td valign="top" width="35%">&nbsp;</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td valign="top" width="35%">&nbsp;</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">Dated: <u>&nbsp; &nbsp;</u><b><u>5/30/2024&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></b></td>
			<td valign="top" width="3%">By</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0);" valign="top" width="35%">/s/&nbsp;David McClung</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td style="padding-left: 18pt;" valign="top" width="35%">David McClung</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td valign="top" width="50%">&nbsp;</td>
			<td valign="top" width="3%">&nbsp;</td>
			<td style="padding-left: 18pt;" valign="top" width="35%">Chief Financial Officer</td>
			<td valign="top" width="12%">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center;">2</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>5
<FILENAME>ex_711395.htm
<DESCRIPTION>EXHIBIT 10.11
<TEXT>
<html><head>
	<title>ex_711395.htm</title>

	<!-- Generated by ThunderDome Portal - 8/9/2024 5:38:30 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.11</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>AMENDMENT TO CHANGE OF CONTROL AND SEVERANCE AGREEMENT</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">This Amendment to the Change in Control and Severance Agreement (the &#8220;Amendment&#8221;) is entered into by and between BioCardia, Inc. (the &#8220;Company&#8221;) and Peter Altman (&#8220;Executive&#8221;) (together, the &#8220;Parties,&#8221; or individually, a &#8220;Party&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>RECITALS</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">WHEREAS, Executive signed the Change in Control and Severance Agreement with the Company on August 22, 2016 (the &#8220;Agreement&#8221;); and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">WHEREAS, the Parties desire to amend the Agreement as set forth in this Amendment.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">NOW, THEREFORE, the Parties hereby agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">1.<u> </u></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Severance Entitlement(s)</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt;">a.&nbsp; &nbsp; &nbsp; &nbsp; Section 3(b) of the Agreement shall be amended to include the following subsection (iv):</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 108pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;">Notwithstanding any other provision set forth in this Agreement, so long as a good faith effort is made to pay executive severance that is due as if the severance were a liability of the BioCardia Board of Directors, for any termination of Executive without Cause under this provision which results due to a winding up of the business of BioCardia, which is followed by disposition of BioCardia assets, Executive agrees that personal resources that are unrelated to the disposition of BioCardia assets resulting from the winding up of the business of BioCardia of any BioCardia officers or BioCardia directors will not be pursued to cover the severance payments Executive is to receive under this agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.<u> </u></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Notice. </u></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">a.&nbsp; &nbsp; &nbsp; &nbsp; Section 9 (iv) (B) will be updated with the following:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;"><u>(</u>B) if to the Company, at the following address:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;">BioCardia, Inc.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;">320 Soquel Way</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;">Sunnyvale, California 94085</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;">Attention: Chief Executive Officer</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">3.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Full Force and Effect</u>. To the extent not expressly amended hereby, the Agreement shall remain in full force and effect.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">4.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Effective Date</u>. This Amendment is effective as of May 30, 2024 (the &#8220;Effective Date&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">5.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; <u>Entire Agreement; No Oral Modification</u>. This Amendment constitute the full and entire understanding and agreement between the Company and Executive with regard to the amendment of the Agreement. This Amendment supersedes any prior promises, agreements, or understandings related to the subject matter hereof and may be amended only in writing signed by the Company&#8217;s Board of Directors.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">6.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<u>Counterparts</u>. This Amendment may be executed in counterparts, each of which shall be deemed to be an original, and all such counterparts shall constitute but one instrument.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>[intentionally blank; signature page follows]</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">IN WITNESS WHEREOF, the Parties have executed this Amendment as of the date set forth below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td style="width: 5%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 20%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 26%;" valign="top" width="50%">&nbsp;</td>
			<td colspan="2" style="width: 4%;" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">EXECUTIVE</p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 5%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 20%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 26%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 4%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 35%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 5%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 20%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 26%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 4%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="width: 35%;" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left; width: 5%;" valign="top" width="50%">Dated:</td>
			<td align="left" style="text-align: left; width: 20%; border-bottom: 1px solid rgb(0, 0, 0);" valign="top" width="50%">
			<p style="margin: 0px 0pt 0px 9pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>5/30/2024</b></p>
			</td>
			<td align="left" style="text-align: left; width: 26%;" valign="top" width="50%">&nbsp;</td>
			<td style="text-align: left; width: 4%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); width: 35%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">/s/&nbsp;David McClung</p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 5%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 20%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 26%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 4%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 35%;" valign="top" width="35%">
			<p style="margin: 0px 0pt 0px 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">David McClung</p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 5%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 20%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 26%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 4%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 35%;" valign="top" width="35%">
			<p style="margin: 0px 0pt 0px 27pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Chief Financial Officer</p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 5%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 20%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 26%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 4%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="35%">&nbsp;</td>
			<td style="width: 10%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 20%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 26%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 4%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="35%">&nbsp;</td>
			<td style="width: 10%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 20%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 26%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 4%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="35%">&nbsp;</td>
			<td style="width: 10%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 20%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 26%;" valign="top" width="50%">&nbsp;</td>
			<td colspan="2" rowspan="1" style="width: 4%;" valign="top" width="3%">COMPANY</td>
			<td style="width: 10%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 20%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 26%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 4%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="35%">&nbsp;</td>
			<td style="width: 10%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 20%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 26%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 4%;" valign="top" width="3%">&nbsp;</td>
			<td style="width: 35%;" valign="top" width="35%">&nbsp;</td>
			<td style="width: 10%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;" valign="top" width="50%">Dated:</td>
			<td style="width: 20%; padding-left: 9pt; border-bottom: 1px solid rgb(0, 0, 0);" valign="top" width="50%"><b>5/30/2024</b></td>
			<td style="width: 26%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 4%;" valign="top" width="3%">By</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); width: 35%;" valign="top" width="35%">/s/&nbsp;Peter Altman</td>
			<td style="width: 10%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 20%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 26%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 4%;" valign="top" width="3%">&nbsp;</td>
			<td style="padding-left: 27pt; width: 35%;" valign="top" width="35%">Peter Altman</td>
			<td style="width: 10%;" valign="top" width="12%">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 20%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 26%;" valign="top" width="50%">&nbsp;</td>
			<td style="width: 4%;" valign="top" width="3%">&nbsp;</td>
			<td style="padding-left: 27pt; width: 35%;" valign="top" width="35%">President and CEO</td>
			<td style="width: 10%;" valign="top" width="12%">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center;">2</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ex_711422.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>ex_711422.htm</title>

	<!-- Generated by ThunderDome Portal - 8/8/2024 8:17:25 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 23.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consent of Independent Registered Public Accounting Firm</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Board of Directors<br>
BioCardia, Inc.:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We consent to the incorporation by reference in the registration statement on Form S-1, of BioCardia, Inc. of our report dated March 27, 2024, which includes an explanatory paragraph as to the Company&#8217;s ability to continue as a going concern, with respect to the consolidated balance sheets of BioCardia, Inc. as of December 31, 2023 and 2022, the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for the years ended December 31, 2023 and 2022, and the related notes, which report appears in the December 31, 2023 annual report on Form 10-K of BioCardia, Inc. We also consent to the reference to us under the heading &#8220;Experts&#8221; in such registration statement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/PKF San Diego, LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">San Diego, California</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">August 9, 2024</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>7
<FILENAME>ex_711396.htm
<DESCRIPTION>EXHIBIT FILING FEES
<TEXT>
<html><head>
	<title>ex_711396.htm</title>

	<!-- Generated by ThunderDome Portal - 8/9/2024 5:38:48 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 107</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Calculation of Filing Fee Table</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM S-1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Registration Statement Under the Securities Act of 1933 </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Form Type)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>BioCardia, Inc. </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact Name of the Registrant as Specified in its Charter)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td colspan="25" style="vertical-align: top; width: 53.5%; border-width: 1px; border-style: solid; border-color: black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Table 1: Newly </b><br>
			<b>Registered Securities</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 3.5%; border-left: 1px solid black; border-right: 1px solid black; border-bottom: 1px solid black;">&nbsp;</td>
			<td colspan="3" style="vertical-align: bottom; width: 3.9%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Security</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Type</b></p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 8.6%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Security Class </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.5%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Fee </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Calculation</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Rule</b></p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.1%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Amount</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Registered</b></p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Proposed </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Maximum</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Offering</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Price Per</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Unit</b></p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 9.2%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Maximum</b><br>
			<b>aggregate</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>offering</b><br>
			<b>price</b>(1)(2)</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.3%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Fee Rate</b></p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 7.4%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Amount of </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>registration </b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>fee</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 3.5%; border-left: 1px solid black; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Fees to be Paid</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 3.9%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Equity</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 8.6%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common stock, par value $0.001 per share (&#8220;Common Stock&#8221;)</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.5%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Rule 457(o)</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.1%; border-right: 1px solid black; border-bottom: 1px solid black;">&nbsp;</td>
			<td colspan="3" style="vertical-align: bottom; width: 5%; border-right: 1px solid black; border-bottom: 1px solid black;">&nbsp;</td>
			<td colspan="3" style="vertical-align: bottom; width: 9.2%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$6,000,000</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.3%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.00014760</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 7.4%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;$885.60</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 3.5%; border-left: 1px solid black; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Fees to be Paid</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 3.9%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Equity</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 8.6%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Pre-Funded Warrants to purchase one share of Common Stock (&#8220;Pre-Funded Warrants&#8221;)(3)(4)(5)</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.5%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Rule 457(g)</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.1%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 9.2%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.3%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 7.4%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 3.5%; border-left: 1px solid black; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Fees to be Paid</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 3.9%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Equity</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 8.6%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common Stock,<br>
			issuable upon the exercise of the Pre-Funded Warrants (4)(5)</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.5%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Rule 457(o)</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.1%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 9.2%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.3%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 7.4%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 3.5%; border-left: 1px solid black; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Fees to be Paid</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 3.9%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Equity</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 8.6%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Warrants to purchase one share of Common Stock (&#8220;Warrants&#8221;) (4)</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.5%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Rule 457(g)</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.1%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 9.2%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.3%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 7.4%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 3.5%; border-left: 1px solid black; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Fees to be Paid</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 3.9%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Equity</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 8.6%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Common Stock,<br>
			issuable upon the exercise of the Warrants(6)</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.5%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Rule 457(o)</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.1%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#8212;</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 9.2%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$3,000,000</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 5.3%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">0.00014760</p>
			</td>
			<td colspan="3" style="vertical-align: bottom; width: 7.4%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$442.80</p>
			</td>
		</tr>
		<tr>
			<td colspan="13" style="vertical-align: top; width: 26.6%; border-right: 1px solid black; border-bottom: 1px solid black; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total Offering Amounts</b></p>
			</td>
			<td colspan="3" style="vertical-align: middle; width: 5%; border-right: 1px solid black; border-bottom: 1px solid black;">&nbsp;</td>
			<td colspan="3" style="vertical-align: bottom; width: 9.2%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$9,000,000</p>
			</td>
			<td colspan="3" style="vertical-align: middle; width: 5.3%; border-right: 1px solid black; border-bottom: 1px solid black;">&nbsp;</td>
			<td colspan="3" style="vertical-align: bottom; width: 7.4%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$1,328.40</p>
			</td>
		</tr>
		<tr>
			<td colspan="13" style="vertical-align: top; width: 26.6%; border-right: 1px solid black; border-bottom: 1px solid black; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Total Fee Offsets</b></p>
			</td>
			<td colspan="3" style="vertical-align: middle; width: 5%; border-right: 1px solid black; border-bottom: 1px solid black;">&nbsp;</td>
			<td colspan="3" style="vertical-align: middle; width: 9.2%; border-right: 1px solid black; border-bottom: 1px solid black;">&nbsp;</td>
			<td colspan="3" style="vertical-align: middle; width: 5.3%; border-right: 1px solid black; border-bottom: 1px solid black;">&nbsp;</td>
			<td colspan="3" style="vertical-align: bottom; width: 7.4%; border-right: 1px solid black; border-bottom: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$0.00</p>
			</td>
		</tr>
		<tr>
			<td colspan="13" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 26.6%; border-right: 1px solid black; border-left: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Net Fee Due</b></p>
			</td>
			<td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 5%; border-right: 1px solid black;">&nbsp;</td>
			<td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 9.2%; border-right: 1px solid black;">&nbsp;</td>
			<td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: middle; width: 5.3%; border-right: 1px solid black;">&nbsp;</td>
			<td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 7.4%; border-right: 1px solid black;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">$1,328.40</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">Pursuant to Rule 416, there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(3)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The proposed maximum aggregate offering price of the shares of Common Stock proposed to be sold in the offering will be reduced on a dollar-for-dollar basis based on the aggregate offering price of the Pre-Funded Warrants offered and sold in the offering (plus the aggregate exercise price of the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants), and as such the proposed aggregate maximum offering price of the shares of Common Stock and Pre-Funded Warrants (including shares of Common Stock issuable upon exercise of the Pre-Funded Warrants), if any, is $6,000,000.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(4)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">No separate registration fee required pursuant to Rule 457(g) under the Securities Act.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(5)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The registrant may issue Pre-Funded Warrants to purchase shares of Common Stock in the offering. The purchase price of each Pre-Funded Warrant will equal the price per share at which shares of Common Stock are being sold to the public in this offering, minus $0.001, which constitutes the pre-funded portion of the exercise price, and the remaining unpaid exercise price of the Pre-Funded Warrants will equal $0.001 per share of Common Stock.</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(6)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">The registration fee is calculated in accordance with Rule 457(o) under the Securities Act, based on an estimate of the proposed maximum aggregate offering price, representing the offering price of the Common Stock included in the registration statement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>bcda-20240809.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/9/2024 8:20:54 PM-->
<xsd:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:bcda="http://www.bcda.com/20240809" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bcda.com/20240809">
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
<xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
<xsd:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>

<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcda-20240809_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcda-20240809_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcda-20240809_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
<link:roleType id="statement-document-and-entity-information" roleURI="http://www.bcda.com/20240809/role/statement-document-and-entity-information">
<link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:presentationLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="bcda_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>bcda-20240809_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/9/2024 8:20:54 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
<link:roleRef roleURI="http://www.bcda.com/20240809/role/statement-document-and-entity-information" xlink:href="bcda-20240809.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:definitionLink xlink:role="http://www.bcda.com/20240809/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>

<link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>


<link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
<link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
<link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
<link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>bcda-20240809_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/9/2024 8:20:54 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document, Type</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Registrant Name</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Incorporation, State or Country Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Tax Identification Number</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Address Line One</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, City or Town</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, State or Province</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Address, Postal Zip Code</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
<link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Filer Category</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
<link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Small Business</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Emerging Growth Company</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>

<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity, Central Index Key</link:label>
<link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>

</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>bcda-20240809_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome Portal - 8/9/2024 8:20:54 PM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://www.bcda.com/20240809/role/statement-document-and-entity-information" xlink:href="bcda-20240809.xsd#statement-document-and-entity-information" xlink:type="simple"/>
<link:presentationLink xlink:role="http://www.bcda.com/20240809/role/statement-document-and-entity-information" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>

<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>

<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
<link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>

</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>bcda20240808_s1img001.jpg
<TEXT>
begin 644 bcda20240808_s1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W 1X# 2(  A$! Q$!_\0
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MT/BW_P @:U_ZZ_TJ'4?(WU.N.#BL3&F]8O4] MI_M%K'-C;O4-CTJ:JFE_\
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M6AU5O/'<P1S1.'1U!5AT(J6O'="\2:UX(==,UJRF>S!^0]2H]O4>U=U;>/\
MPY<0[SJ"1?[,@(-.-1-:F5? U*<O=7,NC1U':BN1U#XC:#:)_H\SW<A'"P+F
MG>%M7UO6;F>]O[0VEAM_<1MU/O5<Z;LC)X6HH<\E9>99\6WDRV":;9N%O;YO
M*C.?NCNQ]O\ &J]I;>*K.RBMH(-&6*-0JJ'EX'Y54T2X_P"$@\;7^I=;:P4V
MT&>A8GYB/^^:[:DM=2JC]DE#YL\IT![GPEX\DT^^$,46H ,!$24#9.,9]Z]-
MO_\ D'7'_7-OY5Q/Q1TYWTFWU6 [9K*0-D#G!(_D:WM'U=-;\("\4_,T+*XS
MR& (-1'W6XG17_>PA77H_4\[\':7>ZCI6M'3KV2VNDF^3;T;KUJ[X&@TV^U.
M:VUV*276K=CM^TR,P(SS@$XK0^$_^JU?_KXJSX]\,S,T?B#228[^U^9]O5U]
M?J*A1]U21V5J]Z\Z$G:]K/Y'?    < 5Y3XX_P"2F:)_O0_^C*[+P?XI@\2:
M8')5;N/B://0^OTKC/')Q\2]%).!F'D_]=*NHTXIHX\'3E3KRC+=)GJZ_=%*
M>AJ$7,  'FI_WT*YW7O&5CI\1M[1C=W\F5CAA&3GWK5M)'#"E.<K)'&1+_:'
MQB+P\B!BS8_V1@UK?%O_ ) MH?\ IK_2M+P-X7FTM)]4U+!U*\)9_P#8!.<5
MF_%O_D#6O_77^E8.+5-MGK1JQGC*<8[15CN=+_Y!EM_US'\JY;4SJ6M>*$.E
M_97BTLD.+@L%,K#_ &?0$5JWVKQZ'X0^WN1F. ;0?XFQP/SIO@RQDL_#T4EQ
M_P ?5T3/,?5F_P#K8K7>R."W)S5/.R,K7]*\3ZUI$]G=1:3L9<@H\FX$<\<4
M?#;5Y+O1&TZY)%U8MY3!NN,\?EC'X5V]>4WLO_"'_$U;C[EE?_?Y[G&3^?\
M.IE[LE(VP[]O2E1:UW1ZO12 @@'UI:U/."BBB@"EJ.E6&L6OV;4;2&Z@#;O+
MF3<,^OZFLG_A /"/_0N:;_X#K110!+;>"_#-G-YMMH5A%)C&Y(%!Q6XJA5"J
M  !@ =J** '5G0Z#I5OJDFIPZ?;I?2##W"Q@.WU-%% &C4%U96U]"8KJ".:,
M_P +KD444 88\!>$E<./#VG!@<@^0.M;MO;06D(AMX4BC7HJ# HHH FHHHH
MBFMXIT*2QJZGJ&&:R9/"7A^61GDTBS9VZDQ#FBBDTF7&I./PNQ9L]#TO3_\
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JCQO?6,%PT>=AD0-C\Z**&@C)K5,O1QI$BHBA448 ':GT44""BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>bcda20240808_s1img002.jpg
<TEXT>
begin 644 bcda20240808_s1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W 1X# 2(  A$! Q$!_\0
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MT/BW_P @:U_ZZ_TJ'4?(WU.N.#BL3&F]8O4] MI_M%K'-C;O4-CTJ:JFE_\
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M6AU5O/'<P1S1.'1U!5AT(J6O'="\2:UX(==,UJRF>S!^0]2H]O4>U=U;>/\
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M?#;5Y+O1&TZY)%U8MY3!NN,\?EC'X5V]>4WLO_"'_$U;C[EE?_?Y[G&3^?\
M.IE[LE(VP[]O2E1:UW1ZO12 @@'UI:U/."BBB@"EJ.E6&L6OV;4;2&Z@#;O+
MF3<,^OZFLG_A /"/_0N:;_X#K110!+;>"_#-G-YMMH5A%)C&Y(%!Q6XJA5"J
M  !@ =J** '5G0Z#I5OJDFIPZ?;I?2##W"Q@.WU-%% &C4%U96U]"8KJ".:,
M_P +KD444 88\!>$E<./#VG!@<@^0.M;MO;06D(AMX4BC7HJ# HHH FHHHH
MBFMXIT*2QJZGJ&&:R9/"7A^61GDTBS9VZDQ#FBBDTF7&I./PNQ9L]#TO3_\
MCTL+>'!S\D8%7RBE2I4$$8(HHII)(4I2EJV5K'3+/38VCLK:*!&.XK&N 35N
MBB@EMMW9#=6L%[;M!<Q)+$XPR.,@U!9:38:=;R06=I%!$YRZ1K@&BBBRW*YI
M)6OH%AI5AI@D%E:Q6XD.YQ&@7)]35PJ&4@]#110A.3;NS.L_#^DZ?<FXL]/M
MX9B.71 #1?Z!I.J3":^T^WN)0NT-(@8@>E%%*R*]I._-?4J?\(9X<_Z UG_W
MZ%:-EI-AIRA+.TA@4#&$0"BBA) ZDWHV7*IZAI=CJD:QWUK%<(IR!(H8"BBG
M8A2:U0EWI5C?VPMKJUBF@7&(W4%1^%6T18T"( % P .U%% [MJS'5GW^BZ;J
JCQO?6,%PT>=AD0-C\Z**&@C)K5,O1QI$BHBA448 ':GT44""BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm139689032094528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity, Registrant Name</a></td>
<td class="text">BioCardia, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document, Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity, Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity, Tax Identification Number</a></td>
<td class="text">23-2753988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity, Address, Address Line One</a></td>
<td class="text">320 Soquel Way<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity, Address, City or Town</a></td>
<td class="text">Sunnyvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity, Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity, Address, Postal Zip Code</a></td>
<td class="text">94085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity, Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity, Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity, Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity, Central Index Key</a></td>
<td class="text">0000925741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M"]<>GSK0.C5:QZGXXLL6N=WFC41N^^5)Z*#HUA3=HQR$BY(JEZK<TA99&FJ
M2$5FLA!&;?&9-#*ZU2\N'8AG->+948BW])G,$_086[&X"KWK(KL'U<3EEHS:
M)U&OVQ[T^PZ^7LW7.XIODB08P+IND/)<_!"-?G-+MJ. +.5C 9S<T:V#L5\S
M]M_'.+-W"^[OK=PTWBMNN64AQ/:)<G"@#6JTP?O0ZMA;*/G$1-SH/[?F;.(
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( /.$"5DZJJ+G0 $  #P"   /
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M-Y-;2>C@W(-@[^&5C!W-CQ]W]P-02P,$%     @ \X0)620>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( /.$"5EED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " #SA E9V[2B3>\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #SA E9
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( /.$"5F-U^3C40,  %X+   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #SA E9
MGZ ;\+$"  #B#   #0              @ &5"P  >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( /.$"5F7BKL<P    !,"   +              "  7$.  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( /.$"5DZJJ+G0 $  #P"   /
M      "  5H/  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #SA E9)!Z;
MHJT   #X 0  &@              @ ''$   >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " #SA E999!YDAD!  #/ P  $P
M    @ &L$0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #V
%$@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>13</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="bcda20240808_s1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bcda.com/20240809/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bcda-20240809.xsd</File>
    <File>bcda-20240809_def.xml</File>
    <File>bcda-20240809_lab.xml</File>
    <File>bcda-20240809_pre.xml</File>
    <File doctype="S-1" isOnlyDei="true" original="bcda20240808_s1.htm">bcda20240808_s1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>bcda20240808_s1img001.jpg</File>
    <File>bcda20240808_s1img002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="14">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>22
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bcda20240808_s1.htm": {
   "nsprefix": "bcda",
   "nsuri": "http://www.bcda.com/20240809",
   "dts": {
    "schema": {
     "local": [
      "bcda-20240809.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "bcda-20240809_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bcda-20240809_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bcda-20240809_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "bcda20240808_s1.htm"
     ]
    }
   },
   "keyStandard": 13,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 17,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 14
   },
   "report": {
    "R1": {
     "role": "http://www.bcda.com/20240809/role/statement-document-and-entity-information",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "d2024S1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcda20240808_s1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "d2024S1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bcda20240808_s1.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document, Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity, Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.bcda.com/20240809/role/statement-document-and-entity-information"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>23
<FILENAME>0001437749-24-025899-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-24-025899-xbrl.zip
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M)KD-N*2PI1G6!%GV7_C\"U!+ P04    " #SA E9T1A ] 4$  #W'P  %0
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MBS8=]N>'W7/S8?Y4UD_^!U!+ P04    " #SA E9\TGKI*8$  !"*@  %0
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MJ@2X4CA$=L08SQ-\ZGNAS"C,I+/L&>H]I]"7R.UIK8H=6IA4@'@3';IQN5W
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MZ'# ;V,?E),B:-(#^P@()0CS*51)&&S2ZU[>]I3\4-4=*\IITS5**J'Q?*D
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MX-,?8^XZGE)!K\M*X.*Z*Y4Q9N"0#-#F"J@L4%69P3T1FN_X2U9@1T(-_BV
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M>Y2D8BCB#*'<N.]KRY0?^R%=@PUH]_MQ,N5'J!T[3#D4 QG(-B7ET9_(-=B
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M-".#N?:(HW W^>W\8Q,>++^^P4I8(MYE8KK7!A!S!BI"LD;PFUCL.DRS8&!
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M^^!K<B:4;_K+:2G\BA;N]K:Z3Y) ? [P-9"LH:\"=9P?J$T(D#V%%X 'FBW
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MF3#EY:KR+%=]V/4(J&I/TCI6W; C)/ Q WS72Q4M426\6>>I9N=5 :YQG;D
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MY) U0R?./0SC7)(W8I@1GV+8*W">%U?76"PR\?[8._WEXQ>__(.]CR;3!F^
M[U/#$"JM\B6]-%-V7],J$='H.%26/N-JK98Y@;".SO:]:]Q1?+@W04[;;FAR
M#_#F1'/\2>[,33X2U%:^5DS[)/8,$N!FGJ"1!S5KC$L%1JZ<&L63;SI410J6
MFL368M"Z8C]G4T97.@_=<!2,![[UJ[F;:"]O/P$%"R\(E&O#F49\)T<V2Z_B
MT:#L4\54PQO<;*"LY#RY\;TPDB1K"F=R/&.6Y]2";%$E(K@E$2@[Y&6"%9XE
M!<482@A2^R1H/OWR$9<341.H\>FY)5>$Y'J&NJ\<2B5_23"Q&/M1@U*>CW5
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MQ+Z,/I=Z-:>ZE/&&?:=<3)7_8#%<_5@,X8AP09E8C[:6Y93/P[/[RQ&^8V#
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M2K/&D#QD]MS.XAAQ^5?4!UI[8^W6WC\\16<Z"P-,GZ!1\"'LT7'S#MK$NG[
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M' )ZT">'CS8$?5QU9(,0!"TW[14=H.7J;I00HPF<YC'IF#@<CB,T^? (D&?
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M_C,(1"SFTP>;!;EB-RF([4&+(+8=;3<U^0&_1,DDS/&/<3*,>IGO??Y\OHF
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MP\;3L:;(/&(RPZ>[E%YLWQY5Z+ :^]:Y_[YI%LJ3M=VX1X&^5V'C#AYRX.R
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MZ10$#!@ 8GM_AR'H  ""I35^ !NLF#H\^$+B6MTIL$3,JS?36)=.9M"6ZVF
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MFME4>C3XU\'> )B]SPG]ERP+#&AI.E!@#QWR,,/(E0.UWOQV5?3[B/(#%.5
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M--'?5=!N7G0":7TDRI:3(<=5WH.EZ@J+V' B=6X,F25&%3?5:H05L,+*5.1
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MOUR(KP<@PM'%N3B].A?7%S>W@+IST<+CY=79V^MW;Z]/;R_?7GU%L+]]]?7
M\O+R[=GI]?GE:8#HVOL:/"_?N(7Q4F=G,H^T#%"5V,-TG.:I'WMI/!]D-2[-
MNCZCG[K8O=R[4=8+;X'S[O>JO)I>ID"VXG(UAYNQ'ELGK6O+>T[(M9:G$P7F
M6)TKV5K?=X8VC5LD&L LP]7IF_:5[5BNSYI2?;>YVP&6ZYY<.Q@U::=XWF#%
M';Z*8E131S^I0 __*=,*&^\?X*WN+YYLB.6_=7+065B'^X^XS]=EUCM+TQ;W
M*K[DSBK)=\@ZXD];@RV!RM<4S<QT[+X74QG:[WU:<X-E#4"9!)WNN^^_^^ZX
M=/HIW?X=RMCBN,RFU H;1>U.GS?@+*/E[>C'>U/&2EWPH^E$\HY J!;#CA>_
M+X=]E?;:!KAOW=>_NF;KQ-F+8&G:6CQ/]O9[6%Y]=?8]*=Q4 [>EO]$)PR55
M.3,A5[*[#3PTPO\Y$A;\CU2[$4RG%LO+[T*^6%[9<_$UX-:;=7\61LO*&;*Z
M\%SN+76BA@R1U=0HR(%?SC*!MPLC(#. : [?!CO++P3"[8/.*3Z/A#FT'TQ=
M/)I F"5#XSTU=[%N[^]PG GE+]UZ$9!+>\[)%7R4/MVE"G8%\41S56O[4G%M
M[FX-L2*'N[LXG=>7$+@CICW9 -C0G(<I_8N0U ?,NJ%VU*EQ:B%J:K3DY#+F
M2$2DT)FGEU>9Z-%6&A7FFTMC/*G#&-@ 75L*MG]8]]^X#*KE"BTQY\AF2XQR
M1H&TEX:A-POW/94&C&KG,5V?T**6GHOG?9)!EVIG@"6W1ID+3GJR7W#8GL%8
MQO?\X*5KNWA8\]88M3N<[_KW2O*M:$Q:/4"W@70;U]*R1\I\TDA<$.5Y0W#0
M+TE4I/GBS67KFROC\F[<<M% 7&LUWL8-'E#X2\'P!Z:,28%91ZC*UIGK9TV7
MNYL5180;LW" N8L3\,#^JDNV@A87<+TP5E;>T46\H;YX>4$K'VEF)[2PTJG_
M8KE/9YNX(P;L#UUWH_"U):V2>+S0'G5T0>]N7%-\N%7FV[OMPBOCV7'+$U9[
MK)_6K2MTI10\?O8T& P&^.?NUC5N;R.5G@Y:#;H+##BE,(+,D7E7Q([_.M@;
M#/:[1FOSZO):QB#>#MJP](8]S&ARG?%Z;C1S/,I\V!2[Z/&>>)N*-W(N#@8!
M_!T\N4^!&4^0$8&1<!WI48D[:7O_J:\(+-1#&]O:L/PUF>("?>(/TR"ZWH$>
MD4L:%6L#F4'M/J-V8ZSM)XBH;B2MUEO1D]&XN0[#HR$HJ!%E )&0MW;,P9,#
M2S_V+A1_!5YCB'2!RR,PF;ATGVE?$LMG\@ALS,(^7;6P5B^"+:B\&PO,1GAL
M> Q&G_</#H$SR[T$-:,"^$A*>_K;0V6_*_Z_C_7)#>5R5,!GWDG0K5ZQZ7S\
M2)_\SU< X4, ]B$ ^V\>@%T_2',\/+F\$K]>WEY=W-R(7W^YN+[@J%W0FQ-2
M,SQ71IKJM]1V!H4&3"G)):<KK8;PXBO1$/YM..Q"8G-KWAN+@]'! 'A4/!+O
M4'<5IW$)8Z,%\)5"? 7:RV$+V*\2T%O,\3I$P\P4.Z(;>ZBVT86K;?26=\*?
M38'_AF-X3/[UZ<WM;BVR>D7J9Q655E+ AV$6S6&K3,HD/OE_4$L#!!0    (
M /.$"5G]-^8_"4$  'GA 0 -    97A?-S$Q,SDS+FAT;>U]ZW/42);OYYV_
M0I?9F341LO$#Z ;31+B!GN5N#[ -/1/SZ496*<NE1B75Z&%3\]??\\J77E5@
MTQ2,.J*Q724I4YDGS_-WSGFRK%?9TR=+K9*G?_B/)W5:9_JI_O#_OCLY.7MT
M=@3?/KG''_[A/^#[_W-X&/U%Y[I4M4ZBV29ZMVSR1)?/BY6.WA1EK;+H,/K^
MWO?W3H]/[T<GQX^/SQZ?GD9O_AH='CY]LM*UBN9+55:Z_N%.4R\.O[\CG^9J
MI7^XLRC*E:H/$UWK>9T6^9UH7N2USN'J6F=ZO2QR_4->W'GZAR?W>,Y/9D6R
MB:IZD]'M>7U8I?_2CV'H=7T>T0<+M4JSS>/HS_]LBOK\7;K25?1*7T>_%"N5
M\X?GT5HE29I?/HZ.TSPZ/CI)\_-HWI1543Z.5%,7YSCFV@RT4N5EFL/%ZP\1
M#53K#_6ARM)+^+!,+Y=F[$^:#*P)7AN\E;GOOUJW_%<<T2=Q5.DR772&A6?-
MGK[XL$QG:1W=/[K_Y-[LZ9-[>!'\6#_]PZXOE>G%'KW3G_-9M3X?> __V9U'
MG[MGT1O0GU>J3%5>/\Z1_+)S60C\V@TU/$9KB%U&\%9V#M2MRW!,V+(GS=,?
M7[Y^=O'+\Y<7<?3RU;.C)_>:I[Q[W^;KGAZ?/(Q>_.^O+]_] ]_WQ:MW+__V
M(GKS\\6K;_?-#U05 >,#%II$>K% IG>EH[^J371V'$?$0P_JI8[^_,?O3T^/
MSU_82YX# Z8/3\[O_H[+4JM9IJ-940+/_^'.,;!GG67".NW?U5K-S=\RI>LT
MJ9=X>(__)&PEA7>&$9'9(&L%X0+2IS377^FR3N<J,]RG+M9T%5Z4M!YZ]C"8
M9YV,7T=?]O"\87ZW WO;PK!@V),C(/&(*7G-DQB>JA$XPU.]K8D%[_Q;4]7I
M8H,GLGGZIBG7105/+!81DN";3.4X_2.0^3I:!]^F%7T=J5(_;K\>_"QQ?^$G
M$L\@I8Z+YW[!8^@V$L*-!K?3O=K>T_-WI]LG_W%$?FO$\NF+_L='#[][=/ZI
MI/_E7Z N(E77I9K7D<J3J 25%?1$/!<S7<%G5RK-B);6&G3&/-<9C%5&<$92
MU&/IG%3-K*IAX!24Y%)7:_@8M+(LK3?Q=&BF0_--'IIU65REB8Z0.O @ .FG
M.6I"J,3 ]R]6ZZS8:!S^>5J"<E.4%9VP9W ZF@R/"WP%'TPG9#HAW^H)616U
M)EE2-?.YKJS*]:Q8K56^03W_Y+OS*IHU59K#]T=?U6'X/6=BCLL8L;\3919%
M]2JM*UKJRQ*>C.O^TG*GMW4Q?Q^]7I/\CJ-7\&^M:J"C<M/^[A?0 <ITCCXQ
M^J;[2?1KGB(GXS\NUFO@=:G"VZ-?T%T$7[W1);F_8 )\-?%!_].W2U"P9?>]
M=>U[S1MX:H)E_0H8&_&F6V5LOZ>E=?JUV87/]2+-6:EE<_"BBIH*Z'RI2YWF
M,1VG19%EQ340092XRZ/K-,LBM5[#W"8.=@,.=J#N\OQZ_F5'$>S31;*"A0<N
MI(!CX4Z)NRA::94ST_NQ4&42@9D"0@9Y'_(<D#G %&O0R"(E.S9#]8T?!L0"
M>VK< 3'H<I&:SX$=$'^Z3NME])8]]]%]WW'0X5G3GK;W="9[&@UL)QP;X(C(
M?G]6UU7_AI;ZGPUHT2L8K8(_,A PN%T%?:D<0>#^P.[@U?7F<*;P^*IK( 8X
MRAC.B7X]>GL4H;C3$>SNNL!X3Y3!N#%_M=!P%>CR**'XLDK/FQ+..2P<7\<*
M3*)CHJZ*Y)[^,%^J_%(CS>&B\DRJ#1#6*H+?KI?I?&E4GQ5\P.(RA6<B\27F
M/IPNC$QOY=8%Q\77PO% 9FI889A]D]<@L.'&WV!^59(R=5XCMXHN^)U!JL9X
MA5![S-H #,*+,1'QSD0\WT+$N-X=TD4VDJ1@)C8JRVBKYB ^V-&=;8!^1#L+
M=P-WVBI@(VK5[KI95P&#J>R@?TUDT":#9 <RB"XN2TVLJI^779<HAG+< XW$
M4!9Y.H^4N0D83DW<#7:G9IX!TFG%2C-Y'2K2.3S^ 'Q0*^ O//S &2?O=FN"
MR("J9O8;S,(P4S?6O,@3Y^.;>,7.1*+'B824DU&]9>&YC$*+>5K]K:N_&%_]
M9RRG0;][!J.61=:_$\4<I'ZID3F*X)6-< : OD)MY/&_]8ZTC?-@FQX]XE!P
M.JC47T1SNQVTZM>Y+JMENFZ1_9,4+<GT*:M1M#<5JE5X2:+(QZ1JWJ7<1"I(
M\5F!MH1?YMX7H-@3?\4(-3#+HEE'!XX^WM U'E'<!3D])^VSZLZ/M;]PLC09
M4!.+2PV?EFP\N(N7.B. 4=7 J[R1J<[1!Y/630V#N#DOTD6]P5FCYR8Z>'#\
M)UE)&; N$)9T5=#KK(MK&&QD7N?&9YW$T1(NOM)ES M' 9UVW!.#.FSQL,I+
MB\!!'SH2SN_-@\$KF0TP;W6]+%#"X,O!L"7()! RL(:?[159T<V+&DT[;U@5
M=8[]>83&XUX>F. T@_X8S3-553_<>?.7'_^GW_'$XQQB:%\&DT\(L44?(<HK
M>-9/[WZYT^=H$S1'Y W0NG>Y."R+Z^Z'Z"*+WOSEU:]_=>\ 5R"DS?_QAR=+
MZPY[<_&7%X<__O+BXG\.+WYZ]^*7QY'*KM6F.A=7'"YEKH/)G,,)XK<Z77\X
M1XT:D6Q_/*;_X#XU?X^'.D\.PZ\Z"_#?S_L7@ $2G_CZ[UX_^SG-WX\N@%T'
MNI]A@!I.$^IR0(0JJ_0=9&OJD%Q*=?'#G;7YH*F+P_5EWJQ^N /F:5G+YTE:
MK3.UH<]/Y3,D208?MHC8^QY)^(<[!#WC#^$)LB1*/@'+8Y%^^.'.H?Q-PP8#
M5<TBN (7D];RASM,3*W5&#IQ'XN6&SE?N(=[+Q9WEXL.035G[M7A>^."$:;X
M6P%F!VDQ*[V:::=9LLZ9HEL%2&@.W#)IR!E&HNQ:9S#JP<FIS'4%XR^17Z<%
M23&GJ *SK\AK4:1Y3<:%,7!08L#SD2WK/(%K&6$;S@JGTCNS-0Q5&NN$WDF^
M'ACJ*/JI3YS!.6U@?KCJ8):S2L=RJBNB9K3PVQ9]FU@<V*K9AL676AE!^0U*
MK7V;'&S[)VJA*D"WK,$FEYWNBV."*-!UM>TT.LJSBN4!D.P2%5+^P)Y!4H%&
MSR"<*+S0'\6<IJ*JX5"38N53J=$]11O&PT*_5?)X>8E%6:PZ:BU,$J:B1"T#
M.5O!A2HM<5O>ZSJZ4EFCT?T*WZ*N5WZTJC?T3-R*S!XFF6/K:*6K%<A16()L
MX]@&O6MP2DO_S^J3U>*(B*H=%K)GV:GTD;IE GL<'5R8S8KJ$FS6A:9WA57&
M&&\MF\6,#?E&QBRW[Y&D1R^++$'.ZZ^@6M3B/S)#D$EU\&-W:'P-WI%P$)@3
MS/7$WN"-U=Z[ W_HF5XPV<A.VY'D2<B=C<<==ZD0*PO!9YXOJ_=5X^C '"2[
M7/$(<0H)A_8(DV39,4SXY*=L*0)!)20>V?>+OF#^*VXM$TSIS*Z1,9YH!^$Q
MU?!3;FG2>*Z(+)L:Z9#X29]UQ=M_O[MX,-%,*^ V.UISM[!Z9IVB1%?S,IT!
M?=/AZCFA0+"PO -J0?<X#S$@YQNR#&F0$]%*#5TZTQ0^!HV]0$VH6,"+:G2[
MIO#21,>P$4#*EZC]T*'>1%FJ"%"94O2R*C 6(!<+@Z-G3^Y!*_,')M=+!"Z4
M'QM9: /$'<VPZSU*:7LW&&T3ULY\W0084Q+."K7?FIALCKL*!%5>(D_%$8HL
M391,H"F!LU6Z):<(9\O\"[ZH4EA(55K@%#-()2% XW":G,8[4L6KHL9%L]R/
M13H<03 P+C%.%RZOT]83C*/T:NI1DV>T,49^RMVH&J4+/L>!8F#,!7(KTQZ*
MMH",AU2\!86=#0Z!%_3^\:.+&!^5UJ1 SK3.*7JS4ANB5LG!86T.EI9D(_PD
M["GQ%E!_A!.5P,#1<GE7 C=ORDWTB[YL,L4Q(+S\)1(P7O$+SK+!N917Z5Q'
METW*2 E1$F4B" %LLDLE$6Z9D_\I>D@U1ZHZ4YSH=BLW:TIR,>/>+$3DJ*M"
M]@(()BF:63U(P(&*VJ7@= '*FS&;,&H,;,HFR*"8AGT2^F6'K&=\M%6O-/>X
M(2L2Z;9' Q72S%!AQ ,P]PT1PY])5<!9>UITYIG81-TED[!H79;%+POVQO?J
MB@[VT:.9DLSUUG0BU:UQN<L=H%W(W_KC<1W.0ZP0B.WDT?</B0$*ISN"*\!0
MH,@=B5FT"(#ASB.CYUD*34C&EI;'^<R(R N(-FL2V6U[NW\+8X! RTL3_T$^
MA^/G^8]PK)<HNN3T&A/9MT"?IFZ TC)]F5;RV'"V],(DGZIFO<XHH$]R D=#
M&M>LR0].?B+:K42[#(/)D4^J B?LTBMJ?O)E*Y9/5DY!+-LA@X#7P'94BPWN
M5@L-9YR<SGPGIR@Q4!4E#9KI#1@,)2Q $@[K73P*9D2:+Q83+6REA724%@RF
MKY]]S?F*/JMZ_U;^ZPPYVOC5#!'\IT/1*Q>K&IG(I^<8W'EZ>'HXA3U'PY[?
M>O1O)V[RVQ@W(<Q+AY'\F!;/@)^G*L9DGB-4ZY_K#.'-.FIKUP1-YJ0KM@M*
M71?[QVKV;EO>;T&/V>3-'K$/2YXK4-K0C2].7-8@.9H:J00TO**,(YU?JLN.
M1YYE^AO830YHO@6#)H7=+M&-#FH;Z9&S(E=@I:-2RJ9W96,<QAMKPAEL YFK
MK/A":D'CCUT.N6[YC(H%.?2!5:F,] C?$,I1MU'KM%;98:E 745?B;."6+%U
MAEU2T$C6C6LR LD5 %J-H@>*E]78K\.&V$2^6\DW&R=?HXKVZ:P<? \TQVG!
MMR[X:MN"5^RX[V'G' PA5+=&'#X>^\1>CR8M^:79NQ$X_4Y/#_1=&S+R[-G@
M\*O:Q!OGY$Y>F*P0-D H)CN8%(JW!8E6^"QTU, ,YR!+D&>@.\]&+C#QA'U1
MWNM0+@N]IO=B^@,\L^HS2IH\Q90$N@T4H$,:*X6G*\I-)?<LY[4DQ=JSB<*)
M3G[$CR?C?)R,33&#?J'7%7:O0<F>:REX8.U?$'S\G%[)AZB(/MG7LI9@95*B
M,Y%L[$8W8^ Z1&NU85 0!F$2^<;*DP68QZWAC2^1C(-YBO>B_]%Y1V4E>/KX
M;+,(X8,F0MM*:,460C-1_8OY0/;,6Z>.^!>S*_#L?N *G+9CVW:L=]R.-V5Q
M6:I5G]ZPYJ_$S\DA?*ML^I "EY,(!ZUD?9;C0G,4 811:0,[)'?30+[1H5]O
MUCHZX'%0 A$B:0FF,:NM&8$)] ==SM,*W:JD_2(?2M(%.89KSG%"7+]]NO*_
MA0%(D[U'4ZN6L:?2 HNJ@46LL7Q+=%TT6<(3(-5YC9$&$&(U:>P6'4,<KKL0
MY)W&@%L^3ZEZ#',;<=.RD'88+<'U5 1S'!!]=M8>W(W@H\%JL(.Y.R,,NP +
MQ]@?;POL3C-'C_J[CHPECNED_UCB&+Y]FXZ,,D%1'Z=13 =VZX']Y_B!_0EA
M*W]E@^IOB#WIR4E5=EL0+1B'.)4@/=F#I<!-C''[-T]XVB4J.Y+P]-(J,[U)
MX#EMBZXP%2"MECKI22_'BL*",!;+F=/,??W+@(@R4)YK&]NB9?A'4;Z7@<VI
M9!)X=?'V^<7_1G_)BAD\^BWQ&2&EO@N$R,1HE^^>L6_ ?KD@UB%?\J#FB7C\
M.]1J-3&R6K*"' SHB*B$=2T*$TJCAQW(\.;269H0N#LOY*YK3(8O-?)EG5A\
MJTFU1X\\>4Z\Y74Y^XRG)074' 03\ZOL,Y&3X3O^'4%T;^M2PZO\WZ*A4*69
M*[/R"CYE=;5KLB",A.H:I!CYV0,0]=Z?L(\^8ASV++.-V7P"$8)M4%SF%#SS
M_%R)!N)!<!4F8V<9811%CQ#GF=E^/AE=.B:5@K+J Y)&#@R_U]<(CL$/4&]!
MJB6Y"=P5R..]3LQHGDO,O4L+Z1V0)AX(<P#@J2R.X9&M@Q 90!H+ .4GD\=F
M@ P!G4"?Q%!H-"+FD<?>_?PG8R_2'_;_<(R<#MY<-:M<;G,@<+K>6$MZ0\1N
M*-Q3%V#O+XLB01AMO>S552==;ZNN5PZ&B'X"E1F.T3^T&BB M. +-G#!WH>;
M]V[=JW$=N]]GVN<:DZ^8U\(AH)I\9"9Y*-!<#*^:@9I@%?*7Y &&9[BJHH(>
M6-N 31<@&F)#3T]]L-/^[?RW #0X^W) @[,):# !#;9RLWH;-\/TAF@L,FB=
MZU+/ 9B2"0CL'T_9N_5OQM=_L/KJQPF4I-"<86V$!T;L*@GT#XF6?DDV[>G6
M/;T:WU,)?_5ZRR7CVYZD@J_M%C+9*MY/'IJ;@D"(J1]8-IFH%Z67Q=&?>S%M
M^=8MO]ZRY4-G-M3:3&VV=5-6C<IMINI466VG3?BP91.:^J.%&7+(2:!]S"9L
MQC>!@_A]2R_7K#G*[R,6S94&0Y(7URC D#]Q%CIA1C@7;Q@6<__TOJV]M]=V
MS]YMZ;^V;JD)>O:[&UQ*?U]@<=J [76OU98=:!=K[=4..8P+PQ7D$)8C0K5=
M(Q<PG^E(JU(.$'#!3'-^?00'LXZ:-4:A:L1F&A#-VAO\LL"$%1N?OM)T+*-Y
MF6();=7OQ V!8K[L,VDH)\<3D6POI+VEDG:[S.\(C>P/-:""&LP&R]\B%&1A
MT1="P788+U)#\=!YL9J9 (BMTBG)VQ.U?7+%ZRTEK]]P_2%8<%-VNE<!EH1;
MO%1J&KE:Z'[]&+/)BVX5:T8,V2K%I1NN,M9.26FY'*"0)[7N"LOLE&E%>5AP
MUT*GF&AY%+W%B%3P<*%(+B,O8;&UJBIUR1EVE$9/X93Y,M57VAR1&E9<8TV4
M*YU5K3-C2X.$%6:9LKFD+.LX-I8R14\^K53WEEK=INUCFUS!)N"&K=1#P/.1
M3#;:;M6OMY2_;A_O[A[( 4ZKJFF9RJJ'.9 \8_"AX>_?^07+8W:%=9Y%P#@"
M!%AX'.NODQ=LUTK;6TIM][8CZ#,,9T7Q_KW6:ZJJ35TM2KT&$I"$=DR=6F&[
M"U=8;A!U@>6'B7[B7E^+H9#OCZ(76#&_=XIN=-*8FGS1D/\494V3D_:!\F &
M"Q(H'5.$=>=:$)=;**<!-?3DX>SPK$LN[KM>]V<W]['P;N%2.::V)_H;<C^C
M)375N0Q+2'KKRDV28+?B"<OQ70Z<-]0HK'EZ\O!@=K=')(2.;]M3J(<"IHW9
M7LD@W;8QG%KSAI/)^ORHSF/J^IOBV7,)LM,^;,\!_VW+/@QX>J**D(5%%^G(
M8+X$QV"+?JCNQ\G4Q>SC]NK]ELSPH49-PTX8IZ&H#-46=KNT<[*M0BH507NT
M&9[*HX@J&58P<7+]45[<T*SV;\._!2S0_2^'!;H_88$F+-#V\@!;Z@.XM-N1
M^%WE<G,_/H:'5QU_?[Y+*&_Q-83R]K9O\*VT".Y;@)W9TK:C=.?I6:??]R>U
M!O[,LS3"72R42'Z^9=]RZ].Z:'^PU*U/C.-Q:G;^F5H%MS8LL"_#70N^LEL7
M?FKW+_C8;F+T-NR?Z'5H=("MEKK-08.5^I"NFE6D+B^QV'>M(]8CO&@(:7P2
MA1 79JM7*'JK[S^('QP_DGOB:)TU7)=!'N(%07PL4N77D99,Z&[KR'8UGM/C
MXU->"!\RR',YP!M$2+RA]@OXL6FC%G%;-&G 8'L+O+!=5IY3,I+^L$Y+;8-]
MU^B7-1E.VB8V+M45Y?MA'I7SU8 46309UU09<2(/O:N;,R\\VE@2()+699@3
M;>ISMXM8Q*Z&DMG9[GYR!?%$T)AV%ZED"6B-5VG15-G&&09^Z^+6%*TO]'Y\
M]N",D[1E&%/[V5:&C"F7K<EY-6)^$=MKQ#<@]T_"[AWCF8TQG@N05BM0B.:2
M_?>+QCHE6+^6$^MWYQGBZ^IA'!VR4E<*3C$J(@N)=9#!WV(5)DW+R_'/)5FH
MK&J3ZDJ-9+W\(K@#%BDW6<5TP^GQZ0/_&JXPVN^EY\80\&";%?WP8?SPX4/+
MKIPW:E$TI6L><?_H^$]WS<O[F"(3*?;2%&7N^'?8 T;/N0BN_T)A?03*0^RL
M:#?\2@6QAGO%T&/"7$Q>?NX[Q6/1L'8?5BK!9%)X@]J48_JD%YJ.['8LP]B1
M_5FM\3!P50X^GR\7#BK# HFDY4S/"YQ]DXO,H3.WDTR*N=6R*WL22*2\4R$#
M>73<"3[<>LMOFI8OX^*ND(M]*1<E#=756@#'P?+4\"NB?N@:IM\F=S?+:<(T
M?>1,W?ICKYTJ,MCIW !Z9(ZM^?$0=V.!E5!"LM5XN.RE.7&X>2U>*46VN0V[
M*7K8XIL'7B<'^@#;&UB5)+E[%/V]M4TC3=N+/+.*F9K7W!A>E)2#]$@?"8O7
M=:C!" &'P?"A<?B%Y\CDC<IAWSI\N7-J_E-J+,?H\58)IP_N"#V?[_HL"^JK
MOW:5J,X.G:Y^59C_1!H5C)O7IP/(H"&0FZ]U$?3,731,'@G";M)9X[%UMX!#
M$B%=C.B@%[;RT*<=:0>)ZQYTQ2GY VHJ:=]MQ3908TF4&=3H;B>GW6K>D%'%
MCU\KGD)O'2+>+.G5QH70&1RF/A#_,]T?7+R=Z@$HF;J#--[DD(/Z+(B0#S47
M+I2G=LVMM4H3U$?(6:\J./C*\3/#56D-Z5M3C,X2&GS?9'0WU5<R[68^3:D[
MBD9;UR")QP$*CD)#-"%5N6*1SOT&EFIHG>YDDZY%&?.1- .E)7DA1$5$Z)RU
M?EEAEO&HF4C7+W@&9C];N+'%\,B.87$BC\/9 O=A$G3L6\:<1M=',D,Z=$_T
MI8K.K$F '.4,M(U))=L.SQMUW_BV$ZMD[WP6Y7?'!+EA&WFQC404IFKN:T?O
M5HH5AON#0"-OM_OU?^4:@(5%(7T.56HRH%<$%-KK:.JW$%Q[\.6":P^FX-K^
M!=>FR,L-8AKWCVQ XNN(P'CH=P]Q.852;C64$@4_K#1^4Q9S4%49BK1_PFW_
MZF^-J39_!>4_76=!/@<JR3\62:K%_?3<UJ*U7::JCB_(%:RE+J3B.@Z!>QP*
M4#*2;S=,NWB#$H,.N]H7&CQY>'JPNBM::V"CD+W15^-.G,W4Q9,=-@CDXL9P
M7M6.BS!RY;K5@;IJDJN=.^"0\Y:PQYS.*^*;%J.Q2W6)4]O<(+"?.O$$1UZF
MJN*SH _9=>$Z;IO&U#+;0A+V39'VZN83G"C[1O4!.^#[-@WW$J;7 Z8*R5)_
MT*NU<1#Y.'R;_V=NP_ZW6&!?A:1MS;"Z;.9U(WV8!\TP--YY3.>K<\-.Q+&=
M.*[&:.,UN;I"98RIY+5S@OF>)34KKG9A&@<77KURBK51G.Y'XUAQ/,5X^EVS
M0[]5-S=L"&BDU5)QHH&=(]RA/ABA*HC5]:VS(Q!C.T2V71B;JAZ&S6F"+:["
MQ]@>KDDC!7HSS36,_.BL[83E/:@K;8E:;,U^P4A@WZQ.@YNITOD-5%W44(/^
M )UTO:G,]4UT4*1UKM%..>\=Q1_#GLMB971&<=AW5,=I$VZD+G6H? #R-0<I
M*)*. #8<7)IVXU;U$XQOK5'B4 QG5=F69]'%9:D]!;&I.G'P:>&W+?SHNF]O
M!1-++4I4TE#OHY"HX,GX^C!G?^%%\COG1(IU]+:<D:;M#'DT]?JI$88 7+J1
M:+%&L&4<QJ%I=2DU.&2>#M1S$%2LL?5!_-(XI@;.76D1+Z5QU'P.7-MX,4$;
M4>D5\PM7BB0H0N*:Q7N?4J,CU]L# ZBE=!G=> %UAPBE@+F$S! 2$\ND,15:
M<:A:VW88"\7MRGNK]X2=?Z9SL_W<C$J/U/:8HQ95.W94ZL#%IGW881]&-X*,
MQ[+18IK VJ_AH/2S)[JFY8SKJ^@Y[<HNNS*Z+5B( UCI#($;V-5/"MI6\Q1_
M]I:X=;RN\ 2*:XZT_2ZP/@_7&2:]^9TQ3$L,V.EUP3:KN!B(\SHO \)OX#VC
M3%T31 MO%$\97DF0)'55B!=-?8CJ4BL&Y8C?K/]9^T=.WP*NX.&7PQ4\G' %
M^X<KV#L6F7X88Y"K(I%R[\P?/?/RP/.BA:&31[XTN^LS1U2:0X69KG-.,4S[
MM4XS_)KB EQR'-AB?>BG0%B8/'=^7MN2@:87*/6']A]A8(<&UN5JWO>\3=0I
M!$/2V:G# QC$N_O'2?>.ZD:)CL"64= +U0_*C"!W4[$QX#URCA!9"1_"4!_X
M)#KMU_;]&E6C;"J@U[";3YZ>H_%18%NZI<H6[3X$^']*FC'I)Q)KXU/+-;3P
M:H%6>WCNGF3&OCJ6T\;B%2>G#T=W=GQKZ2PJ_S02/$0OQ+^%.6/INC8[ZW5'
M)X"Z:+6)SM 3L6DCO5T6+G<[1FP"IP#1.?9'-0D83 +GR-VG[=UE>T?W=Z7>
M:X(R<]I4D&-847]$.%NYQFIW*)M1$4BN)#6-6FC;2*N!3$\ H!V3!BVRI_LO
MIZV3*M,.@C[ARBDGWQE 4-6'$GJNYQ08=>CVX$$VX3Z1ZT"[;6U]X*A07G+%
M3%-;<<Z#GZ6<%X)UO-$"\F6V\2PR97$1?^<UGR+E1"-G(X?WP5%OH'PH>OX"
M[D]9%^9M'VS^!+L]DD1XHYPQW/1NTE@K/D@Z=BND>#28TM.ZF7(<X0FF0N >
M$M($'K\!'/OAUP8>#ZAUPHM_WM([/]NXE*"9J=#R:].UU+0*MG4*!0;4"M02
M=C EN338J(Z[/PSRT*/HOTU";MY*DI1J#3P'KJW8#]1UV8F]U::]"%L;GLT1
MPB&.B7%)OX: \2US*0Z*1(JYY"O8DO:&(AMXBLX357*+WP-1O6%QV6_=L>)8
MT'-O)LJVMT7<9"_UA[G6F)*<ZV@)CR,C;PD6',6EBBQ3H!H<_"=POOCX^/BN
MI+@&29W8Y!P]V5Q\<EBV'44_P0S$C5[9Y+W 1?60$CU'<TAQ.-"-L4,NFD'S
M.14?$7(BSLXM3:3;Q(9K XB08I5K^Z9V.ELKN[BT2_C+:]>1UZ< /X\ZM8&B
M_9.%>\=>1@OLO!/'H&NXQUMI'(:ZA]NX9.(>3H-J30A$'.(WL4LXM00(Y'=P
M<BP3QK-8<3$G,JF1;\ #7>(Y4D2U+$I*Q<#G**L\^;G8O;/\:U'J@KA9&S@Y
MR!\];2[T#UPOBS@2%F?)>. ACG3CJ+B&P\=%Q((*_83IYPHV.G<E?$Z._Q2Z
M9^NB!K.$^_7 O*X*NGN-H%)Z$ZQ:@>$"Y@I2K2QD95+?O8^3>?LC-PV\DK.2
MX)N#![_#[DV'_D8E>F3?7AC4SANJ'X&2">N-HW7BD.C34N\*VNVU4]%,#9;9
ML=@UUF58>JJ+*>2Q",%&#'GLJ7K2VVBE3\CVN8H[H/!%@9Y/8" 33GN[E_&D
M?\]W%7W3"N,*/S@;6>&+008V_J\OI%U7A2\FHC^+3$;.\;:/<YBSCV7PN"04
M-A#U39!@LIW9=A5X-Y34I GD^/Y)AV\!0O/=EX/0?#=!:"8(S7;F_.-M,.>-
MX\Y>"4.?:2<^E&&M2@7WKY<NN=&OY>EE1GXZ>_3X^+?'&O=/BSK=38L:]GU-
M^_U5[?=9_WZ/UMR+A\)BW,YG>/-A8S[[IK>Z:7H)^ 'OL@FZR@"U6FD[<;==
MAPIG-M5B^+@,SVZT^.\J)55<&BWCCEC+'&OE2WCEPK,1G%'MFP0#23R@FAEN
MA,^7DANN.[,\J9/\9,NF^DV\-WZ."I>(A)<DYRNA E.TZJE)\]BS)X*Y:?&.
MGPKV?G;]8EV,27L7*> UG^MU;6)2]*BY_ZA("FS@?DEO5B/9'(B8R[;42\;Z
M"N#L8_WL-Y^J;SU;J<>9@^&%2(;"X+#_;%JB?E8L'D?6;8)(N7-7QF:^U//W
M\+>1#^NR6*78;72#H4;=#B>N<=:U8"!;Y2CBZ."^X9RD5-HV'L:E[.K+BW^-
MBA>HON!5R/%MN?&P(K^+:78%D.?%4Y4+8WJQ/JNCA PAG"UOC8VT^M&TL 0N
M!2>3*UU6VD3P\"[<#)@S-D>O.O6)>],2_1I*7,>A*C(?MW[N'/WAYA,\\JI;
M)UE"JM&L+-[K\A LL)2:*AZ8UB0>:9#<]E:3<O(P2U2+G0#&XN72/BSH;F)-
M@W5&L8+N3'JZ EI@='3P4!X -V'5<#,+^.8[O\4!$U?K@,#&=<ZI]>;:&KA!
M,ON.9'U.Y5N^MW5Q-Q+U"<KWN3K%/(O*9Q=[)PHFS- -4#@'R=VO##3TP@M6
M>,'F"3GT>>K%^'4FB06]L(Q,F@ZXAJ:,5!7U%UA+*]S=+1[F0VVX(ZZ7']J?
MWFMD+E<#X-;O^,A*U >CZZJ^9C&A;,*;*TV,%5CW4'S_(O>U8NE;X(0L0;FC
M12G6&KD9B"OO'Z/\(G;\R7?#L[OHB342;-YK\V[:EQBA*VI!]=@U+E*X*Z(H
M66%_8#*:2 ?MU4UP/[F"U4;@!13/*>BGZ7UD8 >2FX-J:)U)HHT9RUE.;*![
MK9.P[5E;@(\BTSPK+*W\TA9U<<E:"_LKG%CW4[IJ]4%7=X^BG_QQ?35:ZG?L
MHF^X-F7#QR=0-7KA@I(_&/2?\-L3C,>>Y4HYF[E:66W8A\U@$#I=4!*4KKS)
M>-?$VYZ!$T6T&[=&!;HHFDH?1;_"?F>!^EW:61T@%A*U:U#&[)A4Z0;T=M+C
M\QHS/WC@65&\[P  "X[E14F3;?P%)P<0)@JI2\D)\NZZB\#)B$),U.>GJ#5W
MWZ&3 ;HUS2FI3/R/5<S2X]:5X];2]P%[P'8HTGMMOU>%,RW;^,UZ&?::<,0<
M- K@,6D526V?8RNN )[@:\@R [3EUC4ND^U1V'-.$+OO=],(FGHQKS;K8[5]
M64K\UIU!6$T01VRS87<1:O!GLF[QPUZ:P#Z):&(-=_&8&A)\[JCG]U\NZOG]
M%/6<HI[;E.T7/5XZXW,1K[YXU;@?)(NM;KL?V\#;-DV)@89JTGA:*&Y/?UYT
M&RT9;BX2K*_IRC;U9/\XV;[M^I:ZY>^\Z@S4?4SJWRS3M1A8K;0OUQ Q4&.H
MN9QM:-NY*_8CY+8]E/< F]_HEXL0[5G<@UWER4N*5#5E+C^WQ27BCJ:%ZJA5
M$CR5RX/K&]W=%:;@, H!]J7H['"*RD#.B"/;*]826VY9_XT/9MQ(#/0L?85/
M:34#I>:3@<_,P)M]ERS,=YM]>=>ZW]6LTN+54]X[THOWWQN'60ZN]5\W@P7N
M<%[Q%9#ULG(XS5UH #5A\J:ZO'.KW_2C0D$A'UG@-E' KJ!I+3O#',>C#?;^
M!W$(84Y>!4_\M,GE$6M8=&][PE5"5YY?AHH/TL( R(<FF12:I[F=?&V P^UD
M_S*U)V?[+<;6=NJ^:<?OW_-*$T>^8<C.\3 D(H\./HWU,AO?SD/WBG7^6W/-
M:YUA'LK)Z<0WOR3?1$4WS2=.^24YY6CSB>>L]>W"([&7$EH26;]R.@9OV7[L
M6/O\8OHC#]_A@2MILEOP[<$[?3;^&/>X0+UULDG>,YUK[*))&0&6,=%HWE?4
M")HZ/'NW6H_8\%804(W][PX3(JL;<#VBE+S8;> ^YVZ-80)_D3KD(W>Q&U]E
M+@F#VWR-"&1-::K49]Y_QD%E.J-(1?^01HP'M]U3?F@48DX%I49S)(Q"_!94
MP#5+%X0&-'YUO_WU?@C$05+X)#'8P@DQ37TIX>=#Q <$84@ .+.J\$-9DX3[
MIOS,C[Z<G_G1Y&?>/S_SA$.Z ;#GNZ^M=E&[LM<$0OJ\Y8O^8DJ9]BY\N[^9
M:]$PU.FL1^5 @&R^,8C]I(L)B4FMY(0-$<0]$^HMTF8+[*H5@FG[FWC$ QC9
MN 6SWC]YOG>T-%JKIK-C5A?V*F-)NY:>_;7H-1_[82OL>G8D6HYTL4$9$?E9
MF_07US@F[H^\V501@JHYN'!O!Y(;4931SSM/\!'<5GF/ Q +PF#@P5CM]M)B
M+A!=,G9(&@NL\;OJV%XW/J0^4^LIQ'CC6BWOQ"!5?J'+%[UH%;_L5_2=J43<
M,1M'=M>#2@+E8:Z3,X?C:)WIY)+(ND*KGLHC>,A[T%13S;8^6G*;-7XSI[\=
MU1" 9V$@5P8+UWNX)LK92CG)&.5P"UEO0:N!Q*5A;H/TD*ZH/8O'QMHG?X2@
M%/7@QL<@1-0KI5R4/N1NVNJM6ZW')>.JN%)9ZP!5;6;1X\7IL(U1_M#NN]BY
M@)4L0NV%'0&M]"UUIJE7&JEI1@ A[172ZA@AV<P6'&00;,H:S/2-50;[& 81
M51T(7'$?=\4CDZ05H\-GHGT<;,<Y[5Q"J"\0S*;55T[<@R0(R1&)KP\[-4G%
M'0A^,4;P?^.R.IS*P&3^O'$5V?MUM:YV;_#7(R3?S8((HKF$%)<B/P+5[<)Q
MD7^:/,3F8Q2VB4RVDLGE.!; 8*I1Z6:!^-QSOW]>TK$&AY=\8-#>6 <J"68G
M_0C\V45KE29CA5!'R$DXO$],%-?+Q?4<P,W#41$732.GN1W'<V+;,J"MIN*(
MT&^K!G6HO1HH(W;FM!]5_L/[UW$@XT)JT.)<IY.R]:0LQS6(NBGS(;^(F(Q\
M6EY[\=-M$4TFG,XC'68_(!@R&ZE=%IF.?7&1H 3S)8:[A!SG!0IB ZFE$5@9
M"?60_:.3R?]\ X_N]U^[_YG[14Q>Z-_!"\W<JW\#VL6%MOJ4=TA4/8HNK/TR
MJ.J1LS$5YQLSK($9AGPLMC>13:V["+.\S[?IX5. 4/UVXM((UC%CZN#J6A;2
MW-I529SGLW_2^\=M]XYN1SW>?Y,VY\^D^[FGQF+FP9!#1[S7NK9]TDW[]#ZK
ME@0QMD-::]O;R =2^3DD]CFH(ZYTW79([T05GH=])IIFT?2A;/I>C;)_^]Z,
M.[#;Y @U7Z:@.1BJ%[WA$$2!CDGYQ>"2RK"O?84G$0]86L>,Y2'E&&N\7!8J
MJS I6:@^[NGH2><(YH*YI9I*%ZZD;FO%5@/VK/=:$&M,X"70$".4*CT'^Z-&
MB)UI<>S2/^&MTNTI\9U=W;^#]RU 1TZ.OQQVY.1X H_L'WAD[\3):"SIA2IS
M<IL-*Z'1K\A 5UK71L9[K*O-<[N9#J,N#RQ1@(Q^%]5I2TW(0#^S6M;E$-C
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MW[1U; .=/P:]OMD)M5X*O8X<OG$ >T<*\(H2UY?*I@DGG#H+^Q/6U8<<FJF
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ME$'" H)1=[;5[]8>K32"HU<:P-9%\3(2C/.+Y;T% #SJ>=6)W+:2VZ,=*P^
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M]UG#YF\PUN[4HFD]C]3\TWOGVFG<Y"'1%E X&O7R8>H^87H8#@G5$P2'1C!
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MU<LK[T/C'^;W'-$KV)^E_ =02P,$%     @ \X0)69I@D6FT"   -&0   T
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M;3(RI'>_WDCY/_0_7W_],I\->]#/:FSX0"HJ]#,;O6XE_+60_P-02P,$%
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MAE:3<P=5F*:WS/ &TN,1^-DY@H=&T#N%(/N*\F(*<-U)IA@58 ,=,ZPVK&N
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M2P$"% ,4    " #SA E9T1A ] 4$  #W'P  %0              @ &4 P
M8F-D82TR,#(T,#@P.5]D968N>&UL4$L! A0#%     @ \X0)6?-)ZZ2F!
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M,C R-# X,#A?<S%I;6<P,#$N:G!G4$L! A0#%     @ \X0)62MR/_)$#P
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M2P$"% ,4    " #SA E9;_ZF6!$*  "=4@  #0              @ &<:0$
M97A?-S$Q,SDU+FAT;5!+ 0(4 Q0    ( /.$"5F:8)%IM @  #1D   -
M          "  =AS 0!E>%\W,3$S.38N:'1M4$L! A0#%     @ \X0)6?KK
M_:!- P  VPP   T              ( !MWP! &5X7S<Q,30R,BYH=&U02P4&
2      T #0 Y P  +X !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>bcda20240808_s1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bcda-20240809.xsd" xlink:type="simple"/>
    <context id="d2024S1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000925741</identifier>
        </entity>
        <period>
            <startDate>2024-08-09</startDate>
            <endDate>2024-08-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="d2024S1" id="ixv-3506">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="d2024S1" id="ixv-3507">0000925741</dei:EntityCentralIndexKey>
    <dei:EntitySmallBusiness contextRef="d2024S1" id="ixv-3508">true</dei:EntitySmallBusiness>
    <dei:DocumentType contextRef="d2024S1" id="ixv-3518">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="d2024S1" id="ixv-37">BioCardia, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="d2024S1" id="ixv-49">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d2024S1" id="ixv-56">23-2753988</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d2024S1" id="ixv-81">320 Soquel Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d2024S1" id="ixv-85">Sunnyvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d2024S1" id="ixv-87">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d2024S1" id="ixv-89">94085</dei:EntityAddressPostalZipCode>
    <dei:EntityFilerCategory contextRef="d2024S1" id="ixv-3519">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d2024S1" id="ixv-3520">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d2024S1" id="ixv-3521">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
